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ABSTRACT 
The anaerobic intestinal spirochaete Brachyspira pilosicoli is the causative agent of 
“intestinal spirochaetosis” (IS), a disease of humans and a number of animal species. 
IS has been reported in adults and children worldwide but the prevalence in people 
living in poor hygienic conditions, indigenous populations, homosexual males, and in 
immunocompromised people is much higher than in other populations. IS is also 
widespread  in  pigs  and  chickens,  and  causes  significant  economic  impact  in  the 
associated industries. To date attempts to develop a vaccine against B. pilosicoli to 
protect humans and animals have not been successful. 
In this study a reverse vaccinology approach was used, in which 24 putative open 
reading frames (ORFs) derived from a partial genome sequence of B. pilosicoli were 
subjected  to  in  silico  and  laboratory  screening  processes  to  identify  potential 
efficacious  vaccine  antigens.  In  silico  analysis  of  the  ORFs  using  a  range  of 
bioinformatics  algorithms  assigned  12  ORF  products  as  periplasmic,  outer 
membrane, or secretory proteins, and these were given a high priority as potential 
vaccine candidates. The 12 selected ORFs were amplified from a human strain of B. 
pilosicoli (Wes-B) and cloned. Products from nine ORFS were successfully over-
expressed in an Escherichia coli expression system, and then purified using affinity 
chromatography.  
In an in vitro immunogenicity trial all the recombinant proteins except for NAV-P27 
were strongly recognised in Western immunoblots by a mouse serum raised against 
B. pilosicoli strain WesB, and by a subset of convalescent sera from pigs naturally 
and  experimentally  infected  with  B.  pilosicoli.  In  an  analysis  of  in  vivo 
immunogenicity, the post-immunisation mouse sera raised against each recombinant 
protein reacted strongly with each specific proteins, and also recognised the native   v 
protein in extracts of B. pilosicoli strain WesB. Sequence analysis of four randomly 
selected ORFs showed that these were highly conserved amongst the genomes of 
different human and swine strains of B. pilosicoli. Evaluation of all the data obtained 
in  the  reverse  vaccinology  approach  resulted  in  selection  of  four  ORF  products 
(NAV-P3, NAV-13, NAV-22 and NAV-31) as being potentially protective antigens 
to be analysed for their further efficacy. 
These  four  recombinant  proteins  were  assessed  for  their  efficacy  as  vaccine 
components  in  a mouse model of  IS, where the animals  were challenged with  a 
human strain of B. pilosicoli. The proteins all induced systemic and local antibody 
responses,  and  tended  to  reduce  spirochaete  colonisation  following  experimental 
infection. These proteins used individually or in combination now have the potential 
to be further developed into a new vaccine to prevent B. pilosicoli infections.  
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CHAPTER ONE 
 
LITERATURE REVIEW 
 
 
1.1 GENERAL INTRODUCTION 
 
1.1.1 Preface 
This thesis describes a ―genome mining‖ or ―reverse vaccinology‖ approach to the 
identification of potentially efficacious protein subunits to incorporate into a vaccine 
against the anaerobic intestinal spirochaete  Brachyspira pilosicoli. Following this 
approach, the partial genome sequence of B. pilosicoli was obtained and investigated 
using  in  silico  tools  to  predict  potential  vaccine  antigens.  A  total  of  24  well-
annotated  antigens  including  outer  membrane  proteins,  secretory  factors  and 
sequence motifs associated with transport or binding of proteins to the cell surface 
were selected. Following further screening, 12 well-distributed genes were amplified 
from a human strain of B. pilosicoli (Wes-B) and expressed in Escherichia coli. The 
purified proteins then were applied in in vitro and in vivo immunogenicity assays and 
finally  the  best  proteins  were  used  to  immunize  mice,  as  a  model  for  human 
infections.  
      Accordingly as a background to this study, this literature review is set out in two 
parts. The first  half describes  what  is  known  about  intestinal  spirochaetes of the 
genus Brachyspira, and particularly B. pilosicoli including its disease associations, 
epidemiology and current means used for its control. The second part of the review 
outlines methods and refinements that have been used in the ―reverse vaccinology‖ 
approach to vaccine discovery and development. 
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1.1.2. The spirochaetes 
Comparative analysis of 16S rRNA sequences of 50 species of spirochaetes and 3000 
other  bacteria  has  revealed  that  there  are  several  unique  base  signatures  in 
spirochaetes. This  study confirmed that spirochaetes  are a  distinct  monophyletic 
phylum within the bacteria  (Maidak et al., 1994). The order Spirochaetales belongs 
to the class Spirochaetes of the kingdom Eubacteria, and is divided into three major 
phylogenetic  families.  The  first  family  Spirochaetaceae  contains  six  genera; 
Borrelia,  Brevinema,  Cristispira,  Spirochaeta,  Spironema,  and  Treponema.  The 
second  family  ―Serpulinaceae‖  contains  the  genus  Brachyspira  (Serpulina).  The 
third family Leptospiraceae contains the genera Leptomona and Leptospira (Paster & 
Dewhirst,  2001).  Morphologically,  spirochaetes  are  relatively  rod-like,  helically 
coiled, motile, Gram negative bacteria characterized by a unique morphology and 
motility mechanism. The three basic cellular elements of the spirochaetes are the 
special  outer  membrane,  which  encompasses  the  cell;  the  protoplasmic  cylinder, 
which contains the cytoplasm and nucleoid; and the periplasmic flagella, which lie 
between the protoplasmic cylinder and the outer membrane. Although spirochaetes 
are Gram-negative, they stain poorly. They may be demonstrated more clearly by 
Geimsa or Wright stains, India ink or nigrosin, and silver stains. Phase-contrast or 
dark field microscopy is especially useful for the visualization of the spirochaetes. 
     The periplasmic flagella provide a unique mechanism of motility for spirochaetes. 
They  wind  around  the  protoplasmic  cylinder  under  the  outer  membrane  and  are 
responsible  for  the  cells  movement  and  rotation  so  the  cells  can  directly  move 
through the external environment. Periplasmic flagella enable spirochaetes to move 
in a corkscrew-like fashion, so enabling them to swim in a highly viscous, gel-like 
medium, such as that found in connective tissue and which normally inhibits the  
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motility of most other flagellated bacteria (Greenberg & Canale-Parola, 1977; Li et 
al., 2001). 
      Different spirochaetes are free-living or are host-associated bacteria. In nature, 
they are found in water, soil, decaying organic material, and the bodies of plants, 
animals and humans. The majority are saprophytes, but some are pathogenic, causing 
disease in humans and animals such as molluscs, insects, birds, and mammals. There 
are several genera of spirochaetes that are responsible for a variety of human and 
animal diseases. The genus Borrelia contains obligate pathogen members including 
the  causative  agent  of  Lyme  disease  (Borrelia  burgdorferi),  relapsing  fever,  and 
borreliosis. Leptospira interrogans is the agent of leptospirosis or Weil‘s disease, and 
is  a  member  of  Leptospira  genus  that  is  host  associated.  The  genus  Treponema 
contains  host  associated  pathogens  such  as  Treponema  pallidum  and  Treponema 
pertenue,  the  agents  of  syphilis  and  yaws  respectively.  The  genus  Brachyspira 
(Serpulina)  is  a  host-associated  group  of  organisms  that  has  some  important 
members, including those which are characterized by their attachment to the colonic 
mucus  layer  of  mammalian  or  avian  hosts  (Baranton  &  Old,  1995;  Paster  & 
Dewhirst, 2001). 
 
1.1.3 The Brachyspira genus 
The  genus  Brachyspira  (Serpulina)  consists  of  seven  species  of  anaerobic 
spirochaetes that inhabit the large intestines of mammals and birds. The two best 
studied and important members of this genus, B. hyodysenteriae and B. pilosicoli, are 
pathogenic  and  responsible  for  swine  dysentery  and  intestinal  spirochaetosis 
respectively  (Atyeo  et  al.,  1996;  Trott  et  al.,  1996c).  The  strongly  ß-haemolytic 
spirochaete B. hyodysenteriae is the aetiological agent of swine dysentery, which  
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causes bloody diarrhoea, loss of weight and occasionally death in pigs from weaning 
through  the  growing  and  finishing  stages.  B.  pilosicoli,  a  weakly  ß-haemolytic 
spirochaete, is recognized as a pathogen, causing intestinal spirochaetosis in a range 
of species including humans, pigs, dogs, and different species of bird (Trott et al., 
1996c). Intestinal spirochaetosis caused by B. pilosicoli was first described in pigs, 
where experimental infection with what has become the type strain of the species 
(P43/6/78
T) led to mucoid diarrhoea and attachment of the spirochaetes by one cell 
end to the colonic mucosa (Taylor et al., 1980). In the early 1990s, studies using 
multilocus  enzyme  electrophoresis  showed  that  this  spirorochaete  previously 
designated ―Anguillina coli‖ were the same as the majority of isolates that had been 
cultured from humans (Lee et al., 1993b). Hence humans could be colonized by the 
potentially  zoonotic  Brachyspira  pilosicoli,  as  well  as  B.  aalborgi  (Mikosza  & 
Hampson, 2001).  
      Intestinal  spirochaetosis  in  humans  occurs  mainly  in  poor  societies  in 
underdeveloped and developing countries, and sometimes it can be asymptomatic. 
The  majority  of  reports  from  western  societies  have  shown  that  these  intestinal 
spirochaetes are only commonly found in homosexual men (Lee & Hampson, 1992; 
Law et al., 1994). This thesis focuses on human intestinal spirochaetosis caused by 
B.  pilosicoli,  with  much  of  the  experimental  work  conducted  using  human  B. 
pilosicoli strain WesB, which was originally isolated from an Australian Aboriginal 
child with diarrhoea (Lee & Hampson, 1992). Nevertheless, the vaccines produced 
potentially also can be applied to help control B. pilosicoli infections in animals. 
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1.1.4 Brachyspira pilosicoli   
1.1.4.1 Taxonomic and phylogenic position of B. pilosicoli 
Based on the results obtained from 16S rRNA sequence comparisons, some strains of 
weakly haemolytic spirochaetes from within the former genus Serpulina, for example  
P43/6/78
T, HRM-7, and Wes-B, were classified into a new species of  Serpulina, 
called Serpulina  pilosicoli (Lee et al., 1993a; Trott et al., 1997b). Subsequently the 
existence  of  more  than  96%  16S  ribosomal  DNA  sequence  homology  amongst 
strains  of  Brachyspira  aalborgi,  S.  hyodysenteriae,  S.  pilosicoli  and  S.  innocens 
encouraged Ochiai and colleagues (1997) to reclassify all the species of Serpulina as 
Brachyspira.  The  currently  accepted  genus  Brachyspira  contains  seven  official 
species including B. hyodysenteriae, B. innocens, B. murdochii, B. intermedia, B. 
alvinipulli, B. pilosicoli, and B. aalborgi (Hampson et al., 2006b). Other unofficially 
named  species  include  ―B.  pulli‖,  ―B.  canis‖,  and  ―B.  suanatina‖  (Figure  1.1) 
(Råsbäck et al., 2007). 
 
 
1.1.4.2 Morphology of B. pilosicoli 
B.  pilosicoli  (type  strain  P43/6/78
T;  ATCC  51139)  is  a  weakly  β-haemolytic 
anaerobic spirochaete, 4-12 m in length and 0.25-0.3 m in width, weakly Gram 
negative, and motile where viewed under phase contrast or dark field microscopy 
(Jones et al., 1986). It is difficult to distinguish B. pilosicoli from B. aalborgi, which 
is 1.7-6 m long, 0.2 m wide, has pointed ends, and four flagella at each pole. The 
length of the cells depends on the growth conditions; non-optimal and unfavourable 
growth conditions will produce longer and straighter cells or lead to the formation of 
spherical bodies.   
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Figure  1.1 Phylogenetic tree based on almost  complete sequences  of 16S rDNA 
from 66 Brachyspira strains/isolates. The scale bar shows the distance equivalent to 
one substitution per 100 nucleotide positions,  corresponding to  approximately 14 
substitutions in the sequenced gene fragment. Adopted from Råsbäck  et al. (2007).   
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      B. pilosicoli typically has one pointed end and one round end. It has 4-7 flagella 
in a single row at each end, and hence can be distinguished from the other species of 
Brachyspira  such  as  B.  hyodysenteriae,  B.  innocens,  B.  intermedia,  and  B. 
murdochii, which have rounded ends and two rows of 7-14 flagella per cell end (Lee 
et al., 1993c; Taylor & Trott, 1997).  
 
1.2 HUMAN INTESTINAL SPIROCHAETOSIS 
1.2.1 Introduction  
The  first  report  of  the  presence  of  spirochaetes  in  the  lower  part  of  the  human 
intestine dates to 1884 when Escherich considered them to be part of the normal 
intestinal  flora  [Cited  by  Ruane  et  al.,  (1989)].  Further  prevalence  investigations 
based on morphological features of bacterial cells using direct microscopy of faeces 
again suggested that the organisms were commensals (MacFie, 1917). Later, Harland 
and Lee (1967) using electron microscopy observed large numbers of spirochaetes 
attached to epithelial cells of the colorectal mucosa of human patients. Subsequently 
the  majority  of  cases  of  intestinal  spirochaetosis  have  been  reported  from  those 
suffering from a range of gastrointestinal disorders, immunocompromised patients, 
homosexual  men  as  well  as  healthy  individuals  in  many  countries  using  either 
histological or cultural methods of diagnosis.  
 
1.2.2 Aetiological agents of Human Intestinal Spirochaetosis (HIS)  
As previously stated,  at least  two species of anaerobic intestinal  spirochaetes,  B. 
pilosicoli and B. aalborgi colonise the human large intestine (Trott et al., 1996a; 
Trivett-Moore et al., 1998; Mikosza et al., 1999) and are associated with intestinal 
spirochaetosis (IS). Other uncharacterised spirochaetes also occasionally have been  
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detected (Mikosza & Hampson, 2001). Both these two main species of spirochaetes 
have tapered ends and attach by one cell end to the human colorectal epithelium. B. 
aalborgi is 2-6 m long, has eight periplasmic flagellae and is less coiled than B. 
pilosicoli, which also has four periplasmic flagella of each cell end.  
 
1.2.3 Identification of the condition “intestinal spirochaetosis” 
With the advent of electron microscopy and EM diagnostics, Harland and Lee (1967) 
observed large numbers of spirochaetes attached by one end to the colonic and rectal 
epithelium in the biopsy of a patient with gastrointestinal complaints and persistent 
diarrhoea, and then they  used the term  ―intestinal  spirochaetosis‖ to  describe the 
condition. The attachment of the Brachyspira ssp. with the apical cellular membrane 
of enterocytes in histological slides resembles a false brush border of the intestinal 
mucosa (Cizek & Lobova, 2004).  
     Colonisation may occur in one or more than one site, or even scattered along the 
entire length of the large intestine (Lindboe et al., 1993). The colonized spirochaete 
is also capable of inducing mucosal damage, invading to the crypt and surface of the 
epithelium,  and  undergoing  focal  infiltration  of  the  lamina  propria  of  the  large 
intestine (Jensen et al., 2000). In histological diagnosis, intestinal spirochaetosis is 
identified  as  a  thick,  blue  fuzzy  brush  border  on  the  surface  of  the  colorectal 
epithelium (Lindboe et al., 1993). 
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1.2.4 Clinical signs of human intestinal spirochaetosis 
Colonisation of the large intestine with intestinal spirochaetes may result in clinical 
symptoms in humans, including abdominal pain, flatulence, diarrhoea, constipation, 
faecal blood, vomiting and other abdominal complaints (Lindboe et al., 1993; White 
et  al.,  1994;  Mikosza  et  al.,  2001a).  Some  asymptomatic  cases  of  intestinal 
spirochaetosis have been reported even with normal colonic mucosa (Takeuchi et al., 
1974).  Prior  to  the  1990s,  it  was  generally  assumed  that  cases  of  intestinal 
spirochaetosis  in  humans  which  were  diagnosed  on  the  basis  of  histology  were 
caused by B. aalborgi, but we now know that this is not always the case. Hence in 
many older cases where intestinal spirochaetosis has been described, it is not clear 
which aetiological agents were present and/or whether the clinical and pathological 
presentations caused by the two spirochaetal species were the same or different.   
      Lindboe  and  colleagues  (1993)  reported  that  the  predominant  symptoms  of 
patients with histological IS were blood in the faeces, diarrhoea, abdominal pain and 
constipation. In two homosexual individuals with acquired immunodeficiency who 
suffered from  IS, one showed a watery diarrhoea and constipation of one month 
duration.  Another  case  presented  following  three  months  of  persistent  bloody 
diarrhoea (Guccion et al., 1995). In the study of Australian Aboriginal children, most 
who were found to have B. pilosicoli in their faeces had abnormal or watery stools, 
with gastrointestinal disturbances (Lee & Hampson, 1992). Appendiceal intestinal 
spirochaetosis has been described by several investigators (Harland & Lee, 1967; 
Lee et al., 1971; Takeuchi et al., 1974; Henrik-Nielsen et al., 1985; White et al., 
1994;  Yang  &  Lapham, 1997).  It  is  reported  as an uncommon phenomenon that 
affects both sexes, occurring with or without symptoms of acute appendicitis (Yang 
& Lapham, 1997).    
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1.2.5 Prevalence of human intestinal spirochaetosis  
IS in humans occurs world-wide and has been reported from countries including 
England, Ireland, Germany, Italy, Norway, Denmark, Sweden, Switzerland, Greece, 
USA, Australia, South Africa, India, and Russia (Cooper et al., 1986; Teglbjærg, 
1990; Law et al., 1994; Brooke et al., 2001; Mikosza et al., 2001a; Kanavaki et al., 
2002; Calderaro et al., 2003). IS has been reported in adults and children of different 
ages (Lee & Hampson, 1992; Cunha Ferreira et al., 1993; Lindboe et al., 1993). The 
prevalence of  IS in people who are living with a low level of hygienic conditions in 
rural areas of developing countries (Trott et al., 1997c; Margawani et al., 2004), 
indigenous  population  such  as  Australian  Aboriginals  (Lee  &  Hampson,  1992), 
homosexual males (Surawicz et al., 1987) and people infected with HIV (Käsbohrer 
et al., 1990) is much higher than in other populations. Apart from homosexual men, 
HIV infected people, and indigenous populations, the prevalence of IS in developed 
countries  is  low.  Several  studies  have  been  made  on  the  prevalence  of  IS  using 
histological assay of colorectal biopsies (Lindboe et al., 1993) and isolation of B. 
pilosicoli or B. aalborgi from faeces culture (Margawani et al., 2004). 
 
1.2.5.1 Prevalence of IS using histological examination (agent unknown) 
In (1993) Lindboe and colleagues reported 30 cases of IS out of 1205 examined 
colorectal  biopsies,  with  a  7:3  male  predominance  ratio,  from  an  unselected 
population in Norway. This study showed 2.5% prevalence in a normal population. 
Amongst 39 biopsies which were collected for cultural and histological examinations 
from HIV positive patients in Germany, about 44% of untreated individuals had IS 
(Käsbohrer et  al., 1990).  In another study, nineteen colorectal  biopsy specimens, 
which  were  stained  by  Hematein-Eosin-Safran  (HES)  and  examined  by  light  
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microscopy  showed  a  thick,  blue  and  fuzzy  brush  border  as  a  sign  of  intestinal 
spirochaetosis. Further Silver staining by the Warthin-Starry method confirmed the 
presence of numerous spirochetes attached to the epithelial surface in three cases 
(Dauzan et al., 1990).  
 
1.2.5.2 Prevalence of IS using histological examination (agents known) 
In an examination on 681 surgically removed appendices, spirochetes were found in 
13 of the appendices removed from patients clinically suspected to suffer from acute 
appendicitis. The spirochaetes obtained showed a similar morphology to that of B. 
aalborgi (Henrik-Nielsen et al., 1985). In another study spirochaetes were isolated 
from rectal biopsies of three patients, and successfully cultured. Enzymatic reactions 
and electron microscopy revealed spirochaetes resembling B. aalborgi (Gebbers & 
Marder,  1989).  Jensen  and  colleagues  (2001)  applied    fluorescent  in  situ 
hybridization with oligonucleotide probes targeting 16S or 23S rRNA of B. aalborgi, 
B. pilosicoli, and the genus Brachyspira to 40 sections of formalin-fixed, paraffin-
embedded intestinal biopsy specimens from 23 Danish and 15 Norwegian patients 
with  histological  evidence  of  intestinal  spirochaetosis.  The  spirochetes  from  13 
Danish  and  8  Norwegian  patients  (55.3%)  were  identified  as  B.  aalborgi.  The 
spirochaetes in the biopsy specimens from the other 17 patients hybridized only with 
the  Brachyspira  probe,  possibly  demonstrating  the  involvement  of  as-yet-
uncharacterized  Brachyspira  spp.  (Jensen et  al., 2001). Brachyspira aalborgi has 
been  subdivided  into  three  lineages  on  the  basis  of  differences  in  16S  rRNA 
sequences  (Pettersson  et  al.,  2000).  Latter  using  this  information,  Jensen  and 
colleagues applied another specific oligonucleotide probe that targeting spirochaetes 
of B. aalborgi lineages 2 and 3 on 17 human colonic biopsies from individuals from  
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Norway  and  Denmark  with  intestinal  spirochaetosis  caused  by  Brachyspira-like 
organisms that were different from the type strain of B. aalborgi (lineage 1). Two 
Norwegian biopsies were hybridization-positive whereas the 15 other biopsies were 
negative (Jensen et al., 2004).  
      In an earlier investigation, DNA extracted from gastrointestinal biopsy specimens 
of 28 Australian patients with histological evidence of intestinal spirochaetosis (IS) 
was subjected to PCR to amplify segments of the 16S rRNA and NADH oxidase 
genes of B. aalborgi and B. pilosicoli. B. aalborgi was identified in specimens from 
24 (85.7%) patients and B. pilosicoli from 4 (14.3%) patients (2 of whom were also 
positive for B. aalborgi). For two patients, no product was amplified. This study 
demonstrated that B. aalborgi is much more commonly involved in histologically 
identified IS in Australian patients than is B. pilosicoli (Mikosza et al., 2001a). 
 
1.2.5.3 Prevalence of IS using spirochaete isolation from faeces 
In  a  survey  of  five  villages  in  the  Eastern  Highlands  of  Papua  New  Guinea,  B. 
pilosicoli was isolated from rectal swabs from 113 of 496 individuals (22.8%) (Trott 
et al., 1997c). In another study, amongst Australian Aboriginal children and a few 
adults in Western Australia, a B. pilosicoli prevalence of around 32.6% was found by 
faecal culture of 181 samples (Lee & Hampson, 1992). Based on faecal culture, the 
overall prevalence of B. pilosicoli amongst  Indonesians living in rural  and urban 
settings on the island of Bali varied from 3.3 to 23.4 %, with the highest prevalence 
occurring in peri-urban locations (Margawani et al., 2004). In a study in India, 316 
human faecal samples were investigated for detection of B. aalborgi and B. pilosicoli 
DNA using PCR. The result showed that 19 (6%) human faecal samples contained B.  
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aalborgi DNA, 80 (25.3%) contained B. pilosicoli DNA, and 10 (3.2%) contained 
DNA from both species (Munshi et al., 2003).  
 
1.2.6 Pathogenesis of human intestinal spirochaetosis 
Little  is  known  about  the  real  mechanisms  of  intestinal  disorders  caused  by  B. 
pilosicoli or B. aalborgi in humans. Similarly, although B. pilosicoli is recognized as 
an important enteric pathogen of poultry and pigs, the mechanism by which it causes 
diarrhoea is uncertain. Different theories have been proposed for mechanisms of cell 
attachment, diarrhoea, and mucosal or possible systemic invasion of spirochaetes. 
The mechanism of  cell  attachment to  the  gut  mucosa is  unclear.  Since intestinal 
spirochaetes  heavily  colonise  non-neoplastic  but  not  neoplastic  epithelium,  it  has 
been postulated that special cell receptors such as glycosylated surface proteins of 
the epithelial cells may be involved in the chemical attachment process; however, 
subsequently they have been shown to colonize neoplastic cells (Coyne et al., 1995). 
The normal microvillous pattern of the mature epithelial cells also may facilitate the 
mechanical attachment process of the spirochaetal cells by holding them into the gut 
microvilli  (Lee  et  al.,  1971;  Neutra,  1980;  Teglbjærg,  1990).  Regarding    the 
mechanism of  diarrhoea, it has been speculated that attachment of  a large number of 
spirochaetal cells by one end to the colonic or rectal epithelium to form a false brush 
border acts as a mechanical barrier to reduce water absorption in the large intestine 
and cause the watery diarrhoea (Harland & Lee, 1967; Gad et al., 1977). Attachment 
of spirochaetes could damage the epithelial cells and result in replacement of mature 
enterocytes wit immature cells on the colorectal surface (Hampson & Stanton, 1997). 
      There are several reports that B. pilosicoli can invade intestinal epithelial cells 
and migrate to the basal parts of the cells to colonize other enterocytes, goblet cells,  
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macrophages  and  Schwan  cells,  particularly  in  immunocompromised  patients 
(Koval'chuk  &  Gebesh,  1981;  Gebbers  et  al.,  1987;  Guccion  et  al.,  1995; 
Padmanabhan et al., 1996). Irritation of goblet cells might increases mucin secretion, 
which could cause mucoid diarrhoea (Kraaz et al., 2000). B. pilosicoli also has been 
found in the mesenteric lymph nodes of experimentally infected pigs (Hampson et 
al., 1998), and has been  isolated from the blood stream and/or liver biopsies of IS 
patients with complicated bacterial or HIV infections (Kostman et al., 1995; Fournié-
amazouz et al., 1995; Trott et al., 1997b; Kanavaki et al., 2002). In an unusual case 
of  human  intestinal  spirochaetosis  where  the  intestine  was  heavily  colonized, 
spirochaetes were found within occasional Schwann cells, so it is possible that IS 
could disrupt neural transmission and alter colonic motility  (Padmanabhan et al., 
1996). Spirochaetes isolated from the blood of patients with sever clinical disease or 
impaired immunity have been characterized as B. pilosicoli using PCR amplification 
of  B.  pilosicoli  16S  rRNA  gene  and  multilocus  enzyme  electrophoresis.  This 
investigation showed that  B. pilosicoli  can translocate from  the large intestine to 
establish spirochaetemia (Trott et al., 1997b). Together these data support the idea 
that  B.  pilosicoli  may  invade  the  host  cells  and  cause  systemic  infections  under 
exceptional circumstances.    
 
 
1.2.7. Sources and transmission of B. pilosicoli 
Human B. pilosicoli infection might be acquired from contact with other infected 
humans, from environmental sources that are contaminated with faeces, or by contact 
with  infected  animals.  It  can  be  assumed  that  carriers  are  the  main  sources  of 
intestinal infection caused by B. pilosicoli. B. pilosicoli is believe to be transmitted 
through the faecal-oral route (Taylor, 1992). Oxberry and colleagues (1998) showed  
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that B. pilosicoli can survive in the environment for considerable periods of time. For 
instance, it can survive up to 66 days in lake water incubated at 4C and for 4 days at 
25C. Since B. pilosicoli can survive in the environment, it could be postulated that 
the microorganism can be transmitted through contaminated water. In rural regions 
with low hygiene direct contact with faeces of  infected  animals such as pigs, dogs, 
ducks, and other birds, or obtaining dinking water from nearby river or wells with 
poor sanitation are two potential important routes of transmission (Trott et al., 1997c; 
Margawani et al., 2004). 
     In  a  study  carried  out  by  Hampson  and  colleagues  (2006a)  the  relationships 
between  107  B.  pilosicoli  isolates  from  different  parts  of  the  world  (Australia, 
Canada,  France,  Italy,  the  Netherlands,  Oman,  Papua  New  Guinea,  the  United 
Kingdom, and the United States), and from different host species (pigs, chickens, 
ducks, rhea, humans, and dogs) including B. aalborgi strain (NCTC 11492
T) were 
investigated  using  multilocus  enzyme  electrophoresis  (MLEE).  In  this  study,  the 
results from the electrophoretic mobility variations of 15 constitutive enzymes were 
analyzed by interpreting products of different alleles at each enzyme locus. Isolates 
with identical enzymatic profiles at 15 loci were grouped into an electrophoretic type 
(ET).  The constructed dendrogram  using the unweighted  pair-group method with 
arithmetic mean clustering fusion strategy, revealed that B. pilosicoli isolates were 
divided into 80 ETs (mean 1.35 isolates per ET) while B. aalborgi NTCCT 11492 
was distinct in ET81 (Figure 1.2). 
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Figure  1.2  Dendrogram  from  multilocus  enzyme  electrophoresis  data  showing 
relationships  between  107  isolates  of  B.  pilosicoli  originating  from  various  host 
species located in electrophoretic types (ETs) 1–80 and B. aalborgi NCTC 11492T 
located in ET81. Adopted from Hampson et al. (2006a).  
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      There  might  be  a  natural  cross-transmission  of  B.  pilosicoli  amongst  human 
beings, dogs, pigs, birds and other animal species, which have been colonized with 
the  same  strain  of  B.  pilosicoli  (Trott  et  al.,  1995;  Trott  et  al.,  1996c).  Several 
experimental infections of pigs and chicken with human strains of B. pilosicoli (Trott 
& Hampson, 1998),  and the similarity of human and dogs isolates of B. pilosicoli 
deducted from RFLP, MLEE, and PFGE profiles (Koopman et al., 1993b; Trott et 
al., 1998) have demonstrated that there might be  potential zoonotic transmission of 
B. pilosicoli (Hampson et al., 2006a).  
 
1.2.8 Laboratory detection of human intestinal spirochaetes 
Human intestinal spirochaetes are usually identified by histological examination or 
cultivation  of  the  bacterial  cells  from  faecal  or  biopsies  specimens,  followed  by 
phenotypic and/or genetic analysis to determine the species present. Direct PCR from 
DNA  extracted  from  faeces  also  is  possible  as  a  means  of  detection  and  for 
identification of the spirochaetes present. 
 
1.2.8.1 Morphological detection 
Phase contrast and dark field microscopy are useful for identifying spiral shaped 
bacteria,  but  they  can  only  be  confirmed  as  being  spirochaetes  by  electron 
microscopy,  where  the  presenting  of  periplasmic  flagella  is  characteristic  of 
spirochaetes. Different sources of samples including direct faecal or biopsies samples 
and  cultures  prepared  from  faecal  samples  or  biopsies.  As  previously  stated,  B. 
pilosicoli strains have lengths ranging from 4.7- 7.8 m and diameters between 0.25-
0.27 m (Trott et al., 1996b), and are shorter and thinner than other Brachyspira spp.  
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which have an average length of 12 m and an average diameter of  0.4 m (Lee & 
Hampson, 1994). 
       Some species of intestinal spirochaetes can be differentiated according to the 
numbers of periplasmic flagella using transmission or scanning electron microscopy. 
Although B. alborgii is smaller than B. pilosicoli, and can have periplasmic flagella, 
it is difficult to distinguish the two species according to their microscopic features 
using light microscopic or even EM techniques. Biopsies collected from colorectal or 
caecal epithelium can be fixed and stained with different stains such as haematoxylin 
and eosin, silver stains, Geimsa, and Alcian blue. Using  haematoxylin and eosin 
intestinal spirochaetes may appear as a light blue fringe on the apical surface of 
epithelial cells (Ruane et al., 1989).  
 
 1.2.8.2 Detection by culture 
1.2.8.2.1 Solid media 
Various selective blood agar plates with slightly modifications have been used to 
isolate  and  culture  the  different  Brachyspira  spp.,  including  human  intestinal 
spirochaetes.  For  isolation  of  B.  pilosicoli  the  medium  typically  consists  of 
Trypticase Soy Agar (TSA) supplemented with 5% defibrinated bovine blood, 400 
g spectinomycin ml
-1, 25 g vancomycin ml
-1, and 25 g colistin ml
-1 (Tompkins et 
al., 1981; Sanna et al., 1982). Swabs from faeces or intestinal biopsies are rubbed 
onto the plate and the inoculum is diluted by sterile loops to obtain a high density of 
spirochaetes with low contamination. Plates are incubated anaerobically, typically at 
37-41 C in an atmosphere of 94% nitrogen, 6% CO2  and less than 1% O2  for 3-14 
days before growth is observed (Jenkinson & Wingar, 1981).  
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      B. aalborgi is a fastidious anaerobic bacterium and it is difficult to grow it using 
conventional agar plate techniques. The selective medium for B. aalborgi typically 
contains TSA with 10% calf serum supplemented with 400 g spectinomycin ml
-1 
and 5 g polymyxin B ml
-1. The plates are incubated anaerobically at 38.5 C in an 
atmosphere of 95% H2 5% CO2 for about 2-3 weeks (Hovind-Hougen et al., 1982). 
The  presence  of  intestinal  spirochaetes  on  blood  agar  can  be  identified  by  the 
appearance of a zone of weak -haemolysis surrounding a low flat haze of bacterial 
growth (Hudson et al., 1976).  
 
1.2.8.2.2 Liquid medium 
A common liquid medium for propagation of B. pilosicoli has been adapted from 
Kunkle‘s anaerobic broth (Kunkle et al., 1986) which originally was developed for 
B.  hyodysenteriae  and  B.  innocens.  The  medium  contained  Trypticase  Soy  broth 
(TSB)  supplemented  with  2%  foetal  calf  serum  (FCS),  1%  yeast  extract,  0.5% 
glucose,  0.2%  NaHCO3,  0.05%  cysteine  hydrochloride  and  1.5%  ethanoic 
cholesterol at pH 6.85. The oxygen in the medium is removed using a flow of 10% 
CO2  and  90%  N2.  A  pure  culture  of  B.  pilosicoli  at  around  10
8  cells/ml  can  be 
obtained in Kunkle‘s broth incubated at 37-42 C on a rocking platform for 72-96 
hours. 
 
1.2.8.3 Biochemical identification 
On  the  basis  of  indole  production,  appearance  of  beta-haemolysis,  hippurate 
hydrolysis,  alpha-galactosidase,  alpha-glucosidase  and  beta-glucosidase  activities, 
the  Brachyspira  genus  has  been  classified  into  four  main  groups  (Fellström  & 
Gunnarsson,  1995).  Hippurate  hydrolysis  can  be  determined  in  bacterial  culture  
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using  1%  sodium  hippurate  or  by  a  ninhydrin  method  (Kinyon  &  Harris,  1979; 
Fellström & Gunnarsson, 1995). The use of the hippurate hydrolysis test enables 
rapid identification of B. pilosicoli strains (Fellström & Gunnarsson, 1995; Trott et 
al., 1996b). The other enzymatic reactions are obtained using the API-ZYM system 
(bioMeriex), a commercial kit (Table 1.1). 
 
Table 1.1 Some useful biochemical characteristics for differentiation of B. pilosicoli, 
B. aalborgi and B. hyodysenteriae  type strains. 
  
Enzyme 
Reaction
* 
B. pilosicoli  B. aalborgi  B. hyodysenteriae 
Alkaline phosphatase  3  0  1 – 4 
Esterase (C4)  3  0  1 – 3 
Esterase lipase (C8)  2  1  1 – 3 
-Galactosidase  2  0  0 
 Glucosidase  0  0  3 – 5 
 
* Values of 0 to 5 were assigned according to the intensity of colour as compared 
with the colours on a chart provided with the API ZYM kit. 
 
 
1.2.8.4 Detection by Polymerase Chain Reaction (PCR) 
Polymerase  chain  reactions  (PCR)  are  simple,  rapid  and  sensitive  procedures  to 
detect  and differentiate infectious  agents,  especially those that are slow growing, 
fastidious  or  non-cultivable  (Louie  et  al.,  2000).  The  procedure  involves 
amplification of a portion of  DNA to a concentration that can be visualized by gel 
electrophoresis  and  staining  (Saiki  et  al.,  1988).  PCR  has  been  used  to  detect 
intestinal  spirochaetes  from  colorectal  biopsies,  blood,  and  extracted  DNA  from 
faeces (Mikosza et al., 2001b). Different specific PCR primers have been used to 
distinguish  Brachyspira  species.  To  date  three  important  targets  for  detecting 
intestinal spirochaete species have been the 16S ribosomal RNA (Park et al., 1995),  
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the 23S ribosomal RNA (Leser et al., 1997), and the NADH oxidase (nox) gene 
(Atyeo et al., 1999) genes. Using primers targeting a unique signature sequence of 
these three genes, it is possible to differentiate B. pilosicoli from other Brachyspira 
species (Fellström et al., 1997; Stanton et al., 1997). 
 
1.3 MOLECULAR GENETICS OF B. PILOSICOLI 
1.3.1 Physical and genetic map of the B. pilosicoli genome 
The  B.  pilosicoli  genome  is  composed  of  a  single  circular  chromosome  with  an 
average calculated size of 2.45 Mb, which is 750 Kb smaller than B. hyodysenteriae 
genome with an average size of 3.2 Mb (Zuerner et al., 2004). A combined physical 
and genetic map of B. pilosicoli  P43/6/78
T has been constructed using pulse field gel 
electrophoresis and DNA blot hybridization (Figures 1.3 and 1.4). According to the 
results obtaining from multilocus enzyme electrophoresis, it has been deduced that B. 
pilosicoli and B. hyodysenteriae are recombinant species (Trott et al., 1997a; Trott et 
al., 1998). Their genetic structure is influenced by exchange of genetic alleles and 
chromosomal rearrangements. These genetic interchanges contributed to differences 
in the size, organization, and content of the two bacterial genomes that may influence 
the ability of two species to infect different hosts and cause disease (Zuerner et al., 
2004).  
      A set of useful genetic markers has been localised on the physical map of B. 
pilosicoli (Zuerner et al., 2004). These markers also provided a more detailed map 
for B. hyodysenteriae. The gene names are shown in Table 1.2. Copies of most of the 
genes such as cheY, flaA, flaB, fliG, and even hlyA that are responsible for motility, 
chemotaxis, and a haemolysin were detected in both species. Some genes such as 
vspA, vspH, bitB, and fruBC were just detected in B. hyodysenteriae while clpX and  
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mglB were found only in B. pilosicoli (Table.1.2). The following sections describe 
some of these known genes so far detected in B. pilosicoli, and, where appropriate, 
provide comparison with these genes in B. hyodysenteriae.  
 
1.3.2 Beta-haemolysin gene (Hly)  
The  haemolysin  gene  hlyA  in  B.  hyodysenteriae  encodes  an  acyl-carrier  protein 
(ACP) with molecular size of 2.9 Kb. The mechanism of haemolytic activity of the 
HlyA protein is unclear but it is assumed that the mature, lipidated form of HlyA is 
the active form of the protein that lyses erythrocytes (Hsu et al., 2001). Zuerner and 
colleague (2004) showed the presence of an intact copy of hlyA in the genome of B. 
pilosicoli  strain  P43/6/78
T.  Although  the  hlyA  genes  of  B.  pilosicoli  and  B. 
hyodysenteriae  are  nearly  identical,  sequence  variation  detected  in  the  intergenic 
region upstream of hlyA may alter transcription and translation efficiency of this 
gene in B. pilosicoli. In addition, divergence in genes flanking hlyA may affect the 
chemical  composition  of  lipid  attached  to  the  mature  B.  pilosicoli  HlyA  protein 
resulting in reduced haemolytic activity (Zuerner et al., 2004).  
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Figure 1.3 Combined physical and genetic maps of B. pilosicoli strain P43/6/78
T. The physical map is 
drawn  to  scale.  The  positions  of  restriction  sites  are  shown  outside  the  map,  with  approximate 
locations for genes shown within the circular map boundary. The figure is adopted from Zuerner et al. 
(2004). 
 
 
 
 
Figure 1.4 Comparison of genetic organization of B. pilosicoli and B. hyodysenteriae. The two maps 
are rotated so that the gyrA and gyrB genes are in the same orientation, then the maps are linearized 
adjacent to the flaA-tpi locus. Genes are aligned between the two maps by lines. Genes present in one 
species, but not the other are shown in bold. The figure is adopted from Zuerner et al. (2004) 
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Table  1.2 Genes  localized in  Brachyspira genomes, adopted from  Zuerner  et  al. 
(2004) 
Gene  Function  Species of origin 
Bit  Iron-regulated protein  B. hyodysenteriae 
cheY  Chemotaxis  B. hyodysenteriae AY573605A 
clpX  Membrane protease v  B. pilosicoli , AY466377A 
fabF  ACP synthase II  B. hyodysenteriae U94886 
fabF  ACP synthase II  B. pilosicoli AY345132 
fabG  ACP reductase  B. hyodysenteriae U94886 
fabG  ACP reductase  B. pilosicoli AY345132 
flaA  Flagella sheath protein  B. hyodysenteriae 
flaB3  Flagellin core protein  B. hyodysenteriae 
fliG  Motility switch protein  B. hyodysenteriae AY573604A 
fruBC  Phosphotransferase system enzyme IIBC  B. hyodysenteriae 
gap  glyceraldehyde-3-phosphate dehydrogenase  B. hyodysenteriae 
glt  Putative transport protein  B. hyodysenteriae AY575208A 
gyrA  DNA gyrase subunit A  B. hyodysenteriae 
gyrB  DNA gyrase subunit B  B. hyodysenteriae 
hlyA  Beta-hemolysin  B. hyodysenteriae 
hlyA  ACP (homolog of B. hyodysenteriae hlyA)  B. pilosicoli AY345132 
mglB  Galactose/glucose binding protein  B. pilosicoli 
nox  NADH Oxidase  B. hyodysenteriae 
polA  DNA Polymerase I  B. hyodysenteriae AF038544A 
por  Pyruvate oxidoreductase  B. pilosicoli 
ppiB  Cyclophylin  B. hyodysenteriae AY575207A 
rrf  5S rRNA  Leptospira interrogans 
rrl  16S rRNA  L. interrogans 
rrs  23S rRNA  L. interrogans 
tlyA  Potential virulence factor  B. hyodysenteriae 
tlyB  Clp-like protein  B. hyodysenteriae 
tlyA  Potential virulence factor  B. hyodysenteriae 
tlyB  Clp-like protein  B. hyodysenteriae 
tlyC  Putative hemolysin  B. hyodysenteriae 
tpi  Triose-phosphate isomerase  B. hyodysenteriae AP003190B 
VSH-1  Gene transfer agent  B. hyodysenteriae 
vspA  Variable surface protein A  B. hyodysenteriae 
vspH  Variable surface protein H  B. hyodysenteriae 
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1.3.3 RNA genes 
In most bacterial genera the three rRNA genes are co-transcribed and form an operon 
(rrn) with the gene order of rrs (16S), rrl (23S), and rrf (5S). Amongst different 
species  of  spirochaetes,  rRNA  gene  organization  is  variable  (Krawiec  &  Riley, 
1990). The typical rrn operon organization is seen in Treponema pallidum and T. 
phagedenis (Fukunaga et al., 1992a) while in Borrelia the order of rrn operon is 
disrupted by approximately 4 kbp DNA between rrs and rrl, or in B. burgdorferi an 
additional copy of the rrf and rrl genes is located after the original rrl-rrf locus in a 
tandem  repeat  (Fukunaga  et  al.,  1992a;  Schwartz  et  al.,  1992;  Fukunaga  et  al., 
1992b) 
      The organization of ribosomal RNA (rrl, rrs, and rrf ) genes encoding 23S, 16S, 
and  5S  rRNAs  respectively,  in  both    B.  hyodysenteriae  and  B.  pilosicoli  are 
common and present as a single copy, but  disrupted by insertion of a 860 kbp DNA 
segment between rrs and rrl (Zuerner & Stanton, 1994) (Figure 1.4). This pattern of 
rRNA gene organization is unique for B. pilosicoli and B. hyodysenteriae and can be 
used  to  distinguish  members  of  the  Brachyspira  genus  from  other  spirochaetes 
(Zuerner et al., 2004). 
 
 
1.3.4 Flagella-associated genes 
Periplasmic  flagellae  are  unusual  ultrastructural  elements  that  are  responsible  for 
motility  in  spirochaetes.  Genomic  analyses  of  B.  burgdorferi  and  T.  pallidum 
indicate that these spirochaetes have at least 4 to 6 % of their genes dedicated to 
motility and chemotaxis, which emphasizes the role of motility and chemotaxis in the 
survival of these bacteria in the hosts, and shows that colonisation is a key step in 
causing disease (Li et al., 2000). Unlike the simple external flagella in many rod  
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shaped  bacteria,  the  spirochaetal  flagellar  filaments  are  found  in  the  periplasmic 
space  wrapped  around  the  protoplasmic  cylinder  and  are  referred  to  periplasmic 
flagella (PF). In contrast to most bacterial flagella, which consist of a single flagellar 
protein (flagellin), the PF are composed of multiple proteins including core proteins 
(class B proteins: FlaB1, FlaB2, and FlaB3) surrounded by a sheath structure which 
is composed of two class A proteins (FlaA1 and FlaA2) (Rosey et al., 1996).   
      The core proteins FlaB1, FlaB2, and FlaB3 with molecular masses of 37, 34, and 
32 kDa share immunological and N-terminal sequence homology with each other and 
with other spirochaete flagellar core proteins (Koopman et al., 1993a; Rosey et al., 
1996). The sheath proteins FlaA1 and FlaA2 with molecular masses of 44 and 35 
kDa,  share  homology  with  the  flagellar  sheath  proteins  of  T.  pallidum  and 
Spirochaeta but not to any other flagellar proteins (Koopman et al., 1992; Rosey et 
al., 1995). Each protein of FlaA and FlaB classes are encoded by separate genes (Li 
et al., 2000) and all genes that related to motility (flaA, flaB, and fliG) have been 
detected in both B. pilosicoli and B. hyodysenteriae (Zuerner et al., 2004). 
       The FlaA1 protein in B. hyodysenteriae with an apparent molecular mass of 44 
kDa in flagellar preparations has a signal peptide in the first 19 amino acid residues 
which is cleaved from the flagellin before assembly onto the flagella. The calculated 
molecular mass of the mature protein without the signal peptide is 33.8 kDa instead 
of 44 kDa, which indicates that the FlaA1 protein is post-translationally modified 
(Koopman  et  al.,  1992).  Larsen  (2004)  designed  a  set  of  primers  based  on  the 
sequence of B. hyodysenteriae flaA gene (ACC NO. X630061, GenBank, NCBI) to 
amplify  the  gene  in  B.  pilosicoli.  The  results  obtained  from  B.  pilosicoli  flaA 
sequence showed a significant homology (85% identity at nucleotide level and 82% 
identity at peptide level) to a portion of flaA1 gene of B. hyodysenteriae.   
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      The amino acid sequences show 37-51% identity between the N-terminal regions 
of the three FlaB proteins (FlaB1, FlaB2, and FlaB3). These data along with results 
of mutational analysis suggested that FlaB proteins are redundant with respect to 
function  (Li  et  al.,  2000).  The  N-terminal  sequence  of  the  FlaB1  peptide  of  B. 
hyodysenteriae  indicates  the  lack  of  signal  peptide  and  direct  transmembrane 
transport of the protein (Gabe et al., 1995). The sequence of flaB obtained by PCR 
from B. pilosicoli showed 90% identity with a portion (858 bp) of the flaB2 gene in 
B. hyodysenteriae. The 858 bp sequence of B. pilosicoli did not include the whole 
reading frame, and therefore the exact homology between flaB2 of the two species is 
not available yet (Larsen, 2004). 
 
1.3.5 Chromosomal replication genes 
The  DNA  gyrase  gene  is  essential  for  bacterial  chromosomal  replication.  Two 
subunits of bacterial gyrase protein (GyrA and GyrB) are encoded by the gyrA and 
gyrB  genes  respectively,  which  are  located  near  the  chromosomal  origin  of 
replication  (oriC)  (Ogasawara,  1992).  Zuerner  and  colleagues  (1994),  using  a 
specific probe to the gyrA gene in the B. hyodysenteriae B78
T genome, hybridized 
the gene in a fragment in common with tlyC, further narrowing down the area where 
this  gene  could  be  located.  The  DNA  gyrase  genes  (gyrA  and  gyrB)  in 
hyodysenteriae were separated by about 200-400 kbp (Figure 1.2), which is similar 
to T. pallidum with a separation of 45 kbp (Zuerner et al., 2004). According to the 
alignment  of  genetic  maps  of  B.  hyodysenteriae  B78
T  and  B.  pilosicoli  strain 
P43/6/78
T (Figure 1.4), it could be postulated that the gyrA and gyrB genes in B. 
pilosicoli strain P43/6/78
T are separated by a smaller region of DNA than occurs in 
B. hyodysenteriae.  
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      The gyrB gene of B. hyodysenteriae was isolated from a lambdaZAPII library of 
strain B204 genomic DNA and sequenced. The GyrB protein of B. hyodysenteriae 
was made up of 636 amino acids and had an estimated molecular mass of 71.16 kDa. 
This protein was smaller than the E. coli GyrB protein, which has an additional 170-
amino-acid insert at its C-terminal end. Comparison of the putative protein of this 
gene  showed  up  to  55%  peptide  sequence  identity  with  GyrB  proteins  of  other 
bacterial species including those of other spirochaetes including B. burgdorferi, T. 
denticola, and T. pallidum. Four regions of the B. hyodysenteriae protein exhibited 
high sequence similarities (48 to 60%) with E. coli GyrB. Three of these regions are 
conserved domains that differentiate bacterial GyrB proteins from homologous ParE 
proteins, which are subunits of DNA topoisomerase IV (Stanton et al., 2001). 
 
1.3.6 NADH oxidase gene 
The  NADH  oxidase  (nox)  gene  is  1.3  kb,  and  encodes  a  protein  with  an 
approximately  apparent  size  of  47  to  48  kDa  that  has  a  major  role  in  oxygen 
metabolism  in  B.  hyodysenteriae,  along  with  other  proteins  such  as  NADH 
peroxidase and superoxide dismutase (Stanton & Jensen, 1993; Stanton & Sellwood, 
1999). Brachyspirae are aerotolerant anaerobic bacteria, presumably due to the high 
specific activity of NADH oxidase which provides them with a major mechanism for 
oxygen consumption (Stanton et al., 1999). The NADH oxidase is a single-subunit, 
flavin adenine dinucleotide (FDA)-link enzyme that has optimum activity in buffers 
with  a  pH  between  5.5  and  7.0.  In  the  presence  of  oxygen,  beta-NADH,  alpha-
NADPH, or beta-NADPH is rapidly oxidized by the enzyme, and oxygen seems to 
be the only identified electron acceptor for the enzyme. The enzyme activity in B.  
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hyodysenteriae tends to produce more water from reduction of oxygen rather than 
hydrogen peroxide and superoxide (Stanton & Jensen, 1993). 
       Partially sequencing of the NADH oxidase gene (1246 bp) amongst 18 strains of 
intestinal spirochaetes from six species of the genus Brachyspira and the type strain 
513A
T of the human intestinal spirochaete B. aalborgi showed a nucleotide identity 
of 86.3-100% between strains within the genus Brachyspira, whilst the nox gene of 
B. aalborgi  shared 78.8-83.0% nucleotide identity with  the  nox sequences  of the 
various Brachyspira strains. A primer set designed for amplification of the nox gene 
from 21 strains of B. pilosicoli resulted in amplified DNA from 18 strains (Atyeo et 
al., 1999). 
      In a study carried out by Mikosza (2002), partial sequencing of the nox gene 
using DNA extracted from biopsies, faeces, and isolates of patient with B. aalborgi 
infection  showed  a  high  degree  of  genetic  variation  between  the  B.  aalborgi 
sequences  with  almost  35  polymorphism  in  413  bases  with  91.5%  identity.  In 
contrast, very little genetic variation was detected between the partial nox sequences 
of seven isolates of B. pilosicoli, with up to one polymorphism present in 464 bases 
(99.8% identity).    
 
1.3.7 Brachyspira membrane proteins and lipoproteins 
Hampson and colleagues (2006b) proposed a revision to the current nomenclature for 
Brachyspira  membrane  proteins,  lipoproteins  and  their  associated  genes.  In  their 
revised  nomenclature,  they  suggested  a  simple  set  of  guidelines  for  naming 
Brachyspira genes and their products based on abbreviation letters derived from the 
Brachyspira  genus,  nature  of  their  products  and  molecular  masses  of  the  gene 
products. Based on this new method, for B. hyodysenteriae genes and proteins, their  
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names should commence with ‗bh‘, whilst for Brachyspira pilosicoli their names 
should start with ‗bp‘, and so on for the various Brachyspira species. It would also be 
useful to distinguish between membrane proteins (mp) and lipoproteins (lp) in the 
names. They also suggested using the molecular mass of the associated protein after 
the  gene  products,  and  in  the  case  of  proteins  with  similar  mass  these  could  be 
designated  further  by  using  an  alphabetic  listing.  The  application  of  Hampson‘s 
method  of  nomenclature  for  naming  of  some  Brchyspira  genes,  proteins  and 
lipoproteins are summarised in Table 1.3.  
 
Table 1.3 The new nomenclature system for Brachyspira genes, membrane proteins, 
and lipoproteins. 
Old nomenclature  New nomenclature 
Gene 
name 
Product 
name 
Molecular 
weight  
Brachyspira 
species 
Reference 
Gene 
name 
Product 
name 
smpA, 
bmpA 
SmpA, BmpA  16 kDa  hyodysenteriae  Thomas & Sellwood11993; 
Lee et al., 2000 
bhlp16  Bhlp16 
bmpB, 
blpA 
BmpB, BlpA  29.7 kDa  hyodysenteriae  Lee et al., 2000; 
Cullen et al.,2003 
Bhlp29.7  Bhlp29.7 
vspA–H  –  39 kDa  hyodysenteriae  Gabe et al., 1998; 
McCaman et al., 1999, 
2003 
bhmp39a 
bhmp39b 
Bhmp39a 
Bhmp39b 
mglB  MglB  35 kDa  pilosicoli  Zhang et al., 2000  bplp35  Bplp35 
bmpC  BmpC  23 kDa  pilosicoli  Trott et al., 2004  bplp23  Bplp23 
 
 
1.3.7.1 The bhlp16 (bmpA or smpA) gene 
A 16-kDa membrane-associated, surface-exposed, immunodominant lipoprotein was 
first identified by Thomas and Sellwood (1992)  and the gene designated smpA. The 
gene then was renamed bmpA (Brachyspira membrane protein A) to be in agreement 
with the new genus name Brachyspira (Lee et al., 2000). Then in accordance with  
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Hampson‘s  nomenclature,  the  gene  and  its  product  were  renamed  to  bhlp16  and 
Bhlp16 respectively. 
      The  gene  bhlp16  encodes  a  16  kDa  membrane  associated  polypeptide  (outer 
membrane lipoprotein) which is common in B. hyodysenteriae strains (Thomas & 
Sellwood, 1993). The putative open reading frame of bhlp16 encodes a 16.8 kDa 
prolipoprotein, which in its fully acylated and cleaved form has a molecular mass of 
15.1 kDa. There is a signal sequence with positively charged amino acids at position 
1,  2,  and  3  that  represent  a  core  of  hydrophobic  amino  acids.  Also  in  the  open 
reading frame, there is one cysteine at amino acid position 22 from the start codon 
that is part of a potential signal peptidase II cleavage site.  
      Turner  and  colleagues  (1995)  analysed  the  distribution  of  the  bhlp16  gene 
among  40  different  strains  of  intestinal  spirochaetes  by  PCR  and  Southern 
hybridization. They used the whole bhlp16 locus from B. hyodysenteriae strain P18A 
as  a probe for Southern hybridization and internal  primers to  the locus  for PCR 
analysis.  Half  of  the  B.  hyodysenteriae  strains  possessed  a  similar  nucleotide 
sequence, although the PCR was negative for another 12 strains of B. hyodysenteriae. 
Among seven stains of B. innocens, B. intermedia, and B. murdochii, hybridization 
was weak and no PCR products were obtained. These results indicated that there is 
variation  among  bhlp16  loci  in  Brachyspira  strains.  The  bhlp16  gene  has  been 
detected in  B. pilosicoli  strain  95/1000  by PCR analysis using primers internally 
flanking the gene (Movahedi & Hampson, 2007). 
      The Bhlp16 outer membrane lipoprotein of B. hyodysenteriae strain P18A has 
been  expressed,  and  a  monoclonal  antibody  (F325  AC4)  produced  to  develop  a 
diagnostic  ELISA  for  intestinal  spirochaetes  (Sellwood  et  al.,  1995).  Using  this 
monoclonal  antibody,  the  smpA  lipoprotein  was  detected  in  cultures  of  B.  
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hyodysenteriae with a minimum density of 5 × 10
6 cells per ml, and in the faeces of 
challenged pigs containing more than 10
6 excreted spirochaetes cells per gram of 
faeces. 
      Expression of the Bhlp16 protein is environmentally regulated, with decreased 
expression  observed  in  swine  post-infection  (Sellwood  et  al.,  1995).  Monoclonal 
antibodies  generated  against  Bhlp16  agglutinate  and  prevent  the  growth  of  B. 
hyodysenteriae in vitro (Thomas & Sellwood, 1992). This may indicate the potential 
of Bhlp16 as a vaccine candidate, although no in vivo investigation of this potential 
has been reported. The function of Bhlp16 remains unknown. 
 
 
1.3.7.2 The bplp35 (MgIB) gene 
The  gene  encoding  a  36  kDa  lipoprotein  was  identified  by  screening  a  plasmid 
library of B. pilosicoli human strain SP16 genomic DNA with hyperimmune and 
convalescent swine sera (ATCC49776) (Zhang et al., 2000). The predicted amino 
acid  sequence  encoded  by  the  cloned  B.  pilosicoli  gene  had  a  high  degree  of 
similarity and identity to a glucose-galactose Bplp35 (MglB) lipoprotein. Located 
106 bp downstream of the putative bplp35 gene was a 3'-truncated open reading 
frame  with  73.8%  similarity  and  66.3%  identity  to  mglA  of  Escherichia  coli, 
suggesting a gene arrangement within an operon, which is similar to those of other 
bacteria. A single copy of the gene was present in B. pilosicoli, and homologous 
sequences were widely conserved among porcine intestinal spirochaetes including B. 
intermedia, B. innocens, B. murdochii, and an avian strain B. alvinipulli, but not in B. 
hyodysenteriae,  B.  aalborgi,  and  porcine  origin  Treponema  succinifaciens.  The 
deduced  molecular  mass  of  the  mature  Bplp35  lipoprotein  was  consistent  with 
expression by the cloned gene of a polypeptide with an apparent molecular mass of  
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36,000 Da. Because mucin is the principal constituent of the colonic mucus gel and 
consists of glycoproteins that can serve as the substrate for growth and chemotaxis of 
B. pilosicoli in vitro, a role for Bplp35 in mucosal localization of the spirochaete 
appears consistent with the pathogenesis of intestinal spirochaetosis (Zhang et al., 
2000).  
 
1.3.7.3 The bplp23 (BmpC) gene 
The gene encoding an abundant, surface-exposed 23 kDa protein was identified by 
screening a B. pilosicoli 95-1000 genome library with  mAbs (4F2, 2G3, 1G2, 2H3 
and  2E10),  and  was  expressed  in  E.  coli  (Trott  et  al.,  2004).  Sequence  analysis 
showed  that  it  encoded  a  unique  lipoprotein,  designated  Bplp23  (BmpC). 
Recombinant Bplp23 partitioned predominantly in the OM fraction of E. coli strain 
SOLR.  A  mAb  to  Bplp23  was  used  to  screen  a  collection  of  13  genetically 
heterogeneous  strains  of  B.  pilosicoli  isolated  from  five  different  host  species. 
Interestingly, only strain 95-1000 was reactive with the mAb, indicating that either 
the surface-exposed epitope on Bplp23 is variable between strains or that the protein 
is restricted in its distribution within B. pilosicoli. 
 
 
1.3.7.4 The clpX gene 
Trott  and  colleagues  (2003)    identified  a  membrane-bound  61  kDa  clip  protease 
(clpX)  homologue  in  porcine  B.  pilosicoli  strain  95/1000,  using  a  monoclonal 
antibody generated against a B. pilosicoli membrane vesicle preparation to screen a 
B. pilosicoli genome library. They described the clpX protein as an inner membrane 
protein of B. pilosicoli but with a low-density presentation in the outer membrane 
that accounted for the reactivity of the protein with the monoclonal antibody. clpX  
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ATPase  is  a  member  of  a  group  of  molecular  chaperones  involved  in  the 
conformational integrity of proteins under conditions of normal growth as well as 
under stress (Skinner & Trempy, 2001).  
 
1.3.8 Metabolism and nutrient associated genes 
Several genes encoding proteins associated with metabolism and nutrient transport 
have been localized in Brachyspira species. Most of the genes in these classes have 
been found in both B. hyodysenteriae and B. pilosicoli, and localization of these 
genes allows better resolution for comparing the two genomes (Zuerner et al., 2004). 
The location of glt, a putative transporter gene adjacent to the VSH-1 sequences in B. 
hyodysenteriae was of particular interest because it provided a landmark to compare 
the  location  of  VSH-1  insertion  in  these  two  species.  VSH-1  (virus  of  Serpulina 
hyodysenteriae), is a mitomycin C-inducible, non-lytic, phage-like agent with the 
appearance of extrachromosomal DNA, 7-8 kb in size as estimated by agarose gel 
electrophoresis  (Humphrey  et  al.,  1995;  Stanton  et  al.,  2003).  When  purified 
bacteriophages induced from cultures of B. hyodysenteriae A203 (deltaflaA1 593-
762:  cat)  were  added  to  growing  cells  of  strain  A216  (delta  nox  438-760:  kan), 
transductants (Cmr Kmr) were obtained at a frequency of 1.5 x l0 (-6) per phage 
particle. These findings indicate that induced VSH-1 virions package DNA of B. 
hyodysenteriae  and  are  capable  of  transferring  host  genes  between  cells  of 
spirochaetes and these events predate their divergence. This was the first report of 
genetic transduction of a spirochaete (Humphrey et al., 1997). The glt locus was also 
found near VSH-1 sequences in B. pilosicoli. 
 
 
1.4 VIRULENCE FACTORS OF SPIROCHAETES 
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Pathogenicity or virulence is the ability of an organism to cause disease.  Mechanism 
of  pathogenesis  or  virulence  factors  of  bacteria  refers  to  bacterial  products  or 
strategies that contribute to virulence. Virulence factors can be classified into two 
broad categories: those that promote bacterial colonisation (motility, adhesion, and 
invasion) and those that cause damage to the host (toxins and enzymes) (Salyers & 
White, 1994). Spirochaetes are capable of direct swimming through gel-like viscous 
media, such as connective tissue and mucin, which inhibit the motility of the most 
bacteria, and this allows spirochaetes to infect tissues covered with viscous media 
(Greenberg & Canale-Parola, 1977; Berg & Turner, 1979). This capability is due to 
chemotaxis, and motility involving periplasmic flagella, which are critical organs for 
spirochaetal virulence (Ruby & Charon, 1998). 
 
 
1.4.1 Motility 
Spirochaetes  demonstrate  a  corkscrew  motility,  which  works  best  in  viscous 
environments  and  is  likely  to  be  directed  by  chemotaxis  for  a  specific  substrate 
(Kennedy et al., 1988). The motility of B. hyodysenteriae is varied according to the 
nature of its environment. The spirochaetal cells are extremely motile in faeces of 
pigs with SD, whereas cells grown in agar culture are almost non-motile (Joens et al., 
1997). In contrast, spirochaetes in the early exponential phase of growth in broth 
cultures  are  extremely  motile.  The  motility  of  spirochaetal  cells  are  due  to  their 
periplasmic flagella (PF) which are inserted into the ends of the cell and overlap at 
the  middle  of  the  protoplasmic  cylinder  (ter  Huurne  &  Gaastra,  1995).  The 
periplasmic flagella rotate between the outer membrane sheath and the protoplasmic 
cylinder.  Through  a  special  structure  which  is  called  a  hook,  each  flagellum  is 
attached to a motor in the cell membrane. Rotation is powered by a proton motive 
force like other bacteria (Goulbrourne & Greenberg, 1981).  
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      Rosey and colleagues  (1995)  used targeted  mutagenesis of  flaA1 or flaB1 by 
either chromosomal or kanamycin resistance gene cassettes and allelic exchange, and 
produced mutations in B. hyodysenteriae. Both mutants exhibited altered motility in 
vitro, they were less efficient in moving through liquid medium, and they were also 
handicapped in their ability to colonize or produce lesion in the caeca of mice. 
 
1.4.2 Chemotaxis 
Little  is  known  about  chemotaxis  in  pathogenic  spirochaetes  and  its  role  in 
pathogenesis.  The  presence  of  attractants  results  in  increased  smooth  swimming 
while the presence of repellents causes increased reversal of swimming direction 
(Fosnaugh & Greenberg, 1988; Fosnaugh & Greenberg, 1989). The chemotaxis of B. 
pilosicoli porcine isolate P43/6/78
T, human isolate SP16, and canine isolate 16242-
94  was  examined  by  Witters  et  al.  (1999)  who  incubated  each  spirochaete  in  a 
control medium or a medium containing increasing concentrations of D-L serine or 
porcine  gastric  mucin  (PGM).  The  porcine  isolate  had  a  chemotactic  response 
towards  10  mM  D-L  serine,  but  not  towards  PGM.  By  contrast,  the  human  and 
canine isolates were attracted towards 0.1% PGM, but not towards DL-serine. The 
composition of the growth medium appeared to modulate the chemotactic response 
of B. pilosicoli towards PGM; the loss of a chemotactic response of spirochaetes 
grown  in  medium  without  pig  faecal  extract  was  restored  by  growing  the 
spirochaetes  in  medium  containing  0.1%  PGM.  Thus,  B.  pilosicoli  showed  a 
chemotactic response towards PGM which was modulated by the presence of certain 
substrates during the growth phase of the spirochaete. 
1.5 IMMUNE RESPONSE 
1.5.1 Humoral immunity  
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1.5.1.1 Systemic antibody response 
Little is known about the specific immune response against intestinal spirochaetes, 
especially about B. pilosicoli. While some investigations have been done on cellular 
and humeral responses to B. hyodysenteriae, so far only some minor published and 
unpublished  experiments  have  been  made  on  systemic  antibody  responses  to  B. 
pilosicoli. For instance, in an investigation carried out to identify antigens that are 
potentially involved in recovery from intestinal spirochaetosis caused by B. pilosicoli 
in  swine,  Zhang  and  colleagues  (1999)  applied  pre-immune,  hyperimmune,  and 
convalescent swine sera to the whole cell lysate and various detergent extracts of the 
human  isolate  SP16.  The  overall  results  obtained  from  Western  immunoblot 
indicated that recovery from colonic infection can educe serum IgG antibodies to 
specific  B.    pilosicoli  outer  membrane  antigens.  In  an  unpublished  examination 
carried  out  by  our  colleagues  at  Murdoch  University,  experimental  infection  of 
chicken with chicken strain of B. pilosicoli showed systemic IgG response to the 
whole cell preparation of B. pilosicoli using Western immunoblot (David Hampson, 
Murdoch University, personal communication). Due to lack of information about B. 
pilosicoli immunology the subsequent sections have been described the humeral and 
cellular immunity of B. hyodysenteriae to provide a background in this regards.  
      Pigs infected with B. hyodysenteriae have been shown to produce systemic IgA, 
IgM, and IgG (Joens et al., 1984). Since B. hyodysenteriae can produce lesions in 
surgically isolated colonic loops similar to lesion in naturally infected animals, this 
model has  been used to evaluate passive immunity against spirochaetal infection 
(Whipp,  1978).  Inoculation  of  ligated  colonic  loops  with  B.  hyodysenteriae  and 
homologous immune serum, induced passive protection while heterologous immune 
serum only reduced the severity of lesions, and normal sera provided no protection  
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(Joens et al., 1985). Heat inactivated immune serum provided weak protection in the 
segmented colonic loops. According to these results, it can be postulated that leakage 
of complement components and specific antibody into the lumen mediates protection 
against infection (Joens et al., 1985). Nuessen and Joens (1982) suggested that anti-
lipopolysaccharide (LPS) antibodies might have an important role in induction of 
protective immune responses.  
 
1.5.1.2 Colonic antibody response 
Following experimentally infection of pigs with B. hyodysenteriae, specific secretary 
IgA antibodies have been detected in colonic washings (Jenkins & Roberts, 1980). 
Parenterally  immunized  pigs  and  those  recovered  from  disease  have  shown 
significantly higher numbers of IgA, IgM, and IgG antibody secreting cell (ASC) 
specific  to  B.  hyodysenteriae  in  the  lamina  propria  compared  to  non-vaccinated, 
infected swine with acute lesions (Joens et al., 1984; Rees et al., 1989). In general, 
according to these studies, local IgG and IgM antibodies may have a protective role 
against  spirochaetal  infection,  although  Rees  et  al.  (1989)  have  suggested  that 
secretory IgA is an indication of recent exposure to the bacterial cells rather than 
representing a protective response.  
 
1.5.2 Cellular immunity 
Increases  in  circulating  monocytes,  neutrophils,  CD8α
+  cells  and  macrophages 
during  clinical  signs  of  swine  dysentery  have  been  reported  in  several  studies 
(Wilcock & Olander, 1979; Albassam et al., 1985; Jonasson et al., 2004). Jonasson et 
al.  (2006)  have  recently  described  a  two  to  threefold  increase  in  the  number  of 
neutrophils during dysentery, with a peak at the fourth day of clinical signs and at the  
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beginning of the recovery period. The migration of these neutrophils to tissues and 
their inflammatory mediators, such as prostaglandins, nitrous oxide (NO), reactive 
oxygen  species  and  hydrolytic  enzymes,  could  be  important  contributors  to  the 
oedema  and  lesions  associated  with  swine  dysentery.  This  means  the  level  of 
intestinal neutrophil response in B. hyodysenteriae-induced colitis correlates with the 
severity of intestinal macroscopic and microscopic lesions, oedema, and epithelial 
erosions  (Sacco  et  al.,  2000).  In  addition,  a  twofold  increase  in  the  number  of 
monocytes was observed during clinical signs of dysentery (Jonasson et al., 2006). 
      Greer and Wannemuehler (1989) showed that B. hyodysenteriae-derived LPS can 
induce interleukin 1 (IL-1) secretion by murine macrophages, and also an increase of 
tumor necrosis factor alpha (TNF-α) has been reported in the serum of dysenteric 
swine  following  the  onset  of  the  disease  (Nibbelink  et  al.,  1997).  Since  the 
gastrointestinal tract is sensitive to TNF-α, and macrophages are the major producers 
of TNF-α which can facilitate lesion development, it can be postulated that local IL-1 
and TNF-α  production by intestinal B. hyodysenteriae-stimulated macrophages can 
contribute to the pathology of swine dysentery (Beutler et al., 1985; Jonasson et al., 
2006).  
 
1.6 CONTROL OF INTESTINAL SPIROCHAETOSIS 
Development of effective controls for intestinal spirochaetes potential involves the 
use of improved hygiene, vaccines, antimicrobial agents, and eradication. To date, no 
efficient  vaccine  for  intestinal  spirochaetosis  has  been  developed.  Ideally,  an 
efficient  vaccine  should  prevent  shedding  of  the  organism  to  eliminate  further 
transmission  (Galvin  et  al.,  1997).    Humans  and  animals  infected  with  intestinal 
spirochaetes can be treated by administration of antibiotics (Ruane et al., 1989). 
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1.6.1 Use of antimicrobial agents  
 
Antimicrobial  therapy  aimed  at  reducing  infection  may  be  helpful  in  controlling 
intestinal spirochaetosis caused by B. pilosicoli (Ruane et al., 1989; Duhamel et al., 
1998). Neomycin and metronidazole have been used to treat intestinal spirochaetosis 
in humans (Gad et al., 1977; Cotton et al., 1984). Tiamulin, lincomycin, and the 
nitroimidazoles  are  the  most  effective  antibiotics  for  treatment  of  intestinal 
spirochaetes in swine, and these are given through the drinking water.  
      Although  antibiotic  therapy  can  be  used  for  partially  treatment  of  intestinal 
spirochaetosis,  bacterial  resistance  is  a  major  concern.  In  a  study  conducted  by 
Karlsson et al. (2004), the point mutations in positions 2058 and 2059 of the 23S 
rRNA gene was shown to cause macrolide and lincosamide resistance in Swedish 
field isolates of B. pilosicoli. They also found a few isolates with elevated minimum 
inhibitory concentration (MICs) against tiamulin. In another study of antimicrobial 
susceptibility of B. pilosicoli isolates from Swedish pig herds, resistance to tiamulin 
was  found  in  14%  (n=13)  of  the  tested  isolates.  Further  analysing  of  those  13 
resistant  isolates  by    pulsed-field  gel  electrophoresis  (PFGE)  to  assess  their 
relationships, revealed the presence of 10 different PFGE patterns (Pringle et al., 
2006).  Duhamal  and  colleagues  (1998)  demonstrated  that  less  than  half  of  B. 
pilosicoli isolates (47.4%) collected from the United States, the United Kingdom, 
and  Canada  were  susceptible  to  gentamycin,    and  the  remainder  (52.6%)  were 
resistant.  Pringle  et  al.  (2004)  examined  three  groups  of  Brachyspira  spp.  with 
reduced tiamulin susceptibility to try to define resistance mechanisms to the drug. 
Mutations were identified in genes encoding ribosomal protein L3 and 23S rRNA at 
positions proximal to the peptidyl transferase centre. In two groups of B. pilosicoli 
mutants, mutations were found at six nucleotide positions of 23S rRNA and at two  
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amino acid positions of ribosomal protein L3, while in the third group of clinical B. 
hyodysenteriae isolates, only a single mutation was detected at amino acid level of 
ribosomal protein L3. Chemical footprinting experiments show a reduced binding of 
tiamulin  to  ribosomal  subunits  from  mutants  with  decreased  susceptibility  to  the 
drug. This reduction in drug binding is likely to be the resistance mechanism for 
these strains. Hence, the identified mutations located near the tiamulin binding site 
are predicted to be responsible for the resistant phenotype.  
 
 
1.6.2 Eradication  
 
In swine, intestinal spirochaetes can be eradicated from individual farms by total 
depopulation and repopulation with animals free of the disease, or by applying a 
whole  herd  medication/sanitation  programme  without  depopulation  (Harris  & 
Lysons, 1992). Heinonen et al. (2001) successfully eradicated B. pilosicoli from a 
small  herd  of  swine  using  200  p.p.m.  tiamulin  in  their  feed  for  18-30  days. 
Unfortunately re-infection is likely to occur through contamination from wiled birds 
or rodents. 
 
1.6.3 Vaccines for Brachyspira infections  
1.6.3.1 Killed vaccines 
Currently, whole cell bacterins have not been particularly effective for the control of 
infections  with  Brachyspira  species.  For  example,  formalinised  whole  cell  B. 
hyodysenteriae  bacterin  failed  to  protect  pigs  from  disease,  while  a  commercial 
vaccine consisting of a proteinase-digested bacterin  showed partially efficacy in the 
reduction of disease due to B. hyodysenteriae (Waters et al., 1999). Pigs vaccinated 
with  a  whole  cell  B.  pilosicoli  bacterin  similarly  were  not  protected  following  
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experimental infection with B. pilosicoli (Hampson et al., 2000). Interestingly, Olson 
et al (1994)  showed that swine vaccinated with bacterin developed clinical sign 
earlier, had more severe disease, and died sooner than unvaccinated control animals. 
It could be concluded that parenteral vaccine do not provide sufficient protection 
against  disease,  and  also  that  sometimes  vaccination  may  induce  a  damaging 
hypersensitive immune response. 
 
1.6.3.2 Attenuated vaccines 
Jenkins  et  al.  (1987)  showed  that  oral  immunization  with  an  avirulent  B. 
hyodysenteriae strain could provide partial protection against colonisation with B. 
hyodysenteriae.  Later,  several  studies    were  carried  out  to  develop  genetically 
attenuated  strains  using  different  site  mutations  in  a  virulent  strain  of  B. 
hyodysenteriae (ter Huurne et al., 1992; Hyatt et al., 1994; Rosey et al., 1995; Rosey 
et al., 1996; Stanton et al., 1999; Stanton et al., 2001). ter Huurne et al., (1992) 
prepared a mutant of B. hyodysenteriae through the disruption of the tly gene which 
is responsible for haemolysin activity. Mice infected with the tly
- mutant had fewer 
caecal lesions than mice infected with the wild-type B. hyodysenteriae. 
      The construction of  specific  periplasmic flagellar single mutations  (flaA1 and 
flaB1) resulted in in vitro motility alteration and less efficiency in movement through 
a liquid medium; furthermore, the dual flagellar mutant was severely attenuated in 
murine  challenge  experiments  (Rosey  et  al.,  1995;  Rosey  et  al.,  1996).    Mutant 
strains deficient in NADH oxidase activity were at least 100-fold more sensitive to 
oxygen  exposure  than  the  wild-type  parent  strain  of  B.  hyodysenteriae.  In  swine 
experimental infections, the nox mutants were less virulent, with less colonisation 
than a wild strain, and infected animals displayed mild, transient signs of disease,  
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with no deaths (Stanton et al., 2001). To date none of the constructed mutants has 
produced  a  sufficient  immune  response  to  protect  animals  against  intestinal 
spirochaetes. 
 
1.6.3.3 Recombinant subunit vaccines 
The first attempt to produce a recombinant subunit vaccine against B. hyodysenteriae 
was carried out by Gabe et al. (1995) who prepared a 38-kDa FlaB1 recombinant 
protein.  Swine  vaccinated  with  recombinant  FlaB1  were  not  protected  from  an 
experimental challenge. Subsequently, several studies were undertaken to develop 
and  evaluate  recombinant  protein  based  vaccines  against  disease  caused  by  B. 
hyodysenteriae (Joens et al., 1993; Lee et al., 2000; La et al., 2004).  
      Lee et al. (2000) prepared a recombinant E. coli clone of BmpB, which was  
formalinised  and  used  for  vaccination  of  pigs.  Sera  from  the  immunized  pigs 
recognized  a  30  kDa  lipoprotein  in  outer  membrane  preparations  of  B. 
hyodysenteriae. In a more recent study, this 29.7 kDa outer-membrane lipoprotein of 
B. hyodysenteriae (BmpB) was  expressed in E. coli as  a histidine-tagged protein 
(His6-BmpB), or as an eight-kDa carboxy-terminal portion fused to maltose-binding 
protein  (MBP-BmpB-F604).  Vaccination  of  pigs  with  these  two  recombinant 
proteins followed by oral challenge resulted in development of disease in 50-60% of 
un-vaccinated controls and in 17-40% of His6-BmpB vaccinated pigs, while pigs 
vaccinated with MBP-BmpB-F604 showed no serum titres against BmpB, nor were 
they  protected  (La  et  al.,  2004).  The  results  of  using  BmpB  are  promising,  and 
encourage further use of this approach to generate a protective immune response 
against intestinal spirochaetosis. 
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1.6.3.4 DNA vaccines 
The B. hyodysenteriae ftnA gene which encodes a putative ferritin protein (FtnA) was 
delivered either as DNA or as a recombinant subunit vaccine in a mouse model of B. 
hyodysenteriae infection. Vaccine efficacy was monitored by caecal pathology and 
quantification of B. hyodysenteriae numbers in the caeca of infected mice using real-
time PCR. Although both the DNA and recombinant protein vaccines were able to 
generate antigen specific antibody responses in the vaccinated mice, none of these 
mice were protected from disease (Davis et al., 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7 THE “REVERSE VACCINNOLOGY APPROACH”  
1.7.1 Introduction  
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Within the last decade, a combination of recombinant DNA technology and whole 
genome  sequencing  of  bacteria  has  led  to  new  approaches  to  vaccine  design 
(Scarselli et al., 2005), and a genome based generation of vaccines is appearing. 
Genomic  data  now  readily  can  be  used  to  help  identify  proteins  encoded  by  a 
microorganism, and these can be screened to find potential vaccine candidates. This 
genomic approach to vaccine development has been termed ―reverse vaccinology‖ 
(Rappuoli, 2000b; Mora et al., 2003) and, together with associated technology are 
illustrated in Figure 1.5.  
      The reverse vaccinology approach starts from the whole genomic sequence, and 
through computer analysis or other genomic approaches, predicts those proteins that 
are most likely to be good vaccine components. The approach is widely applicable 
as, at the time of writing, 717 complete and 75 incomplete bacterial genomes and 
426  completed  and  uncompleted  genomes  of  other  microorganism  are  already 
publicly  available  in  the  Genomes  OnLine  database 
(http://wit.integratedgenomics.com/GOLD/), and the genome sequences of more than 
370  microorganisms  are  available  in  the  CBS  genome  atlas  database 
(http://www.cbs.dtu.dk/services/GenomeAtlas).  The  total  number  of  completed 
bacterial  genome  sequences  has  more  than  doubled  over  the  past  two  years. 
Furthermore,  with  the  availabilities  of  new  sequencing  technologies  it  is  now 
possible at a relatively low cost to determine the complete genome sequence of a 
pathogen  in  a  matter  of  weeks  (and  less  than  a  day  for  one  sequenced  E.  coli 
genome). Hence the lack of availability of genomic sequence is no longer a major 
constraint  to  taking  this  new  approach  to  vaccine  development.  In  this  literature 
review, emphasis is placed on the potential of reverse vaccinology to identify new 
bacterial molecules for use in recombinant vaccines for bacterial pathogens.  
 
46 
 
1.7.2 The application of reverse vaccinology in vaccine design  
The  reverse  vaccinology  approach  using  in  silico  analysis  of  a  whole  bacterial 
genome was first applied to identify antigens as potential candidates for a vaccine 
against  serogroup  B  meningococcus  (Rappuoli,  2001).  Meningococcal  meningitis 
and  septicaemia  caused  by  Neisseria  meningitidis,  a  Gram-negative  capsulated 
bacterium, is  a severe disease that potentially  can kill  children and  young adults 
within hours. The occurrence of sequence variation in surface-exposed proteins and 
cross-reactivity of the serogroup B capsular polysaccharide with human tissues and 
its capacity to induce auto-antibodies, has made the use of capsular polysaccharide as 
the  basis  of  a  vaccine  problematic.  Therefore,  the  genome  mining  approach  to 
vaccine  development  was  a  good  alternative  way  to  select  genes  that  encode 
potentially  protective  products,  and  to  design  an  efficient  vaccine  against 
meningococcal meningitis (Tettelin et al., 2000). 
      Using this approach, 570 open reading frames (ORFs) were deduced from the 
whole genome sequence of a virulent serogroup B strain (MC58) using computer 
analysis. A subset of these, consisting of genes predicted to encode  70 predicted 
lipoproteins,  96  periplasmic  proteins,  87  inner  membrane  proteins,  45  outer 
membrane proteins, and 52 proteins with uncertain prediction, were expressed in E. 
coli.  The  recombinant  proteins  were  purified  and  used  to  immunize  mice. 
Immunogenicity  analysis  was  undertaken  using  enzyme-linked  immunosorbent 
assays  (ELISA)  with  the  mouse  sera.  Fluorescence  activated  cell  sorter  (FACS) 
analysis was used to detect and screen proteins that were present on the surface of a 
set of MenB strains selected to represent the diversity of invasive strains within the 
natural population of this species. In addition, antisera were tested for bactericidal  
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activity,  a  property  that  correlates  with  protection  in  the  host.  Ninety-one  novel 
surface-exposed  proteins  were  identified,  29  of  which  induced  bactericidal 
antibodies. Finally, the sequence variability of the potential vaccine candidates was 
evaluated among multiple isolates and serogroups of N. meningitidis to select five 
conserved proteins for vaccine design (Pizza et al., 2000).  
      The  MenB  vaccine  candidate  discovery  programme  using  the  reverse 
vaccinology approach has opened the gates for creative methods in vaccine discovery 
for other bacterial pathogens. A recent example of applying a reverse vaccinology 
approach in the field of veterinary bacterial vaccine design is the identification of 
eight  protective  proteins  which  were  potentially  exposed  on  the  surface  of  the 
bacterium Dichelobacter nodosus, the causative agent of ovine footrot (Myers et al., 
2007). Ovine footrot is a highly contagious disease of the feet of sheep that leads to 
severe  lameness  and  subsequent  losses  in  wool  and  meat  production. The  whole 
genome of the virulent serogroup G of D. nodosus strain VCS1703A (1.4 Mb) was 
shotgun sequenced. Amongst 1,299 predicted protein-coding genes in  D. nodous, 
1,032 genes were similar to those encoding known proteins, 131 were conserved 
hypothetical, and 136 genes were hypothetical. Using bioinformatics screening tools, 
the genes encoding 99 predicted surface-exposed or secreted protein candidates were 
identified,  and  87  genes  were  successfully  cloned  and  expressed.  Purified 
recombinant proteins were screened against pooled immune and pre-immune sheep 
sera, and eventually eight potential protective proteins were selected for development 
of a novel recombinant vaccine.  
     Other  examples  of  bacterial  pathogens  that  have  been  studied  using  reverse 
vaccinology  include  Bacillus  anthracis  (Ariel  et  al.,  2002),  Streptococcus 
pneumoniae  (Wizemann  et  al.,  2001),  Staphylococcus  aureus  (Etz  et  al.,  2002;  
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Vytvytska  et  al.,  2002),  Chlamydia  pneumoniae  (Montigiani  et  al.,  2002), 
Porphyromonas gingivalis (Käsbohrer et al., 1990), Edwardsiella tarda (Srinivasa 
Rao et al., 2003 ) (Srinivasa Rao et al., 2003 ), Mycobacterium tuberculosis (Betts, 
2002),  and  Leptospira  interrogans  (Marcia  Gamberini  et  al.,  2005).  In  our  own 
laboratory  we  are  using  this  approach  to  develop  new  recombinant  vaccines  for 
enteric infections in pigs and poultry caused by intestinal spirochaetes of the genus 
Brachyspira. 
 
1.7.3 Advantages and disadvantages of reverse vaccinology 
There are a number of novel features in the reverse vaccinology approach that have 
helped to stimulate interest in its application, including in vaccine research projects 
that  have  been  partially  or  totally  abandoned  because  of  failures  in  previous 
approaches  (Grandi,  2001).  Using  the  genome  sequence,  the  analysis  begins  by 
selecting virtually all relevant proteins that a pathogen can express either in vivo or in 
vitro, without prior knowledge of their abundance, immunogenicity or expression 
during infection. Theoretically, all genes of a pathogen can be analysed when a high 
throughput system is available to screen them for expression and immunogenicity. 
Some limiting steps include a lack of algorithms that can be used to make a good 
correlation  between  antigens  and  their  likely  protection  immune  responses,  an 
inability  to  identify  non-protein  antigens  including  polysaccharides  or  CD1- 
restricted  antigens  such  as  glycolipids,  and  finally  a  potential  lack  of  available 
methods to measure in vitro efficacy instead of using an animal model of efficacy 
(Rappuoli, 2001).                 
 
1.7.4 Genome-based approaches: strategies in vaccine design  
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The availability of a complete genome sequences can be used for the following three 
experimental strategies: (1) in-silico analysis, (2) functional genomics, and (3) a pan-
genomic  approach  (Figure  1.5).  The  three  strategies  consist  of  four  steps:  (1) 
selection of a set of genes from the whole genome; (2) high throughput cloning and 
expression of the selected genes; (3) purification of the recombinant proteins; and (4) 
in vitro and in vivo assays for identification of protective candidates (Grandi, 2001).       
      For in silico analysis, a set of bioinformatics algorithms is applied typically to 
identify genes encoding proteins that are surface exposed, secreted or are virulence 
factors,  as  these  are  considered  to  be  the  most  important  molecules  in  inducing 
protective immune responses. After selection, the genes are cloned and expressed in 
heterologous systems. The recombinant proteins are then purified and used for in 
vitro and in vivo immunogenicity assays for identification of protective candidate 
molecules. 
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Figure 1.5  Interplay between the different approaches in reverse vaccinology for 
vaccine design. A set of potential antigens can be identified by: (1) in silico analysis 
of the genome sequences, using algorithms that can predict genes encoding surface-
exposed,  secretory  and  virulence  antigens;  (2)  functional  genomics  approaches, 
including DNA microarray, in vivo expression technology (IVET), in vivo induced 
antigen  technology  (IVIAT),  signature-tagged  mutagenesis  (STM),  all  aimed  at 
identifying  virulence  factors,  and  proteomics  techniques  to  identify  membrane-
associated  proteins;  and  (3)  pan-genomic  approach,    comparing    more  than  one 
genome for the same bacterial species to overcome  problems represented by gene 
presence and variability between  isolates of the species. 
 
1.7.4.1 In silico analysis for detection of virulence factors 
  
In  practice,  virulence  factors  either  alone  or  in  combination  with  other  bacterial 
components are constituents of many of the current vaccine formulations. For this 
reason,  the  search  for  virulence  associated  factors  of  bacterial  pathogens  is  
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considered to be an important step in vaccine discovery. In general, there are several 
approaches available to identify virulence genes.  
      Comparison of the predicted coding sequence with the known genes in a database 
using a BlastP or BlastN homology search tools are a convenient way to identify a 
putative virulence gene. Blast programmes allow functional annotation of a set of 
genes derived from a pathogen genome and recognize motifs that they share with 
genes of known function. Since typically 20% of the predicted ORFs in a genome do 
not match anything in the databases, and an additional 15-20% have homologies with 
genes of unknown function, Blast sequence comparison cannot be used for prediction 
of new families of virulence factors (Grandi, 2001). 
      Another  approach  to  assigning  new  virulence  genes  is  searching  for 
pathogenicity islands (PAIs). Typical PAIs are distinct regions of DNA (10-200 kb in 
size)  that  are  present  in  the  genome  of  pathogenic  bacteria  but  absent  in  non-
pathogenic strains of the same or related species. PAIs usually harbour one or more 
virulence genes that are frequently interspersed with other mobility elements, such as 
insertion sequence (IS) elements. A characteristic feature of PAI is that the mol % G 
+ C content differs from that of the core genome. The reason for this variation is not 
known,  but  it  is  believed  that  the  horizontally  acquired  PAI  still  has  the  base 
composition of the donor species. This feature is often used to identify new PAIs. 
PAIs are usually located adjacent to tRNA genes because these act as anchor points 
for  insertion  of  foreign  DNA  that  has  been  acquired  by  horizontal  gene  transfer 
(HGT). After acquisition, a DNA fragment that contains a tRNA gene can insert into 
the  recipients  genome  by  recombination  between  the  tRNA  genes.  Some 
bacteriophages that are able to transfer bacterial virulence genes as passengers in 
their  genomes  also  use  tRNA  genes  as  specific  insertion  points  in  the  bacterial  
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genome. PAIs are usually associated with mobile genetic elements. They are often 
flanked by direct repeats (DR) that are defined as DNA sequences of 16 to 20 bp 
with  a  perfect  or  nearly  perfect  sequence  repetition  (Schmidt  &  Hensel,  2004). 
Therefore, the differences in the G + C content of PAIs, the presence of tandem 
repeats,  the association  of PAIs  with  tRNA genes,  and the presence of integrase 
determinants and other mobility loci are useful clues in the search for new virulence 
genes. Once a potential virulence gene is identified, its function can be assessed for 
example  by  gene  inactivation  studies  coupled  with  using  the  mutated  strain  in 
experimental in vitro or in vivo assays that correlate with disease production. The 
products  of  virulence  genes  can  be  used  as  recombinant  vaccine  components,  or 
alternatively strains with inactivated virulence genes potentially could be used as the 
basis of rationally attenuated live vaccines. 
 
1.7.4.2 In silico analysis for detection of secreted or surface-associated proteins 
Since secreted or surface proteins are the most easily accessible microbial antigens to 
the immune system, they are favoured candidates for vaccine development (Zagursky 
& Russell, 2001). Several computer programmes are now available to search for 
gene products with a subcellular localization spanning the cytoplasm to the outer 
membrane, according to their special structures and signatures (eg. secretory leader 
sequence, transmembrane helices) that are related to secreted or surface proteins.  
      PSORTb  (http://www.psort.org/psortb/)  is  an  expert  tool  for  predicting  the 
location of proteins in Gram negative bacteria (Nakai, 2000). This programme can 
predict the location of a protein in one of four subcellular regions; the cytoplasm, 
cytoplasmic membrane, periplasm, and outer membrane or extracellular space, with 
an  accuracy  of  83%.  SignalP  (http://www.cbs.dtu.dk/services/SignalP/)  is  another  
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predictive tool to determine the presence and location of signal peptidase I (SPaseI) 
cleavage  sites  within  the  N-terminal  70  amino  acids  of  secreted  proteins  in 
eukaryotes,  Gram-negative  and Gram-positive bacteria.  The accuracy of cleavage 
site prediction by this programme is about 90 percent for Gram-negative bacteria 
(Bendtsen et al., 2004). SpLip is a novel and sensitive algorithm for the prediction of 
spirochaetal lipoproteins (Setubal et al., 2006). This algorithm appears to be more 
accurate than other programmes such as Psort and LipoP algorithms for detecting the 
presence and location of signal peptidase II (SPaseII) cleavage sites in lipoproteins of 
spirochaetes. The lipoproteins must have a cysteine after the cleavage site, whereas 
the SPaseI-cleaved signal peptide can have several different amino acids in the first 
position  after  the  cleavage  site.  TMpred 
(http://www.ch.embnet.org/software/TMPRED_form.html)  is  an  algorithm  for 
detection  of  N-terminal  transmembrane  helices.  Other  useful  signatures  for 
membrane-associated  proteins  are  the  presence  of  aromatic  residues  at  the  C-
terminus of proteins and the Leu (Ala/Val) - Leu-Ala (Ser) - Gly (Ala) - Cys motif at 
the N-terminus of lipoproteins (in the three letter amino acid code, where Cys is the 
first amino acid of the mature protein) (Grandi, 2001). 
 
 
 
1.7.4.3 Functional genomics in vaccine design 
Functional  genomics  is  the  functional  expression  of  an  organism‘s  genomic 
information.  This  is  determined  using  wide  experimental  computational/statistical 
approaches, which are involved in many processes where genes, RNAs, proteins, and 
metabolites interact with each other (Figure 1.6). The aim of functional genomics is  
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Genotype 
to reveal the link between a specific genotype and its corresponding phenotype. The 
phenotype results from the expression of genes through conversion into systemic, 
catalytic,  and  regulatory  products,  and  is  a  complex  function  of  genotype  and 
environment (Dharmadi & Gonzalez, 2004). Knowledge of functional genomics can 
assist in the selection of appropriate bacterial vaccine components. 
 
1.7.4.3.1 Proteomics 
For most bacterial pathogens, those proteins that are located outside the bacterial 
membrane  are  very  important  in  inducing  immune  responses.  Although 
bioinformatics  tools  can  predict  the  cellular  location  of  bacterial  proteins  using 
homology searches, they are not capable of providing a perfect indication of protein 
subcellular  localization.  In  addition,  the  expression,  quality  and  quantity  of  cell 
surface  protein  composition  vary  due  to  environmental  pressures  and  host 
metabolism (Grandi, 2001). Therefore, it is often difficult to predict the function of a 
protein  based  on  homology  to  other  proteins,  or  even  their  three-dimensional 
structure.  
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Figure  1.6  High  throughput  approaches  in  protein  targeting  and  vaccine 
development. High-speed DNA sequencing is now linked with transcriptome, and 
proteome profiling to enable rapidly discovery of vaccine candidates. 
 
       The  high-throughput  capacity  of  mass  spectrometry  (MS),  coupled  with  two 
dimension gel electrophoresis (2-DE) separation of proteins, and genome sequencing 
has  introduced  a  new  research  field  (proteomics)  which  allows  quantification  of 
protein expression and decoding of the mechanisms of gene expression control in 
biological processes (Figure 1.6) (Thongboonkerd & Klein, 2004).  
      Proteomics  can  be  divided  into  three  main  areas:  1)  ―protein  micro-
characterization‖, which  deals with large-scale identification of proteins and their 
post-translational  modifications;  2)  ―differential  display‖  proteomics,  a  way  to 
compare protein quantities and investigate the pathogenicity of  pathogens in regards 
to their protein expression levels; 3) ―protein-protein interactions‖ using techniques 
such  as  mass  spectrometry  (Pandey  &  Mann,  2000).  These  three  applications  in 
conjunction with the characterization of membrane and surface-associated proteins 
are particularly important for vaccine development (Serruto et al., 2004).  
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     In  the  proteomics  approach  to  bacterial  vaccine  development,  either  the  total 
bacterial  proteins  or  preferably  extracted  surface  proteins  (surfaceome)  are  first 
resolved  into  their  individual  components  using  2-DE.  Each  separated  protein  is 
digested into its discrete peptide fragments using a suitable enzyme, the molecular 
mass of each proteolytic digested fragment is then accurately measured using matrix-
assisted  laser  desorption/ionization  time-of-flight  mass  spectrometry  (MALDI-
TOFMS). Finally the generated peptide-mass fingerprint of proteolytic peptides is 
used as an input to a database search of predicted masses that would arise from 
digestion of a list of known proteins. If a protein sequence in the reference list gives 
rise to a significant number of predicted masses that match the experimental values, 
there is some evidence that this protein was present in the original sample (Grandi, 
2001; Hernandez et al., 2006). This comparison allows identification of about 70-
80% of the analysed proteins, and the remaining 20-30% with no hits in the database 
can  be  identified  using  tandem  mass  spectrometry,  which  provides  sequence 
information on the proteolytic peptides (Grandi, 2001). The proteomic approach is 
severely limited by the large number of proteins expressed by the pathogen under in 
vitro growth conditions (Etz et al., 2002). 
       In  order  to  characterize  the  surface  proteins  of  Chlamydia  pneumoniae, 
Montigiani et al. (2002) used the approach of genomics combined with proteomics. 
The authors purified 124 recombinant proteins, which were used to raise antibodies 
to test for their ability to bind to the surface of chlamydial cells in a fluorescence-
activated cell sorter (FACS) analysis. This led to the identification of 53 putative 
surface-exposed proteins. To confirm the specificity of the sera used in the FACS 
analysis, total proteins from elementary body preparations were separated by 2-DE, 
and subjected to Western blot analysis. The positive spots were then analysed by  
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mass spectrometry. This approach allowed the identification of 28 surface-exposed 
proteins suitable for a novel vaccine. 
      Another example where proteomics has been used to study bacterial pathogenesis 
and identification of  vaccine  candidates  is  the  construction of a two-dimensional 
database of the proteome of H. influenzae. The whole genome sequence consists of 
about 1742 open reading frames. Langen et al. (2000) analysed the soluble protein 
fraction of H. influenzae by 2-DE. To visualize low-copy-number gene products, a 
series  of  protein  extraction  and  several  chromatographic  steps,  including  heparin 
chromatography,  chromatofocusing  and  hydrophobic  interaction  chromatography 
were applied. Five hundred and two different proteins were identified by MALDI-
TOFMS and amino acid composition analysis.  
      The combination of proteomics with serological analysis [SERological Proteome 
Analysis (SERPA)] was used by Vytvytska et al. (2002) for identification of vaccine 
candidates against Staphylococcus aureus. In SERPA the bacterial surface proteins 
were first resolved by 2-DE and then electro-transferred onto a membrane which was 
blotted  with  different  serum  pools  from  humans  with  S.  aureus  infections.  This 
approach identified a set of highly immunoreactive staphylococcal proteins. Twenty 
one spots were analysed by MALDI-TOFMS and 15 proteins, including known and 
novel vaccine candidates, were identified (Vytvytska et al., 2002).  
 
 
1.7.4.3.2 DNA microarray analysis 
Microarray technology can be used to study the transcriptional response of bacteria 
to  a  variety  of  environmental  stresses  (such  as  heat  shock,  starvation,  serum 
treatment and contact with eukaryotic cells), to capture the transcriptome of bacteria  
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growing within infected cells, tissues or animal models, and to evaluate mutations or 
key factors in regulatory and metabolic pathways (Bryant, 2004; Claus et al., 2007). 
Whole genome microarrays are usually hybridized with cDNA that is prepared from 
extracted RNA of a microorganism grown under different growth conditions (eg in 
vivo versus in  vitro growth). Gene expression then can be analysed in either the 
pathogen or the host, thus allowing investigation of both sides of the host–pathogen 
interaction (Rappuoli, 2000a).  
       The use of DNA microarrays is also a powerful technology for investigating 
genotype,  genome  diversity  and  relatedness  of  bacteria,  via  comparative  genome 
hybridization (CGH) (Bryant, 2004; Serruto & Rappuoli, 2006). In particular, the 
comparative  genomic  hybridization  (CGH)  approach  circumvents  the  need  for 
sequencing multiple closely related genomes to determine whether particular genes 
encoding candidate vaccine components are widely distributed through the species. 
Briefly, through differential hybridization of probes generated from a test genomic 
DNA, for which the sequence is available, CGH reveals regions of loss (or retention) 
with respect to the reference strain. Owing to its intrinsic technical limitations, CGH 
analysis necessarily fails to detect acquisition events with respect to the reference 
strains. However, the increasing number of CGH studies directed towards detecting 
gene presence or absence profiles in bacterial populations (Schoolnik, 2002; Bryant, 
2004) permits a more accurate evaluation of the genetic stability of a great number of 
bacterial pathogens (Scarselli et al., 2005; Serruto & Rappuoli, 2006). 
      The first example where microarray technology was successfully used to identify 
potential vaccine candidates, as well as new virulence genes, was in the case of N. 
meningitidis, where gene regulation was studied after interaction of N. meningitides 
to human epithelial cells (Grifantini et al., 2002). RNA was isolated from adherent  
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and non-adherent bacteria and comparatively analysed on DNA microarrays carrying 
the entire collection of PCR-amplified meningococcus B genes. The authors found 
that bacterial adhesion to epithelial cells altered the expression of approximately 350 
genes: 189 genes were up-regulated and 151 genes were down-regulated. Most of the 
regulated genes could be grouped into five major categories: adhesion genes; host–
pathogen cross-talk genes; amino acid and selenocysteine biosynthesis genes; DNA 
metabolism genes; and hypothetical genes. Moreover, of the 12 adhesion induced 
surface-exposed antigens identified, five were able to induce bactericidal antibodies. 
None of the 12 genes identified by transcriptional profiling were identified by in 
silico mining of strain MC58. In conclusion, the study showed that DNA microarray 
technology can be used to identify potential vaccine candidates, and complements 
other genome mining methods.       
      Although DNA microarrays can be used to study the transcriptional response of 
many organisms to genetic and environmental changes, there are some limitations to 
this technology: 
1. Since most bacterial RNAs have been extracted from microorganisms grown 
in  vitro,  the  microarray  expression  profiles  cannot  reveal  the  true  in  vivo 
interactions between host and pathogen (Grandi, 2001). 
2.  The use of DNA microarrays is a semiquantitatve method due to the lack of 
linearity  and  proportionality  of  mRNA/cDNA  concentration  to  signal 
intensity at high concentration.  
3.  An inherent limitation of DNA microarrays is that the resulting transcriptome 
does not account for post-transcriptional events.  
4.  The processing and analysis of transcriptome data remains a bottleneck.  
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Overall,  the  DNA  microarray  technologies  in  conjunction  with  other 
genome/system-wide  analyses  (e.g.,  proteomics,  metabolomics,  fluxomics, 
phenomics, etc.) can be used to provide a useful assessment of genotype-phenotype 
relationships in bacteria (Dharmadi & Gonzalez, 2004). 
 
1.7.4.3.3 Other technologies 
Somewhat  older  technologies  exist  that  can  complement  the  newer  genomic 
techniques  to  a  greater  or  lesser  extent.  These  include  1)  in  vivo  expression 
technology (IVET), where virulence genes that are transcriptionally induced during 
infection can be identified (Mahan, 1993);  2) signature tagged mutagenesis (STM), 
where microbial genes essential for growth and infection within an animal host, or 
within host cells are identified (Hensel et al., 1995); and 3) in vivo induced antigen 
technology (IVIAT) where gene products of a pathogen that are expressed in vivo 
and which are targeted by the host immune system are identified (Handfield, 2000). 
These methods can help to identify virulence factors, gene products that are essential 
in microbial survival in the host, and/or gene products that naturally induce a strong 
immune  response.  Such  information  potentially  could  be  used  to  identify  new 
molecules for subunit vaccines, or could help in the development of live avirulent 
vaccines. These techniques are somewhat slow and technically demanding, but the 
availability of whole genomic can greatly improve their potential by assisting the 
design  of  gene  libraries  intended  for  experimental  screening,  as  well  as  rapid 
identification of genes by short-fragment sequencing (Scarselli, 2005). Hence these 
techniques can have a role in complementing the basic reverse vaccinology approach 
to vaccine development.  
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1.7.4.4 The pan-genomic approach in vaccine design 
Although  many  bacterial  genomes  have  been  sequenced,  sequences  of  different 
strains or isolates from a given bacterial species are rarely available. The genomic 
sequence  of  a  single  strain  provides  a  huge  potential  resource  to  determine 
relationships  between genotype and phenotypes within the species, but  it fails to 
differentiate genetic variation between strains (eg avirulent and virulent strains), and 
subsequent determination of the most useful potential vaccine candidates (Serruto & 
Rappuoli, 2006).  
      Identification of vaccine candidates  against infection caused by  Streptococcus 
agalactiae, a group B streptococcus (GBS), was a successful example of applying 
multiple genomic approaches in vaccine design. GBS is responsible for infection and 
death in human infants, and also mastitis in cattle. Several DNA microarray analyses 
revealed that one genome sequence was insufficient to develop a universal vaccine 
against GBS (Schuchat & Wenger, 1994; Tettelin et al., 2002). Therefore a pan-
genomic approach using all available genome sequences of Strept. agalactiae was 
used  to  compare  the  different  whole  genomes  and  divide  the  genome  into  two 
subgenomes: a core genome containing genes present in all strains, and a dispensable 
genome composed of genes absent from one or more strain, including genes that are 
unique to each strain (Tettelin et al., 2005). While the core genome usually contains 
genes  which  are  responsible  for  the  basic  bacterial  metabolisms,  the  dispensable 
genome  includes  genes  that  are  responsible  for  genetic  diversity,  pathogenicity, 
colonisation, and antibiotic resistance (Medini, 2005).  
      Through the application of the pan-genome concept to GBS vaccine discovery, 
using  bioinformatics  algorithms,  amongst  the  identified  putative  surface-exposed 
proteins, 396 were encoded by core genes and 193 were from variable genes. Nearly  
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half of the identified genes were expressed in E. coli as soluble recombinant proteins. 
The purified proteins then were evaluated for identification of a protective immune 
response.  Of  four  antigens  which  were  capable  of  inducing  a  strong  immune 
response, only one, the Sip protein, was part of the core genome. Each of the genes 
encoding the other three antigens was present in approximately 75% of strains. When 
the four antigens were given simultaneously as a vaccine, nearly universal protection 
was  observed  against  challenge  with  a  panel  of  strains  representing  the  major 
pathogenic GBS serotypes (Brodeur et al., 2000; Maione et al., 2005).  
       The successful use of multi-strain genome analysis and the screening described 
for GBS provides the basis for the potential development of universal protein-based 
vaccines against other important and highly variable bacterial pathogens. The pan-
genome  concept  has  shown  that  the  initial  strategy  of  sequencing  one  or  two 
genomes per species is not necessarily sufficient, and that multiple strains may need 
to be sequenced to understand the basics of bacterial species and to overcome the 
problem represented by gene variability (Mora et al., 2005; Barocchi et al., 2006).  
      In  another  example,  the  pan-genomic  approach  was  used  to  select  potential 
candidates for a recombinant subunit vaccine against rickettsial septicaemia (SRS) in 
fish  caused  by  Piscirickettsia  salmonis.  Through  a  comparison  of  P.  salmonis 
genomes, 15 ORFs encoding heat shock proteins, virulence factors, membrane bound 
and  other  surface  exposed  antigens  were  selected  and  expressed.  From  seven 
promising  antigens,  three  different  combinations  of  two  or  three  antigens  were 
formulated  for  an  efficacy  trial.  Finally,  the  formulation  containing  recombinant 
chaperonines Hsp60, Hsp70 and flagellar protein FlgG of P. salmonis achieved the 
highest level of protection, with a relative percent survival (RPS) of 95% (Wilhelma 
et al., 2006).  
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1.8 AIMS, OBJECTIVES AND HYPOTHESIS OF THE PROJECT 
 
To  date,  attempts  to  develop  an  efficient  bacterin  vaccine  against  intestinal 
spirochaetosis (IS) caused by B. pilosicoli have failed. The availability of advanced 
whole genome sequencing techniques and sequence analysing using bioinformatics 
tools  in  conjunction  with  other  molecular  biological  techniques  such  as  DNA 
microarray, in vitro and in vivo expression technology, and pan-genomic concept, 
have facilitated discovery of  vaccine antigens discovery and enabled researchers to 
create  new approaches in the era of vaccine development which is called ―reverse 
vaccinology‖.  This  new  concept  of  vaccine  discovery  was  applied  in  the  current 
study to identify the potential protective antigens to formulate a possible recombinant 
subunit vaccine against intestinal spirochaetosis caused by B. pilosicoli. 
     Therefore, the main aim of this project was to develop a subunit recombinant 
vaccine  for  B.  pilosicoli,  using  available  whole  genome  sequence  data  that  has 
recently  become  available  in  our  laboratory.  In  order  to  achieve  this  aim,  the 
objectives of this study were as follows: 
 
1) To apply bioinformatics algorithms on a semi-complete genome sequence of B. 
pilosicoli  to  identify  a  set  of  genes  encoding  proteins,  including  surface-exposed 
outer membrane proteins, transmembrane proteins, and secreted proteins.  
2) To analyse the distribution of the selected genes amongst different strains of B. 
pilosicoli to select genes that are well distributed. 
3)  To  clone  the  well-conserved  genes  in  proper  vectors  and  produce  their 
recombinant proteins.  
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4) To evaluate the immunogenicity of the purified proteins using in vitro and in vivo 
assays to select highly immunogenic proteins.  
5) To evaluate the efficacy of the selected proteins in an experimental animal model 
and  determine  their  potential  for  use  in  a  possible  recombinant  subunit  vaccine 
against intestinal spirochaetosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
2.1 INTRODUCTION  
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Prior  to  the  commencement  of  the  current  work,  the  genome  of  Australian  B. 
pilosicoli  strain  95/1000,  a  virulent  strain  isolated  from  pig  with  diarrhoea,  was 
sequenced using a shotgun sequencing method under a commercial contract with the 
Australian  Genome  Research  Facility  (AGRF),  University  of  Queensland.  In  the 
whole genome shotgun sequence (WGSS) strategy, the B. pilosicoli chromosomal 
DNA  was  extracted  by  the  cetyltrimethylammonium  bromide  method  (CTAB 
method) in order to prepare high quality chromosomal DNA suitable for preparation 
of genomic DNA libraries. The approximate size of the genome then was assessed by 
pulse field gel electrophoresis. The genomic DNA was sheared and cloned in the 
pSMART  vector  system  (Lucigen)  allowing  for  construction  of  shotgun  plasmid 
libraries of different sizes. Each shotgun plasmid library with an approximate size of 
2-3 kb or 3-10 kb was sequenced six times. The quality of each sequence was first 
scored using phred, and the resulting quality and sequence data then assembled using 
phrap, and subsequently viewed using consed [Phred and phrap software package 
(http://bozeman.mbt.washington.edu/phredphrapcosed.html)].  Following  assembly, 
open  reading  frames  (ORFs)  were  identified  using  local  software  (Glimmer  and 
GeneMark)  by  colleagues  in  the  Centre  for  Comparative  Genomics  (CCG)  at 
Murdoch  University.  A  large  number  of  ORFs  ultimately  were  identified  from 
around 75 % of the completed genome sequences of B. pilosicoli, but this PhD study 
only focused on a small subset of ORFs that were allocated for further study at the 
commencement  of  the  sequencing.  Thus,  the  selected  24  ORFs  for  this  study 
represented a portion of all the identified ORFs for the whole project, with some 
concerns  and  considerations  in  regards  to  commercial  issues  and  confidentiality 
influencing the choice of ORFs to be studied. Abbreviation used in this chapter and 
all other chapters of this thesis are listed in pages XXIII and XXIV. Manufacturers of  
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reagents, instruments, and software are listed in appendix A1-A3. Details of buffers, 
solutions, and bacterial culture media are provided in appendix B1-B5. The results of 
sequence alignments are presented in appendix C1-C4. 
  
2.2 IN SILICO ANALYSIS OF THE SELECTED ORFS 
 
2.2.1 Homology search 
Initially a search of sequence databases was made to determine if  similar protein 
sequences had associated functions (Zagursky & Russell, 2001). The selected ORFs 
first  were  analysed  using  Blast  (ftp.ncbi.nlm.nih.gov),  to  search  for  similarity 
between query sequences and sequences in a nucleotide database (Blastn) and  a 
peptide database (BlastP) (Altschul et al., 1990).  
 
2.2.2 Domain or motif search 
Two databases of protein domain families, Pfam (Bateman et al., 2002) and CDD 
(Marchler-Bauer et al., 2003), then were searched to determine the structural and 
functional building blocks of ORF products or protein domains. 
 
2.2.3 Prediction of subcellular location of ORF products 
Four  bioinformatics  algorithms  including  PSORTb,  SignalP,  LipoP,  and  TMpred 
were used to predict the subcellular localization of the ORF products.  
      PSORTb,  version  2.0  (http://www.psort.org/psortb/)  is  an  expert  tool  for 
predicting the location of proteins in Gram negative bacteria  (Nakai, 2000). This 
program  can  predict  the  location  of  a  protein  in  one  of  four  subcellular  regions 
including  cytoplasm,  inner  membrane,  periplasm,  or  outer  membrane  with  an 
accuracy of 83%.   
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      SignalP,  version  3.0  HMM  (http://www.cbs.dtu.dk/services/SignalP/)  is  a 
predictive tool to determine the presence and location of signal peptidase I (SPaseI) 
cleavage  sites  within  the  N-terminal  70  amino  acids  of  the  secreted  proteins  in 
eukaryotes, as well as Gram-negative and Gram positive bacteria. The accuracy of 
cleavage site prediction by this program for Gram negative bacteria is about 90.2 
percent (Bendtsen et al., 2004). 
      LipoP 1.0 (http://www.cbs.dtu.dk/services/LipoP/) is a prediction algorithm for 
discrimination  of  lipoproteins from  signal  peptides. This  algorithm appears to  be 
more accurate than Psort for detecting the presence and location of signal peptidase 
II (SPaseII) cleavage sites in lipoproteins (Setubal et al., 2006).  
TMpred  (http://www.ch.embnet.org/software/TMPRED_form.html)  also  was  used   
as an algorithm for N-terminal transmembrane helices detection.  
 
 
 
2.2.4 Estimation of molecular weight and isoelectric pH (Iep) of ORF products 
 
Theoretical molecular weight and iso-electric pH (Iep) of the ORF products were 
estimated using the BioEdit Sequence Alignment Editor version 4.8.6 (Hall, 1999). 
The G+C content of the ORFs also were calculated as the G + C content of the third 
nucleotide position of all the codons. 
 
 
 
 
 
 
 
2.3 GENE DISTRIBUTION ANALYSIS BY PCR 
 
2.3.1 Introduction  
 
68 
A set of candidate genes from the B. pilosicoli 95/1000 genome that were annotated 
for their associated functions using several bioinformatics programs was selected and  
screened for their distribution by PCR amongst different strains of B. pilosicoli. The 
most conserved gene candidates with more than 80% distribution amongst different 
strains of B. pilosicoli, including the WesB human strain, were selected to develop a 
possible recombinant vaccine. 
 
2.3.2 Strains 
 
A set of 25 B. pilosicoli strains including 19 porcine strains, 5 human strains, and 
sequenced strain 95/1000 used as a positive control, were selected for preparation of 
spirochaetal cells and their DNA. Two human strains of B. aalborgi also were used 
as negative controls (Table.2.1). 
 
2.3.3 Cultivation of intestinal spirochaetes 
The strains were obtained as frozen stocks (Mid-log phase bacteria in Kunkle‘s pre-
reduced  anaerobic  broth  kept  at  -80  C),  from  the  culture  collection  held  at  the 
Reference  Centre  for  Intestinal  Spirochaetes,  Murdoch  University.  They  were 
thawed,  and  revived  onto  Trypticase  Soy  Agar  (TCA-CVS)  plates  containing 
defibrinated  ovine  blood,  spectinomycin,  colistin,  and  vancomycin  (Jenkinson  & 
Wingar, 1981). The plates were incubated for 7-10 days at 37 C in an anaerobic 
environment  generated  using  anaerobic  Gaspak  Plus  sachets.  In  case  of  genomic 
DNA preparation, the purity of each plate culture was examined by phase-contrast 
microscopy and  pure cells were propagated in 10 ml and then 100 ml of modified 
Kunkle‘s pre-reduced anaerobic broth, containing 3.5% (v/v) foetal calf serum and 
0.5%  (v/v)  newborn  calf  serum  (Kunkle  et  al.,  1986)  (Ram  Naresh.  Murdoch 
University, personal communication).  
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Table 2.1 B. pilosicoli and B. aalborgi strains used in gene distribution studies by 
PCR analysis. 
 
Working ID  Strain ID  Host  Origin 
B. pilosicoli:       
P1  D9201243  Porcine  USA 
P2  140416A  Porcine  QLD 
P3  3295  Porcine  VIC 
P4  HRM7A*  Human  Italy 
P5  M1  Porcine  UK 
P6  2717  Porcine  VIC 
P7  L72  Porcine  QLD 
P8  Wandalup 015/c138  Porcine  WA 
P9  Windridge W25  Porcine  NSW 
P11  Willowgrove 7  Porcine  VIC 
P12  Willowgrove IA8  Porcine  VIC 
P13  HRM 7  Human  Italy 
P14  95.0635.6  Porcine  QLD 
P15  95.2078.2  Porcine  QLD 
P16  95.3281.0  Porcine  QLD 
P17  95/1000  Porcine  WA 
P18  155/4  Porcine  WA 
P19  H60-2  Human  WA 
P20  Q5 (4662.4)  Porcine  QLD 
P21  P43/6/78
T **  Porcine  Scotland 
P23  Wandalup F  Porcine  WA 
N1  HRM2B  Human  WA 
N2  Margaret  Human  WA 
N3  “S.Jonesii”  Human  USA 
N4  V1H91  Human  WA 
N5  WesB  Human  WA 
B. aalborgi:       
A1  513
T  Human  Denmark 
A2  Z17  Human  Australia 
 
Note: * HRM7A is an isolate of HRM7, QLD = Queensland, VIC = Victoria, WA = 
Western Australia, and ** P43/6/78
T is the type strain of B. pilosicoli. 
 
2.3.4 Preparation of genomic DNA  
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The preparation of bacterial genomic DNA consists of two steps: a technique to lyse 
the cells gently and solubilize the DNA, followed by enzymatic or chemical methods 
to remove contaminating proteins, RNA, and other macromolecules.  
 
2.3.4.1 Miniprep of bacterial genomic DNA using the DNeasy
TM Tissue Kit
   
The  DNeasy
TM  Tissue  kit  (QIAGEN)  was  used  to  extract  spirochaetal  genomic 
DNA.  The  29  strains  of  B.  pilosicoli  were  grown  to  mid-log  phase  in  5ml  pre-
reduced anaerobic Trypticase soy broth (Kunkle et al., 1986). Cells were harvested 
by centrifuging for 20 minutes at 4000 ×g at 4C. A 2 × 10
9 cell pellet of each strain 
was completely resuspended in 180 l resuspension buffer (ATL, supplied with the 
DNeasy
TM Tissue kit). The lysis solution (proteinase K, 20 l) was then added and 
mixed by vortexing. The mixture was incubated at 55C for 1 hour. RNA treatment 
was carried out using 20 l of RNase A (100 mg/ml) in each sample followed by 
incubation  at  room  temperature  for  2  minutes.  After  complete  lysis,  400  l  of 
neutralisation/binding buffer  (AL-ethanol  mixture) was  added and mixed well by 
vortexing.  The  mixture  was  then  applied  into  a  DNeasy  mini  binding  column, 
followed by centrifugation at 6000 ×g for 1 min. The column was washed two times 
with 500 l of the first washing buffer (AW1) and then with the second washing 
buffer  (AW2).  Finally  the  DNA  was  eluted  from  the  column  by  adding  100  l 
elution buffer (Buffer AE) and then centrifuged for 1 min at 6000 ×g. The eluted 
DNA was stored at -20C.  
 
 
  
 
71 
2.3.4.2  Large  scale  preparation  of  bacterial  genomic  DNA  using  the  CTAB 
method  
DNA from B. pilosicoli strain WesB was extracted using a slight modification of the 
cetyltrimethylammonium  bromide  (CTAB)  method  (Ausubel  et  al.,  2003).  To 
prepare the bacterial cell lysate, 100 ml of pre-reduced anaerobic Trypticase Soy 
broth (Kunkle et al., 1986) was inoculated with 1% of a mid-log phase B. pilosicoli 
strain WesB seed culture.  At mid-exponential phase growth, the cells were harvested 
by centrifugation at 4000xg and resuspended gently in 9.5 ml TE buffer, 0.5 ml of 
10% SDS, and 50 l of 20 mg/ml proteinase K then incubated at 37C for 1 hour. 
After completion of cell lysis, the precipitation and purification of DNA were carried 
out by adding 1.8 ml of 5 M NaCl to the cell lysate and mixing well before 1.5 ml 
CTAB/NaCl solution was added and the mixture incubated for 20 min at 65C. An 
equal  volume  of  chloroform/isoamyl  alcohol  was  added,  mixed  thoroughly  and 
centrifuged for 10 min at 6000 xg, at room temperature to separate the phases. The 
clear supernatant was transferred into a fresh tube using a wide-bored pipette. The 
DNA was precipitated with a 0.6 volume isopropanol, and the precipitated DNA was 
washed with 70% ethanol. The supernatant was removed and the pellet was briefly 
dried in a lyophilizer and then resuspended in 4 ml TE buffer. To avoid interference 
of residual RNA in DNA quantification, 4 l RNaseA (100mg/ml) was added to 200 
l of the final resuspended DNA and incubated for 2 min at room temperature before 
this sample was used for DNA quantification.  
 
2.3.4.3 Genomic DNA quantification and qualification 
The concentrations of extracted DNA from different strains of  B. pilosicoli were 
calculated  by  measuring  the  absorbance  at  260nm  (A260)  of  the  solution  in  a  
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spectrometer (Lambda 25 UV / Vis) using UV WINLAB software. DNA dilutions of 
1:50, 1:100, and 1:200 were prepared in a 125 l total volume with ultra pure water 
in a quartz cuvette. The concentration of each dilution was quantified at  A260 by 
comparison of the adsorption value to that of the pure water.  
      To confirm the extracted DNA was from B. pilosicoli, a set of primers from the 
16S rRNA gene was  designed according to  work done  previously by Park et  al. 
(1995) and La et al. (2003). The designed forward (Acoli1: AGA GGA AAG TTT 
TTT CGC TTC) and reverse (Pilo-16-R: GCA CCT ATG TTA AAC GTC CTT G) 
primers  were  checked  for  their  specificity  by  performing  a  BLAST  search  with 
sequences from GenBank, and then used to amplify of 823 base pairs product. All 
amplification mixtures consisted of a reaction mix of 1x PCR reaction buffer, 1.0 
Unit of Tth Plus DNA polymerase, 1.5 mM of MgCl2, 5 mmole of each dNTP, 10 
pmole of each primer and 1l of DNA template of 20 mg/ml proteinase K were 
added. The cell suspension was thoroughly mixed and incubated at 37C for 1 hour. 
After completion of cell lysis, the precipitation and prepared to a total volume of 25 
l.  All  reactions  were  performed  on  an  Applied  Biosystems  2400  or  9600 
thermocycler. Thermocycling conditions consisted of 5 min preheating at 94C with 
32 cycles of polymerization (including 30 sec. denaturing at 94C, 30 sec. annealing 
at 52C, and 30 sec. extension at 72C), and a 5 min final extension at 72C. 
 
2.3.5 Design and specification of primers for gene distribution studies  
The design of the oligonucleotides was carried out according to the general rules of 
primer  designing  (Newton  &  Graham,  1994)  using  SeqEd  Version  1.0.3.  Once 
primers were found to meet defined criteria, the Amplify program version 1.2 by 
Bill Engels (University of Wisconsin) was used to simulate PCR conditions, predict  
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possible PCR products produced from the given DNA template, the size of product, 
and the prevention of any primer dimers. Results from the Amplify program were 
used to evaluate and select appropriate sets of primers (Table 2.2). All the designed 
primers were purchased from GeneWorks. For some putative ORFs that were poorly 
distributed  as  assessed  in  the  PCR  with  the  first  set  of  primers,  a  second  set  of 
primers  was  designed  to  be  complementary  to  different  positions  of  the  internal 
region of each putative ORF (vaccine candidate gene). 
 
2.3.6 Polymerase chain reaction (PCR) 
The  polymerase  chain  reaction  (PCR)  was  typically  performed  using  Taq  DNA 
polymerases and 1x PCR buffer, 1.5 mM MgCl2 and 0.2mM of each dNTP. Other 
components including primers and template (DNA clone or genomic DNA) were 
varied  in  order  to  optimize  the  specificity  and  yield  of  the  PCR  reaction.  The 
thermocycling protocol  differed depending  on the primer pairs  and the length  of 
template used for the reactions.  
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Table 2.2 Internal primers used for distribution study of the putative ORFs amongst 
different strains of intestinal spirochaetes. 
Primers for Gene Distribution Study 
Gene 
Candidate  Oligo Name  Oligo Sequence (5´→ 3´) 
Oligo 
size 
(bp) 
TM 
(°C) 
Product 
Size 
(bp) 
NAV-PX: 
 PX.1.DF1  GGATTCTATGTCTGCCATATCTG  23  58 
1785 
 PX.1785.DR1  CAAGCCCCACAAAAGACACG  20  53 
 PX.369.DF2  ATGAGCAAAAAAAATAATAAGG  22  53 
878 
 PX.1246.DR2  TCAAGCCATATAAGTTTTATC  21  56 
NAV-P3: 
P3.1.DF1 
ATGAAAAAATATATTTTAATATTATTT
TTTATAAT 
35  47 
1581 
P3.1581.DR1  CTTCTCTACATAAGCATAGAAAAATC  25  52 
P3.396.DF2  CATAAAAGGAGAATTGCCACTAAC  28  52 
788 
P3.1183.DR2  CTTTCCACATCTGCTGAATAGC  22  53 
NAV-P5: 
P5.242.DF1  AGAGAGGACCTATTGACGGAC  21  50 
332 
P5.573.DR1  ATCACCGCTTCTCTCTTCACC  21  51 
NAV-P8: 
P8.4.DF1  AGTCATAATTTAAGGCTAGCATTC  24  50 
1503 
P8.1506.DR1  AAAGAAGAAACCAGCTTTCTTCAC  24  52 
P8.380.DF2  TTAGTGAGGTTGGTATAAGAAAGC  24  52 
778 
P8.1156.DR2  GTAAATCTTAAAGGAGAAATATAGC  25  52 
NAV-P9: 
P9.1.DF1  ATGAGCGAAAATATTAAAAAAAATAATG  28  48 
943 
P9.943.DR1  TTCCTTTCATAAATAATATTAAAAGG  26  47 
P9.263.DF2  ACAGAAACTTTGGTACAGAAACTG  24  52 
449 
P9.711.DR2  ATCAGCATTTTCTCTGATTCTATC  24  50 
NAV-P13: 
P13.268.DF1  CCTGGATTTTTATTTGAGCCTG  22  51 
555 
P13.822.DR1  TCATAAACAGAACCGCCAAGC  21  52 
NAV-P15:  
P15.294.DF  AGAAGTTTCTGAAGATATGGCAC  23  52 
596 
P15.889.DR1  CATCAGCCTCTTCTGCATTG  20  52 
NAV-P18: 
P18.260.DF1  GATTAGCCGATGCTCTGCCTC  21  56 
734 
P18.993.DR1  AACAAGTCCAGAAGTTCCGCC  21  54 
NAV-P19: 
P19.268.DF1  GTGGGTGTTGGAAGTGCTAAG  21  54 
551 
P19.818.DR1  CATGCCACTCCACCAGATAATG  22  55 
NAV-P20: 
P20.343.DF1  GCTGTTGATCCAAAAACTGCC  21  52 
852 
P20.1194.DR1  CATACTCTGAACAGCATCAGC  21  52 
NAV-P21: 
P21.578.DF1  GAGGAAGGAGCGCAAACAG  19  53 
1308 
P21.1885.DR1  CATTAAGCCCAATGCCAGCC  20  54 
P21.924.DF2  TAGTCATGATGGTGAATATATAGG  24  50 
917 
P21.1840.DR2  CTTCAATATGACCTAAGTTATTGC  24  50  
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Table 2.2 Internal primers used for distribution study of the putative ORFs amongst 
different strains of intestinal spirochaetes (continued). 
Primers for Gene Distribution Study  
Gene 
Candidate  Oligo Name  Oligo Sequence (5´→ 3´) 
Oligo 
size 
(bp) 
TM 
(°C) 
Product 
Size 
(bp) 
NAV-P22: 
P22.265.DF1  GAGATAATGCTAAATGGTCTGA  22  49 
478 
P22.742.DR1  TTCCTTTAATGCTGGGTATGCT  22  51 
NAV-P23: 
P23.365.DF1  GGTTGGGAATGGTTATGCCAG  21  54 
705 
P23.1069.DR1  AAATAGGGCATTGTCCGTCTAC  22  53 
NAV-P24: 
P24.391.DF1  GACCCTAAAACAGCTTCACC  20  52 
852 
P24.1242.DR1  TCCACATCTCTTGAATTGCCT  21  50 
NAV-P25: 
P25.228.DF1  TAACAGAAGTATTGGCGAGAG  21  50 
566 
P25.793.DR1  CAGAGCTTCTTAAAGTATGCC  21  50 
NAV-P27: 
P27.314.DF1  GACTCCTGCTGATGCTTTTG  20  52 
479 
P27.792.DR1  CATTCTCACTTTCTGATCTCC  21  50 
NAV-P29: 
P29.322.DF1  GACATACCAGCAGTAGCTTC  20  52 
573 
P29.894.DR1  AGGAGTGTTTAATCCGCCAG  20  52 
NAV-P30: 
P30.175.DF1  GATAATGGAGAGATAGTTGGC  21  50 
505 
P30.679.DR1  TTTTTCTAAGGCCTACACTAAG  22  49 
NAV-P31: 
P31.210.DF1  AGCCAAAGAAGTTGCAAACCG  21  52 
380 
P31.589.DR1  TCACAGCATCTATTCTCTTAGC  22  51 
NAV-P45: 
P45.278.DF1  CAACATACACGCCGCTATGC      20  54 
359 
P45.636.DR1  CCAGAAATGAGAGAATGAGCC  21  52 
NAV-P50: 
P50.152.DF1  TTGGGAATAAAGCTTCTCTCAC  22  51 
607 
P50.758.DR1  ATTCTGCTGTCATTGTTAAAACC  23  50 
NAV-P51: 
P51.67.DF1  ATTAGAGAAGTTAAGCCTCCGC  22  53 
656 
P51.722.DR1  CCCCAGCCTATATTACTCACC  21  54 
P51.295.DF2  GATGACTGTTTACCAGATAAGTC  23  52 
541 
P51.835.DR2  CATCAATATCTATACTAGTCTCTAC  25  51 
NAV-P52: 
P52.69.DF1  AAGGAAAGCAAAACCGCCTCG  21  54 
662 
P52.730.DR1  GTGTAGAATCATTACCCCAACC  22  53 
P52.225.DF2  ATGTGGTTTAGCTGTATCTGG  21  50 
419 
P52.643.DR2  TCCATTGATAATCCCAAGTATC  22  49 
NAV-P53: 
P53.294.DF1  CAGTGAGGGTTCACTTGGAGC  21  56 
696 
P53.989.DR1  CTATGTCCCATATGTCCTCTTTC  23  53 
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2.3.6.1 Polymerase chain reaction composition 
The amplification mixture consisted of 1 x PCR buffer, 1.5 mM MgCl2, 0.6U of Taq 
DNA polymerase, 0.25 mM of each dNTP, 12.5 pM of each primer, and 50-100 ng 
chromosomal DNA template (genomic DNA) in a total volume of 25 l reaction. All 
reactions  were loaded into 0.2 ml thin-walled thermocycling tubes, and  ultrapure 
water was used to make up the reaction volume. 
 
2.3.6.2 PCR optimization and thermocycling conditions 
The thermocycling protocols differed depending on the primer pairs and the length of 
templates used for the reactions. The variables were the annealing temperature and 
the extension time in each polymerization cycle. The PCR reactions for each primer 
set were optimized by first running at the predicted Tm and then altering the Tm by 
one or two degrees at  a time to obtain a single, specific PCR product of the predicted 
size.  The  optimized  PCR  thermocycling  conditions  used  in  this  study  for 
amplification of the selected genes are shown in Table 2.3. 
 
2.3.7 Agarose gel electrophoresis 
    
Agarose gel electrophoresis was carried out as described by Sambrook et al. (1989). 
The equipment used was a Mini Sub™ DNA cell or Wide Mini Sub™ DNA cell 
apparatus. Low melting point or standard agarose were used as appropriate. Agarose 
gels  consisted  of  0.8-1.2%  agarose  and  0.5  g/ml  ethidium  bromide.  The  DNA 
samples  were  mixed  with  gel  tracking  dye  and  loaded  by  micropipette  into  the 
sample wells. Molecular markers used in this study for displaying bands of known 
sizes were the 100 bp ladder, and the 1 kb ladder.  
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      Agarose  gel  electrophoresis  was  performed  in  1x  TAE  buffer  (40  mM  Tris-
acetate, 5 mM EDTA, pH 8.0) as described by Sambrook et al. (1989). Gels were 
electrophoresed at 80V for 60 min and then viewed over ultraviolet light with a UVP 
transilluminator.  Photographs  of  gels  were  taken  using  the  Gel-Doc  1000  and 
Molecular  Analyst  Software  version  1.4.  On  some  occasions  gels  were  not  pre-
stained as described above but were post-stained in a 1g/ml solution of ethidium 
bromide in 1x TAE for 10-15 min and de-stained for 5-10 min before viewing over 
ultraviolet light.  
 
 
2.4 GENE SEQUENCING AND COMPARATIVE ANALYSIS  
 
2.4.1 Introduction 
Genes NAV-P3, NAV-P8, NAV-P9, and NAV-PX from the incomplete sequence of B. 
pilosicoli strain 95/1000 were randomly selected and then the first three genes were 
sequenced in five human strains and the porcine type strain of B. pilosicoli for gene 
homology analysis and gene conservation. Since the NAV-PX gene is similar to clpX 
gene  that  previously  has  been  published  in  GeneBank  (accession  number: 
AY466377)  in  this  study  it  has  been  sequenced  amongst  20  different  strains  of 
Brachyspira to put the obtained information in a publication without confidentiality 
and the sequences were used for homology analysis and phylogenetic study.  
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Table 2.3 Optimized PCR thermocycling conditions for distribution study of the 
putative ORFs using distribution primers. 
Candidate 
Genes 
Primer Set 
First 
Denaturation 
Polymerization cycles 
Final 
Extension 
Number 
of  
Cycles  Denaturation  Annealing  Extension 
NAV-PX 
PX.1.DF1 
PX.1785.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1.5 min 
72 C 
7 min  35 
PX.369.DF2 
PX.1246.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
* NAV-P3 
** P3.1.DF1 
P3.1581.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1.5 min 
72 C 
7 min 
35 
P3.396.DF2 
P3.1183.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
NAV-P5 
P5.242.DF1 
P5.573.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 
72 C 
5 min 
35 
NAV-P8 
P8.4.DF1 
P8.1506.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
P8.380.DF2 
P8.1156.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1.5 min 
72 C 
7 min 
35 
NAV-P9 
P9.1.DF1 
P9.943.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
P9.263.DF2 
P9.711.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1.5 min 
72 C 
7 min 
35 
NAV-P13 
P13.268.DF1 
P13.822.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
NAV-P15 
P15.294.DF1 
P15.889.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min 
35 
NAV-P18 
P18.260.DF1 
P18.993.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min 
35 
NAV-P19 
P19.268.DF1 
P19.818.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min 
35 
NAV-P20 
P20.343.DF1 
P20.1194.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
NAV-P21 
P21.578.DF1 
P21.1885.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
P21.924.DF2 
P21.1840.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
NAV-P22  P22.265.DF1 
P22.742.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min 
35 
NAV-P23 
P23.365.DF1 
P23.1069.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
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Table 2.3 Optimized PCR thermocycling conditions for distribution study of the 
putative ORFs using distribution primers (continued). 
Candidate 
Genes  Primer Set  First 
Denaturation 
Polymerization cycles 
  Final 
Extension 
 
Number 
of  
Cycles  Denaturation  Annealing  Extension 
NAV-P24 
P24.391.DF1 
P24.1242.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min  35 
NAV-P25 
P25.228.DF1 
P25.793.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min  35 
NAV-P27 
P27.314.DF1 
P27.792.DR1  
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec 
72 C 
7 min  35 
NAV-P29 
P29.322.DF1 
P29.894.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min  35 
NAV-P30 
P30.175.DF1 
P30.679.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min  35 
NAV-P31 
P31.210.DF1 
P31.589.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min  35 
NAV-P45 
P45.278.DF1 
P45.636.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
7 min  35 
NAV-P50 
P50.152.DF1 
P50.758.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min  35 
NAV-P51 
P51.67.DF1 
P51.722.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min  35 
P51.295.DF2 
P51.835.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min 
35 
NAV-P52 
P52.69.DF1 
P52.730.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min  35 
P52.225.DF2 
P52.643.DR2 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
30 Sc. 
72 C 
7 min 
35 
NAV-P53 
P53.294.DF1 
P53.989.DR1 
94 C 
5 min. 
94 C 
30 Sec. 
57 C 
30 Sec. 
72 C 
1 min 
72 C 
7 min  35 
 
* NAV indicates the abbreviation of Novartis Animal Vaccines, P indicates that the 
gene is specific for B. pilosicoli, number indicates the gene number; ** P and the 
subsequent  number  indicate  the  primer  is  specific  for  the  numbered  gene  of  B. 
pilosicoli, the second number after the dot indicates sequence position, DF and DR 
indicate forward and reverse primers for distribution study. 
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2.4.2 Design and specification of primers for gene sequencing  
The design of primers for sequencing of the selected NAV-P3, NAV-P8, NAV-P9, and 
NAV-PX genes was carried out according to the method described in section 2.3.5. 
To sequence the whole coding region  of each gene several  sets  of primers were 
designed to be complementary with the gene sequence plus extended areas from both 
sides of the gene. The sequences and specifications of designed primers are presented 
in Table 2.4. The primers used for sequencing were purchased from GeneWorks.  
 
2.4.3 Sequencing reactions 
The full NAV-PX gene was sequenced from 12 strains of B. pilosicoli, 3 strains of B. 
innocens, 2 strains each of B. hyodysenteriae and B. intermedia, and 1 strain of B. 
aalborgi. The full NAV-P3, NAV-P8, and NAV-P9 were sequenced from 6 strains of 
B. pilosicoli including 5 human strains (HRM2B, Margaret, ―S. Jonesii‖, V1H91, and    
WesB), and type strain P43/6/78
T of B. pilosicoli. Initially an external primer set 
(Table 2.4), amplifying the extended gene that included the coding region of each 
gene was applied to chromosomal DNA from Brachyspira species strains in 50 l 
PCR reactions. The PCR products were purified using an UltraClean PCR Clean-up 
Kit. The purified PCR products then were sequenced using the sequencing primer 
sets (Table 2.4) using the ABI PRISM
TM Dye Terminator Cycle Sequencing Ready 
Reaction Mix, and an ABI 373A DNA sequencer, according to the manufacturer‘s 
specifications. 
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Table 2.4 PCR primes for sequencing of the NAV-PX, NAV-P3, NAV-P8, NAV-P9 
genes. 
 
Gene 
 
Primer 
Set  Oligo Name  Oligo Sequence (5´→ 3´) 
Oligo 
Size 
(bp) 
Oligo
TM 
(C) 
NAV-PX: 
 
1
st set: 
PX. -140.SF1  AATATTGGCGATATAGTAAAGG  26  52 
PX.697.SR1  GACCAATACTTGAATAAGGCTC  25  53 
2
nd set: 
PX.579.SF2  GTCTTCCATTTGCACGTGCAG  26  50 
PX.1286.SR2  GCTCCCATATTCATAGTAGAAG  23  53 
3
rd set: 
PX. 1162.SF3  CCAGAGTTTATAGGAAGAATACC  24  52 
PX. +63.SR3  CATTATTTGCCAACTCCATTACTG  25  53 
NAVP-3: 
 
1
st set: 
NP3. -51.SF1  AAACAATCATTATAATAATCTTATT
TCC  28  48 
NP3.831.SR1  TATTCCAAGCAAAGGTACATAAT  24  50 
2
nd set: 
NP3.751.SF2  GGAAGCAATCCTCCATTACAAG  22  53 
NP3.+51.SR2  ATTATAATAGGGGGATTAGTTTCC  24  50 
NAVP-8:  1
st set: 
NA8.-77.SF1  GAAGAGTTAGAAAAGCACAATCTG  25  54 
NA8.+75.SR2  CAGCACCTATAGATTGACCTAC  22  53 
NAVP-9:  1
st set: 
NA9. -60.SF1  TACAAAACTTGTGAAGAAAGCTGG  25  49 
NA9.+120.SR1  ATCGTATATACATTGTATACCACTG  25  51 
 
 
2.4.4 Gene similarity and phylogenetic analysis 
The sequence data were edited using SeqEd v1.0.3. The obtained sequences for NAV-
P3,  NAV-P8,  and  NAV-P9  compared  with  their  related  sequences  in  genome 
sequence of B. pilosicoli strain 95/1000  while for the NAV-PX gene the obtained 
sequences compared with GenBank sequence of the NAV-PX gene of B. pilosicoli 
strain 95/1000 (accession number: AY466377). The nucleotide and translated protein 
sequences were aligned using ClustalX and ClustalW multiple alignment software to 
obtain  a  similarity  matrix  of  different  strains  of  Brachyspira.  Neighbor-Joining 
phylogenetic trees based on a distance matrix obtained from sequences of NAV-PX 
gene in 20 strains of Brachyspira were drawn using BioEdit Sequence Alignment 
Editor and MEGA 3.1.  
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2.5 RECOMBINANT DNA TECHNIQUES 
2.5.1 Cloning and transformation  
 
2.5.1.1 Preparation of competent E. coli 
Competent  E.  coli  cells  were  prepared  according  to  the  method  described  by 
Hanahan (1983), with some modification.  The desired E. coli strain (JM109, BL21 
or Top10) was streaked on 2xYT agar (without antibiotic), and incubated at 37C 
overnight. The following day, a well-isolated single colony was transferred into 10 
ml 2xYT broth in a 50 ml falcon tube and incubated at 37C overnight with shaking 
(250 rpm). Then 250 ml of 2xYT broth in a 1000 ml conical flask was seeded with 
2.5 ml (1%) of overnight E. coli culture and incubated on a shaker (250 rpm) at 37C 
until the OD600 reached 0.45-0.55, as determined with UV-Vis spectrophotometer. 
The cells then were transferred into a pre-chilled polypropylene centrifuge tube (250 
ml) and the tube was kept in ice-water for 2 hours. The cells were centrifuged at 
2500 x g for 15 min in a pre-chilled centrifuge at 4C. The supernatant was poured 
off and discarded. The bacterial pellet was gently resuspended in 10 ml of ice-cold 
trituration buffer (100 mM CaCl2, 70 mM Mg Cl2, 40 mM CH3COONa, pH 5.5) and 
then diluted to 250 ml with the same buffer. The cells were left on ice for 45 min 
before  centrifugation  at  1800 x  g  for  10  min at  4C.  The  cell  pellet  was  gently 
resuspended in 25 ml of ice-cold trituration buffer and 6.25 ml of ice-cold 80% (v/v) 
glycerol  as  cryopreservant  was  added  dropwise  to  the  cells  (final  glycerol 
concentration was 20% v/v). The cells were then aliquoted in batches of 200 µl into 
1.5  pre-chilled  microcentrifuge  tubes.  The  dispensed  cells  were  snap-frozen  by 
immediate immersion in liquid nitrogen and stored at -80C until required. 
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2.5.1.2 Designing of primers for cloning  
The oligonucleotides for cloning of putative ORFs or genes in proper vectors were 
designed in-frame to the genes, with restriction endonuclease sites on both ends. The 
design of the primers was carried out according to the procedure described in section 
2.3.5. The designed primers with their specification are listed in Table 2.5. 
 
 
2.5.1.3 PCR amplification of the gene of interest  
The  putative  ORFs  were  amplified  from  B.  pilosicoli  strain  WesB  chromosomal 
DNA. For some genes with predicted signal peptides or transmembrane helices, the 
primers were designed to exclude these. The PCR was performed in a total volume of 
50 µl, consisting of 1 x PCR buffer, 1.5 mM MgCl2, 0.6U of Taq DNA polymerase, 
0.06U of Pfu DNA polymerase, 0.25 mM of each dNTP, 12.5 pM of each primer, 
and 50-100 ng chromosomal DNA template (genomic DNA). 
 
 
2.5.1.4 DNA purification 
2.5.1.4.1 Purification of PCR product 
The UltraClean
TM PCR Clean-up
TM Kit was employed to clean-up PCR products. 
The PCR product was mixed with 5 volumes of SpinBind buffer then applied to a 
spin  filter  unit.  After  centrifugation  for  30  seconds  at  10,000  xg  in  a  tabletop 
microcentrifuge, the liquid flow-through was discarded and the filter was washed 
with 300 µl Spinclean buffer followed by 30 second centrifugation at 10,000 xg. The 
wash flow was discarded and the spin column centrifuged for 1 min at 10,000 xg. 
The  column  was  transferred  to  a  fresh  Eppendorf  tube  and  DNA  was  eluted  by 
addition of 50l elution buffer (10 mM Tris) solution (provided with the kit) to the  
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center of the column and centrifugation for 1 min at 10,000 xg. The eluted DNA was 
stored at -20C until required. 
Table 2.5 Restricted oligonucleotides used for amplification of the putative ORFs in 
order to undertake gene cloning. 
*Oligo Name  **Res. 
Sites  Oligo Sequence (5´→ 3´)  TM 
(°C) 
Oligo 
Size (bp) 
NAV-PX.4.CF1  BamHI  AGAGGATCCAGCAAA AAAAATAATAAGGAA   56  30 
NAV-PX.1785.CR1  EcoRI  TAAGAATTC TCAAGCCATATAAGTTTTATC   53  30 
NAV-P3-43.CF2  BamHI  ATAGGATCC TGCAGCAAAAATAATACAAATAAT TCT  59  37 
NAV-P3-1584.CR2  EcoRI  AAAGAATTCTTACTTCTCTACATAAGCATAGAAAAAT  57  37 
NAV-P5-4.CF1  BamHI  ATAGGATCCGATAATATATTAAACACTGCTAATC  57  34 
NAV-P5-654.CR1  EcoRI  ATAGAATTCCTGTTGTGCTTGAGTAGTGTTATT  58  33 
NAV-P8-4.CF1  BamHI  GGATCCAGTCATAATTTAAGGCTAGCA  57  27 
NAV-P8-1509CR1  EcoRI  GAATTCAATAAAGAAGAAACCAGCTTT  52  27 
NAV-P9-4,CF1  BamHI  GGATCCAGCGAAAATATTAAAAAAAATAA  52  29 
NAV-P9-943.CR1  EcoRI  GAATTCTGCTTTTTTTCCTTTCATAAATA  52  29 
NAV-P13-67.CF2  BamHI  ATAGGATCCGGGTATGAATTGGCTTTGATTAC  60  32 
NAV-P13-1059.CR1  EcoRI  ATAGAATTCCTGTATAAAATTAACTTTAACAATATTTA  54  38 
NAV-P15-4.CF1  BamHI  ATAGGATCCACATCAAAGAAAAAATATTATCTAT  55  34 
NAV-P15-1010.CR1  EcoRI  ATAGAATTCAAAACTCTCGTTCGTTGCTA  56  29 
NAV-P18-4.CF1  BamHI  ATAGGATCCGAAGTTATATTAATTTATTTATTTG  53  34 
NAV-P18-1380.CR1  EcoRI  ATAGAATTCTTCTTCGTCCTTTTCTATATT  53  30 
NAV-P19-4.CF1  BamHI  ATAGGATCCAAAATATTAGGTATAGATACTTC  55  32 
NAV-P19-1023.CR1  EcoRI  ATAGAATTCGTTTTTTATGCTTTTATTTTTATTAT  51  35 
NAV-P-20-64.CF1  BamHI  ATAGGATCCGAAATAATTACAAATAATGAAATTGTT  55  36 
NAV-P-20-1593.CR1  EcoRI  ATAGAATTCCTCTAAATAAGCATTAAAAAATCTG  55  34 
NAVP-21-4.TCF1  NdeI  ATACATATGGAAAACAATTTGAATATAAAAACACA  54  35 
NAVP21-1200TCR1  BamHI  ATAGGATCCAAAACTCTCGTTCGTTGCTA  59  29 
NAVP-22-70.CF1  BamHI  ATAGGATCCGAAGTGATAAAGGTTACTGTTG  59  31 
NAVP-22-1050.CR1  EcoRI  ATAGAATTCTAATCTCTTTGATACGCTAAAATAA  55  34 
NAV-P23-4.CF1  BamHI  ATAGGATCCGACATAATTATTGTAATAATACTTATAC  57  37 
NAV-P23-1269.CR1  EcoRI  ATAGAATTCATTCTCTTCTAATTTTTCTACTATGA  55  35  
 
85 
 
Table 2.5 Restricted oligonucleotides used for amplification of the putative ORFs in 
order to undertake gene cloning (continued). 
*Oligo Name 
**Res. 
Sites 
Oligo Sequence (5´→ 3´) 
TM 
(°C) 
Oligo 
Size (bp) 
NAV-P24-4.CF1  BamHI  ATAGGATCCACTTACAATCTTAAAACAAAAAACTT  56  35 
NAV-P24-1641.CR1  EcoRI  ATAGAATTCTTCTTCAATATATGCATAATTAAATC  54  35 
NAV-P25-CF1  BamHI  ATAGGATCCTTTACTTATTTCGTAATCAAAAGAA  56  34 
NAV-P25-1038.CR1  EcoRI  ATAGAATTCCATCTTGCCTCCAACTTTTATT  56  31 
NAV-P-27-4.CF1  BamHI  ATAGGATCCGTAAAAAATACAAATTATTGGGCTT  57  34 
NAV-P-27-948.CR1  EcoRI  ATAGAATTCTTGCTCTTTAGAGGCATAAGTA  56  31 
NAV-P29-4.CF1  BamHI  ATAGGATCCAGAAAATTTAAATACACAAGAGTAAGAA  58  37 
NAV-P29-1176.CR1  EcoRI  ATAGAATTCTCTTCTTTTAATGAATTTTCCTATAGGT  57  37 
NAV-P30-70.CF1  BamHI  ATAGGATCCAATACTGAAGTATCCTCAGCAG  60  31 
NAV-P30-813.CR1  EcoRI  ATAGAATTCTCCTTTTATAAATACATCTTTACCA  55  34 
NAV-P-31-4.CF1  BamHI  ATAGGATCCTCACAAGCATCTTCTGCCG  61  28 
NAV-P-31-813.CR1  EcoRI  ATAGAATTCTCCTCTTACAAAAACATCTTTAC  55  32 
NAV-P45-4.CF1  BamHI  ATAGGATCCACCGCTAATTCAAAATGCATTA  58  31 
NAV-P45-660.CR1  EcoRI  ATAGAATTCAGAAATCACATATTGGTATAAAAA  53  33 
NAV-P50-4.CF1  BamHI  ATAGGATCCGGTAGGCGAATATTAAATTTTGT  58  32 
NAV-P5O-1017.CR1  EcoRI  ATAGAATTCTTTATAAATTTCAATAGCCCTATC  54  33 
NAVP51-4.CF1  BamHI  ATAGGATCCAAAAAAGCAGTACTTTTTATAATTTT  55  35 
NAVP51-113.CR1  EcoRI  ATAGAATTCAATACCAATTTTTTTATATAAATTATC  52  36 
NAVP52-4.CF1  BamHI  ATAGGATCCAAAAAAGCAGTTTTATTCATGATA  56  33 
NAVP52-996.CR1  EcoRI  ATAGAATTCTATTCCTATTTTCCTATATAAATC  53  33 
NAV-P53-4.CF1  BamHI  ATAGGATCCAAATCAAGAGAAAAAAATATAAAAAA  54  35 
NAV-P53-1188.CR1  EcoRI  ATAGAATTCGTCAATATAATGCGGAGCG  57  28 
 
* NAV indicates the abbreviation of Novartis Animal Vaccines, P indicates that the 
gene is specific for B. pilosicoli, number indicates the gene number, the number after 
the  dash  indicates  sequence  position,  FC  and  RC  indicate  forward  and  reverse 
primers for cloning purpose. ** Res. sites: Restriction sites. 
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2.5.1.4.2 Purification of restriction digests 
Restriction digests (digested PCR products or plasmid vector) were cleaned up using 
either the UltraClean
TM PCR Clean-up
TM Kit or the QIAquick Gel Extraction Kit. 
DNA fragments were purified from gels of various percentages of agarose (standard 
or low-melt agarose gels in TAE buffer), depending on the fragment sizes of the 
DNA. To minimise exposure of the DNA to UV light, DNA bands were quickly 
excised from gels using a clean, sterile razor blade or scalpel, with the amount of gel 
for each extraction usually being less than 250 mg. The QIAquick Gel Extraction Kit 
was employed for DNA purification. Three volumes of buffer QG (supplied with the 
kit) were added to 1 volume of gel for DNA fragments of 70 bp to 10 kb. The 
mixture was then incubated at 50C for 10 min and mixed by flicking until the gel 
slice had completely dissolved and the mixture had turned yellow. One gel volume of 
isopropanol was added to the sample and mixed well, then the sample was applied to 
the QIAquick column and centrifuged for 1 min. The flow-through was discarded 
and  the  column  was  washed  with  0.5  ml  of  QG  buffer  and  0.75  ml  PE  buffer 
(supplied with the kit), each followed by 1 min of centrifugation. The flow-through 
was discarded and the column was centrifuged for an additional 1 min. DNA was 
eluted by applying 30-50 l of buffer EB (10 mM Tris, pH 8.5, supplied with the kit) 
to the centre of the column followed by 1 min centrifugation, and stored at –20C 
until  used.  All  centrifugation  steps  were  carried  out  at  17,900  xg  in  a  table-top 
centrifuge.  
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2.5.1.4.3 Purification of vector plasmids 
QIAprep Spin Miniprep Kits were used for purification of plasmids either for cloning 
or  for  sequencing.  This  kit  was  utilised  according  to  the  QIAprep
R  Miniprep 
Handbook. Three ml of 2x YT broth supplemented with 100 µg/ml ampicillin in a 10 
ml falcon tube was inoculated with a single bacterial colony using a sterile loop. 
Capped loosely, the culture was grown at 37C overnight with vigorous agitation 
(250 rpm). The cells were pelleted at 4,000 xg for 10 min before being resuspended 
in 250l of buffer P1 (supplied with the kit) and transferred to a microcentrifuge 
tube. A 250l volume of buffer P2 was used to lyse the cells, and the solution was 
neutralised by the addition of 350l of buffer N3. Following centrifugation for 10 
min, the supernatant was transferred into the spin column in the kit. The column was 
centrifuged for 1 min and the voided fluid discarded. The column was washed twice, 
first in 0.5ml of buffer PB followed by centrifugation for 1 min. The eluted fluid was 
discarded, and 0.75ml of buffer PE was added, centrifuged again for 1min and the 
eluted fluid discarded. The column was transferred to a new microfuge tube and 20-
50l of TE buffer was applied into the column. The plasmid DNA was collected by 
centrifugation for 1 min and stored at -20C. In this procedure, all centrifugation 
steps  for  DNA  purification  were  carried  out  at  17900  x  g  in  a  table-top 
microcentrifuge.  
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2.5.1.4.4 Purification of sequencing reactions 
Unincorporated nucleotides and reactants present in the sequencing reaction were 
removed by an ethanol precipitation procedure as described in the Prism
TM Ready 
DyeDeoxy
TM  Cycle  Sequencing  Protocol  (revision  A,  August  1995;  Applied 
Biosystems, ABI). To precipitate DNA, 1 µl of 3M sodium acetate (pH 5.2), 1µl of  
125 mM EDTA (disodium salt, pH 8.0) and 25 µl of 100% absolute ethanol were 
mixed gently  with 10 µl sequence reaction in a 0.6 ml pre-chilled tube. The mixture 
was incubated on ice for 20-30 min and then centrifuged at 19,000 xg for 30 min at 
room  temperature  in  a  table-top  microcentrifuge.  As  much  of  the  supernatant  as 
possible was carefully but quickly discarded such that the pellet remained untouched. 
In order to wash the pellet and remove any trace of dye terminator, 500 µl of pre-
chilled 70% (v/v) ethanol was gently added down the side of the tube, followed by 
centrifugation for 5 min at 19,000 xg at 4C. After discarding the supernatant the 
pellets were either air dried at 37C for 30 min or dried under vacuum in a SpeedVac 
Savant Concentrator for about 15 min at room temperature, and resuspended in an 
appropriate buffer or double-distilled deionised water (DDW). 
 
 
2.5.1.5 Digestion of restricted DNA and vector DNA 
The restricted amplified DNA and pTrcHis A or pET-19b vector DNA were digested 
using appropriate restriction endonucleases in single or double digestion reactions. 
The restriction enzyme digest was performed in a total volume of 20-50 µl based on 
the DNA concentration using 2-10 fold excess of enzyme over DNA. The restriction 
digestion usually was performed in a 20 µl reaction consisting of 2 µl of appropriate 
10 x restriction enzyme buffer, 0.2 µl acetylated bovine serum albumin (BSA) (10 
µg/ µl), 5-10 µl DNA (with total concentration of 0.2-1 µg), restriction enzyme 0.4- 
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10 U, and sterile pure water up to 20 µl in a 0.6 ml microtube. The reaction was 
gently  mixed  by  flicking  followed  by  centrifuging  for  a  few  seconds  in  a 
microcentrifuge. The tube then was incubated at 37C for 4 hours. The digestion 
reaction was stopped by heating at 65 C for 15 min and the digested DNA was 
cleaned up either by using an UltraClean
TM PCR Clean-up
TM Kit or a QIAquick Gel 
Extraction Kit.  
 
2.5.1.6 Ligation of DNA 
The ligation reactions were performed using a 1:1, 1:3 or sometimes a 3:1 insert 
DNA to plasmid vector molar ratio. The reactions contained 2 µl of ligase, 10 x 
buffer, 200 ng vector DNA, the calculated amount of insert DNA fragment according 
to conversion of molar ratios to mass ratios equation [(ng vector × kb size of insert / 
kb size of vector) × molar ratio of insert / vector = ng of insert], 1 Weiss unit of T4 
DNA ligase, and nuclease-free water up to 10 µl. The reaction mixture was incubated 
overnight at 15C.  
 
2.5.1.7 Transformation of competent E. coli cells  
E. coli JM109 competent cells were used for all transformations to produce a high 
copy of transformed vector plasmid, while mostly E. coli BL21 Star 
TM (DE3) pLys 
competent cells were used to construct a transformant to express protein. The batch 
of competent cells was thawed on ice and aliquoted into several pre-chilled 1.5 ml 
microcentrifuge  tubes  each  containing  50  µl  cells.  Five  microliters  of  ligation 
reaction or purified transformed plasmid DNA was added to 50 µl competent cells 
and mixed gently with swirling. The cells were incubated on ice for 30 min, heat-
shocked (50-60 second at 42C) and cooled on ice for 2 min. The LB broth in a  
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volume of 300 µl was gently added to the cells and incubated on a shaker (225 rpm) 
at 37C for 1 h. A100-200 µl of the cells was plated directly onto a 2x YT plate 
containing 100 µg/ml ampicillin, and incubated overnight at 37C. 
 
2.5.1.8 Screening of recombinant vector using direct colony PCR 
To identify recombinant bacteria harbouring the recombinant plasmid, twelve well 
grown and separated single colonies (at least 1 mm in diameter) were selected on the 
original or master plate. The selected colonies  were transferred onto a 2 x YT plates 
containing 100  µg/ml ampicillin using a sterile applicator to prepare a replica of 
them, and then the bulk of each colony was resuspended in 50 µl lysis buffer (TE, pH 
8 containing 1 % Triton 100) to prepare DNA templates for PCR screening. The 
suspension was mixed by vortexing and then heated in boiling water for 5-10 min to 
lyse the cells and denature DNases. The reaction mix was centrifuged at 12,000 xg 
for 1 min to remove the cell debris, and 5 l of supernatant was used as a template 
for PCR amplification using forward and reverse primers specific to pTrcHis A or 
pET-19b  vectors  (Table  2.6).  PCR  reactions  were  carried  out  according  to  the 
protocol described in section 2.3.6.1. PCR thermocycling conditions are presented in 
Table 2.7. 
Twelve microliter of the PCR product was mixed with 1.2 l of 10 x loading dye and 
then applied to the well of a 1% gel containing 0.5 g ethidium bromide, with perfect 
DNA markers I adjacent well. 
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Table 2.6 Vector-specific primers of pTrcHis A and pET-19b. 
Plasmid 
Vector  Oligo Name  Oligo Sequence (5´→ 3´) 
Oligo Size 
(bp) 
Expected 
TM 
(°C) 
pTrcHis A 
pTrcHis.FP  GAGGTATATATTAATGTATCG  21  44 
pTrcHis.RP  TCTTCTCTCATCCGCCAAAAC  21  52 
pET-19b 
pET-19b.FP  AGGGGAATTGTGAGCGGATAAC  22  55 
pET-19b.RP  CTTGCGGGATATCCGGATATAG  22  55 
 
 
 
Table 2.7 Optimized PCR thermocycling conditions for screening of recombinant 
vector plasmid using specific vector primers 
 
Primer Set 
First 
Denaturation 
Polymerization cycles  Final 
Extension 
Numbr of 
Cycles  Denaturation  Annealing  Extension 
pTrcHis.FP 
pTrcHis.RP 
94 C 
5 min. 
94 C 
30 Sec. 
52C 
30 Sec. 
72 C 
1-2 min 
72 C 
7 min 
35 
pET-19b.FP 
pET-19b.RP 
94 C 
5 min. 
94 C 
1min 
55 C 
1min 
72 C 
2 min 
72 C 
6 min 
35 
 
 
2.5.1.9 Analysis of recombinant vector by sequencing 
After positive clones were identified, the plasmids were isolated in order to analyse 
the recombinant vector sequence, and then used to transform a proper expression 
host.  The  protocol  described  in  section  2.5.1.4.3  was  used  to  propagate  the 
transformed E. coli cells and prepare the purified recombinant vector plasmid DNA. 
       The correct DNA sequence and reading frame between the vector sequence and 
insert was confirmed by sequencing. Sequencing reaction mixtures (10 l) contained 
2  l  fluorescent  dye  terminator  premix  and  1  l  of  5  x  dilution  buffer,  2  l  of 
forward or reverse vector primers (2.5 pmol / l, Table 2.5), 300-600 ng of template  
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DNA and pure water to 10 l. Sequencing reactions were applied on a thermocycler 
using the following conditions: initial denaturing at 96C for 2.5 min, 25 cycles of a 
denaturing step at 96C for 10 seconds, an annealing step at 50C for 5 seconds and 
extension  at  60C  for  4  min.  The  sequencing  reaction  was  cleaned  up  from 
unincorporated nucleotides and reactants by the ethanol precipitation procedure as 
described in section 2.5.1.4.4. The clean reaction then was sequenced using an ABI 
373A  DNA  sequencer,  according  to  the  manufacturer‘s  specifications.  The 
chromatogram  was  edited  and  analysed  using  SeqEd  version  1.0.3  or  BioEdit 
version 4.7.8 to confirm the accuracy of the sequence and to ensure correct in-frame 
translation  compared  with  the  putative  ORF  sequence  and  the  translated  protein. 
Once a recombinant clone of the correct sequence was identified, protein expression 
was conducted. 
 
2.5.2 Recombinant protein expression 
2.5.2.1 Screening of expressing clones  
Transformed  E. coli  colonies (usually 4-8) that were harbouring the recombinant 
vector with the correct in-frame insert sequence were selected and inoculated into 3 
ml of 2x YT broth containing 100 g/ml ampicillin in 10 ml falcon tubes. The tubes 
were loosely capped and incubated on a shaker (225 rpm), at 37C until the OD600 
reached  0.6-0.8  (about  3  h),  then  the  culture  was  induced  with  isopropyl  β-D-
thiogalactoside  (IPTG)  to  a  final  concentration  of  1  mM.  The  incubation  was 
continued  for  3-8  h.  The  tubes  were  kept  on  ice  for  5  min  and  the  cells  were 
harvested by  centrifugation  at  4,000 x g for 10 min at  4C. Forty microliters  of 
supernatant (medium) were kept on ice for subsequent investigation for secretory 
proteins in the medium. The pellets were resuspended with 150 l denature lysis  
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buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M urea, pH 8.0,: capable of solubilising 
all soluble and insoluble fractions of protein) and mixed well on a vortex, then lysed 
on  a  vertical  shaker  for  30  min  at  room  temperature.  The  denatured  lysate  was 
separated  by  centrifugation  at  10,000  xg  for  30  min.  Forty  microliters  of  clear 
denatured lysate was also kept at on ice for SDS-PAGE and Western blot analysis. 
Non-induced culture was included to compare bacterial protein expression. The best 
clones that highly expressed the target recombinant proteins with the expected size 
shown by SDS-PAGE and Western blot analysis were selected for optimization and 
small scale expression.  
 
2.5.2.2 Determination of target protein solubility 
To distinguish between soluble and insoluble fractions for each protein of interest, 12 
ml of the transformed E. coli culture was prepared. One ml of the culture was used to 
determine OD, and immediately before induction another one ml of non-induced 
culture  was  taken  and  pelleted  for  further  analysis.  The  rest  of  the  culture  was 
induced and then pelleted according to the method described in section 2.5.2.1. The 
culture pellets were resuspended with 500 l of cold native lysis buffer (50 mM Tris-
HCl, 50 mM NaCl, pH 8.0) and transferred into 1.5 ml pre-chilled microcentrifuge 
tubes on ice. The cells were lysed by four cycles of freezing in liquid nitrogen and 
thawing in cold water, and then by sonication on ice four times for 30 second, with 1 
min rest between each burst, using a microtip with the power level set between 3-5, 
at 40-50 pulses per second. The clear native lysate was separated from the cell debris 
by centrifugation at 10,000 xg for 30 min at 4C. Forty microliters of clear native 
lysate was kept on ice for SDS-PAGE and Western blot analysis. The cell debris was 
resuspended with denature lysis buffer (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M  
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urea, pH 8.0), mixed gently with a vortex, then lysed on a rotating mixer at a slow 
setting  for  30  min  at  room  temperature.  The  denatured  lysate  was  separated  by 
centrifugation at 10,000 xg for 30 min. Forty microliters of clear denatured lysate 
was also kept on ice. The samples were mixed with SDS-PAGE sample buffer and 
subjected to SDS-PAGE analysis to determine the solubility of the target proteins.  
 
 
2.5.2.3 Optimization of protein expression level 
 
2.5.2.3.1 Selection of highly expressing clones 
  
The transformed E. coli that best expressed a target protein based on the results of 
the expression screening step was selected and streaked on a 2x YT plate containing 
100 g/ml ampicillin using a standard bacterial plating technique, to obtain several 
separated colonies. Eight well-grown and separated colonies were re-plated on a new 
2x YT plate containing 100 g/ml ampicillin and then each colony was transferred 
into 3 ml 2x YT broth containing 100 g/ml ampicillin in a 10 ml falcon tube as 
starter culture, and incubated with shaking of 225 rpm at 37C to an appropriate 
OD600 of 0.5.  
     Ten ml of fresh and pre-warmed 2x YT broth containing 100 g/ml ampicillin in 
a  50  ml  falcon  tube  was  seeded  with  a  1%  E.  coli  starter  culture.  The  culture 
incubation,  induction  conditions,  and  expression  evaluation  were  carried  out 
according to the method explained in section 2.5.2.1. Based on the results obtained 
from SDS-PAGE and Western blot, highly expressing clones were selected for time-
course analysis of protein expression. 
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2.5.2.3.2 Time-course analysis of protein expression 
 
A time-course analysis of the level of protein expression was used to optimize the 
expression of a given protein construct. The optimal induction period was established 
for each protein by checking the level of the expected protein present at various 
times after induction in the soluble and insoluble fractions (based on the solubility of 
a target protein), according to the following procedure.      
      Fifty ml of pre-warmed 2x YT broth supplemented with 100 g/ml ampicillin in 
a 250 ml conical flask was seeded with 1% of a starter culture of transformed E. coli. 
The culture incubation and induction conditions were similar to those detailed in 
section 2.5.2.1. Samples (one ml) of the culture were collected just before induction 
and hourly after induction and centrifuged at 4,000 rpm for 10 min at 4C. Then, 
based on the solubility  of the target  protein, the cell pellets  were lysed with  the 
appropriate lysis buffer and the clear lysates were analysed directly by SDS-PAGE.    
 
 
2.5.2.3.3 Small-scale protein expression 
 
A  small-scale  expression  and  purification  experiment  were  performed  before 
proceeding with a large scale preparation. A 50 ml culture of transformed E. coli was 
prepared and pelleted according to the standard method of culture and optimised 
condition  of  expression  (sections  2.5.2.3).  Following  the  procedure  explained  in 
section 2.5.2.2, the cleared lysate was prepared by mixing the pellet with 2.5 ml of 
either native or denature lysis buffer, and then purified by nickel-nitrilotriacetic acid 
(Ni-NTA) metal-affinity chromatography. 
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2.5.2.3.4 Large-scale protein expression 
Large-scale preparation of cultures (500-1000 ml) for protein production involved a 
procedure similar to that performed in standard culture, with a minor modification. 
One percent of starter culture (OD600  0.5)  of recombinant E. coli was added to fresh 
and pre-warmed 2x YT broth with 100 g/ml ampicillin and allowed to grow with 
shaking at 37
oC. When the OD600 of cells reached 0.5-0.8 (about 3 h), fusion gene 
expression  was  induced  by  adding  IPTG  to  a  final  concentration  of  1  mM.  The 
culture was then incubated at 37
oC for an additional 3-8 h, and after being cooled on 
ice for 10 min, the cells were harvested by centrifugation (4,000 xg, 10 min, 4
oC) and 
stored  at  -70
  oC  for  subsequent  protein  purification.  One  ml  of  non-induced  and 
induced culture samples were used to compare and analyze the results of protein 
purification by SDS-PAGE or Western blot analysis.  
 
2.5.3 Recombinant protein purification 
Depending on protein location and solubility, the purification of His6-tagged fusion 
proteins  was  performed  under  native  or  denaturing  conditions  by  affinity 
chromatography  using  nickel-nitrilotriacetic  acid  (Ni-NTA)  metal-affinity 
chromatography.  All  the  purification  procedures  were  carried  out  based  on  the 
QIAexpressionist
TM handbook for high-level expression and purification of 6xHis-
tagged proteins. 
 
2.5.3.1 Purification of soluble protein 
For proteins that were expressed as a soluble fraction, purification was performed 
under native conditions. In this method, the cell pellet was taken from -80
oC and  
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thawed on ice for 15 min, followed by resuspending the cells with native lysis buffer 
containing  10  mM  imidazole,  20  mM  beta-mercapthoethanol,  and  a  proteinase 
inhibitor cocktail 1:200. The cells were mixed gently with a vortex apparatus and 
lysed by sonication (4 x 30 second bursts using a microtip, 1 min rest between each 
burst, power level set at 5, and 100 pulses  per sec). The clear native lysate was 
separated by centrifugation at 10,000 xg for 30 min at 4
oC. One ml of 50% Ni-NTA 
slurry then was added to 10 ml of lysate and mixed gently on a rotating shaker (200 
rpm at 4
oC for 1 h). The lysate- Ni-NTA mixture was loaded into a column and 
washed 3-4 times with wash buffer containing 20 mM immidazole, with stepping 
amounts  of 10, 5, and  0 mM  of beta-mercapthoethanol. The tagged recombinant 
protein  was  eluted  eight  times  with  2  ml  of  elution  buffer  containing  250  mM 
imidazole.    
 
2.5.3.2 Purification of insoluble protein 
To look for insoluble aggregates (inclusion bodies) the cell pellet was taken from -80 
oC  and  thawed  on  ice  for  15  min.  One  gram  of  cell  pellet  (wet  weight)  was 
resuspended in 20 ml of denaturing lysis buffer containing 10 mM immidazole and 
lysed for 1 h on a rotating shaker at room temperature. The clear lysate was separated 
by centrifugation at 10,000 xg for 30 min at room temperature. Two ml of 50% Ni-
NTA slurry was added to 20 ml of the clear lysate and mixed gently on a rotating 
shaker  (200  rpm  at  room  temperature  for  1  hour).  The  lysate-resin  mixture  was 
loaded carefully into an empty column and washed 3-4 times with 10 ml of wash 
buffer  containing  20  mM  immidazole.  The  recombinant  protein  was  eluted  eight 
times with 2 ml of elution buffer containing 250 mM immidazole.   
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2.5.3.3 Protein treatment  
 
Conventional  dialysis  was  used  to  separate  small  molecules  (salts)  from  large 
molecules  (proteins  of  interest),  as  previously  described  (Craig,  1967;  McPhie, 
1971).  Dialysis  tubing  was  clamped  at  one  end  and  was  filled  with  the  elution 
containing recombinant protein. The other end of the tube was clamped so that there 
was enough space for expansion. The filled tube was gently squeezed to check the 
integrity of the membrane and clamps. The filled dialysis membrane was immersed 
in a beaker containing 2 litres cold distilled water at 4
oC with gentle stirring. Dialysis 
was continued for 4 days, changing the distilled water twice a day. The dialysed 
protein was sterilized by passing through a 0.45 µm membrane filter, freeze-dried at 
-80
 oC for 48-72 h and the protein powder was stored at -20
oC. 
 
2.5.4 Protein quantification and purity assays 
2.5.4.1 SDS-polyacrylamide gel electrophoresis 
Proteins of interest were separated by sodium dodecyl sulphate - polyacrylamide gel 
elecrophoresis (SDS-PAGE) in a discontinuous buffer system using a 12.5 % (w/v)  
resolving  gel  (2.5  ml  Tris-Cl  1.5  M,  pH  8.8;  0.1  ml  SDS  10%;  4.15  ml 
acrylamide/Bis 30%; 3.2 ml H2O; 50 µl APS 10%; and 10 µl TEMED) and a 4 % 
(w/v)  stacking  gel  (1.25 ml Tris-Cl  0.5 M, pH 6.8; 0.05 ml SDS 10%;  0.65 ml 
acrylamide/Bis 30%; 3.05 ml H2O; 25 µl APS 10%; and 5 µl TEMED) in  BIORAD 
gel plates (1mm), using the method described by Laemmli (1970). The gel plates 
were assembled in the central cooling core in a BIORAD mini protean II tank with 
running buffer (25mM Tris, 192mM glycine and 1 % [w/v] SDS).  
     The protein samples were mixed with SDS loading buffer (125 mM Tris-Cl, pH 
6.8; 4% SDS; 20% v/v glycerol; 20 mM DDT; 0.02% bromophenol blue) and boiled  
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for 5 min. The samples and five microlitres of 100 kDa pre-stained protein marker 
were then loaded into the separate wells of the prepared mini-gel and electrophoresed 
in parallel at 180V for 60 min. Gels were either stained with standard Coomassie 
blue solution to obtain the approximate size and the band density of a target protein, 
or subjected to Western immunoblot for further analysis. 
 
2.5.4.2 Coomassie staining 
For staining,  gels  were  placed in 50ml  of Coomassie staining  solution  and  were 
stained  overnight  at  room  temperature  on  a  horizontal  rocker.  Once  stained,  the 
excess  Coomassie  stain  was  removed  by  placing  the  stained  gel  in  de-staining 
solution I and de-staining solution II subsequently. The last de-staining solution was 
replaced at least twice until the gel was fully de-stained. The de-stained gels were 
scanned or photographed. 
 
2.5.4.3 Immunoblot detection of histidine tagged protein 
SDS-PAGE gels were immobilized on a nitrocellulose membrane (Hybond-C extra, 
0.45 m pore size) using a BIORAD mini protean II transfer tank in transfer buffer, 
and transferred overnight at 30 volts at 4°C. Once removed from the transfer tank the 
nitrocellulose membrane was stained using Ponceau stain and placed in a skim milk 
blocking solution (TBS-T containing 5 % [w/v] Diplomat skim milk), for 60 min on 
a horizontal rocker at room temperature. The blocking solution was removed and the 
membrane was washed three times with TBS-T, each for five min. The membrane 
was placed in a TBS-T solution containing a 1:4000 dilution of primary antibody 
(mouse ant-His IgG) for 60 min on a rocker at room temperature. The membrane was 
then  washed  three  times  each  for  5  min  with  TBS-T  and  incubated  in  a  TBS-T  
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solution containing a 1:6000 dilution of secondary antibody (goat anti-mouse IgG-
AP  conjugate) for 60 min on a rocker  at  room  temperature. The membrane was 
washed three times with TBS, each for five min, and the antigen-antibody bands 
were visualized by incubating the membrane in a fresh alkaline phosphatase (AP) 
staining  solution  for  5-15  min  until  colour  development  was  completed. 
Development was stopped by washing the membrane twice in dd water, each for 5 
min. Immediately after development the membrane was photographed, air-dried and 
stored in the dark.  
 
2.5.4.4 Protein quantification 
Quantification of total protein (ng/µl) was undertaken using a Biorad Protein Assay 
kit. BSA standards (160µL) prepared in duplicate containing 80 ng to 10 ng of BSA 
per  well  were  pipetted  into  marked  wells  on  the  ELISA  plate.  Dilutions  of  the 
proteins to be quantified were made (1:2, 1:4 and 1:8) and loaded into separate wells 
(final volume 160µl). Forty microlitres of  Bradford reagent was added to all  the 
wells,  making  sure  that  the  reagent  and  proteins  were  mixed  thoroughly.  The 
absorbance of the plate was read after 5-15min using the micro plate reader (model 
3550-UV) at OD595 nm. The BSA dilutions were plotted against their OD595 nm to 
give an equation which was used to determine the concentration of the unknown 
protein. 
     Quantification of purified recombinant protein was also carried out by loading 
protein standards (mixed BSA and lysosyme) at concentrations of 100, 250, 500, and 
1000 ng and serial dilutions of the protein sample in different wells of an SDS-PAGE 
gel. After electrophoresis the gel was destained and the gel image acquired using a 
densitometer (proxPRESS Proteomic Imaging System). The retrieved image of the  
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protein  samples  and  protein  standards  were  analyzed  using  the  Proteome  1D 
Analyser version V 1.10 to calculate the protein concentration of the samples. 
 
2.6 IMMUNOGENICITY ANALYSIS OF RECOMBINANT PROTEINS 
2.6.1 In vitro immunogenicity analysis 
In  vitro  immunogenicity  analysis  consisted  of  assays  to  investigate  interactions 
between recombinant proteins as an antigen with polyclonal antibodies against B. 
pilosicoli using the Western blot technique. The polyclonal antibodies were obtained 
from the serum collection held at the Centre for Intestinal Spirochaete Research, 
Murdoch  University.  They  originated  from  different  sources,  including  swine 
naturally  and  experimentally  infected  with  B.  pilosicoli  (Tables  2.8).  The  mouse 
polyclonal  antibody  against  B.  pilosicoli  WesB  strain  was  prepared  by 
hyperimmunisation (two subcutaneous injections with two weeks interval) of mice 
with B. pilosicoli whole cell bacterin.  
 
2.6.1.1 Immuno-blot reactivity of recombinant proteins with convalescent swine 
sera 
Ten micrograms of each recombinant His6-protein was separated by SDS-PAGE and 
eletro-transferred  to  a  nitrocellulose  membrane,  blocked  with  skimmed  milk  and 
assembled into a multi-probe apparatus as previously described. The different pig 
convalescent sera (Table 2.8) diluted 50-100 fold were added to the membrane and 
incubated for 1h followed by three washes. The membrane then was reacted with a 1: 
5000  dilution  of  anti-Pig  IgG-alkaline  phosphate  conjugate.  The  membrane  was 
developed with developing buffer containing NBT and BCIP after three washes.  
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Table 2.8 Source of sera from healthy swine (pre-infection) and swine that had been 
experimentally infected with B. pilosicoli. 
 
Work 
ID  Origin  Description 
N1-N3  Murdoch   Pre-infection pigs  
M1-M3  Murdoch   Hyperimmunised pig with formalinised B. pilosicoli – pigs showing 
seroconversion at PM 
P1-P6  Murdoch   Experimental infection with B. pilosicoli – pigs showing seroconversion at PM 
P7-P13  Murdoch   Experimental infection with B. pilosicoli – pigs colonised at PM (caecal swab) 
 
 
2.6.1.2 Immuno-blot reactivity of recombinant proteins with mouse polyclonal 
antisera to WesB 
Whole  cell  bacterin  was  prepared  from  B.  pilosicoli  strain  WesB,  as  previously 
described  (Hampson  et  al.,  2000).  A  total  of  10
8  formalinized  WesB  cells  were 
emulsified in an equal volume of Freund‘s  Incomplete Adjuvant (FIA) in a total 
volume  of  100  l  and  administered  subcutaneously  into  a  five  5-week-old  male 
C3H/HeJ  mice  three  times  at  two-week  intervals.  Three  weeks  after  the  last 
inoculation,  the  mice  were  euthanized  by  methoxyflurane  inhalation  followed  by 
cervical dislocation, and then blood was collected by cardiac puncture and the serum 
was separated and stored at -20
OC until used in Western blot analysis. 
      A total of 20-50 ng of each purified recombinant His6-proteins was applied to 
two  12.5%  SDS-PAGE  gels,  and  electrophoretically  transferred  to  nitrocellulose 
membranes. The membranes were blocked for 1 h with 5% non-fat dried milk in 
TBS-T  and  then  each  membrane  was  reacted  separately  (1h  incubation  at  room 
temperature) with 100 folded dilutions in TBS-T of the polyclonal mouse antiserum 
raised against WesB whole cell bacterin, and a negative (control) mouse serum. The 
membranes  were  incubated  with  anti-mouse  IgG  alkaline  phosphatase  conjugate  
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diluted 5000 folded in TBS-T for 1h at room temperature, and developed using an 
AP staining solution (BCIP/NBT). 
 
2.6.2 In vivo immunogenicity analysis 
In the in vivo immunogenicity experiment, each recombinant protein was used to 
vaccinate  mice  and  induce  an  immune  response.  The  immunogenicity  of  each 
recombinant protein then was confirmed using Western blot against both whole cell 
protein preparations of B. pilosicoli and each recombinant His6- protein. 
 
2.6.2.1 Immunising mice using recombinant proteins  
Fifty  C3H/HeJ  male  mice  of  5  weeks  of  age  were  obtained  from  the  Western 
Australian State Animal Resource Centre and were housed in 10 groups of five mice 
in  the  Animal  House  at  Murdoch  University.  Nine  groups  of  mice  (vaccinated 
groups) were injected subcutaneously twice at a 2 week interval with 100 g of each 
His6-recombinant protein, resuspended in 50 l PBS, and  emulsified in an equal 
volume of Freund‘s Incomplete Adjuvant in a total volume of 100 l. The last group 
of five mice was left unvaccinated. Two weeks after the last inoculation, all the mice 
were euthanized and the blood collected as described previously. 
 
2.6.2.2 Western blot analysis of sera from mice immunized with recombinant 
proteins 
The  mouse  sera  were  analysed  by  Western  blot  against  both  whole  cell  protein 
preparations of B. pilosicoli and each recombinant His6-protein. For preparation of 
whole cell proteins, cells of B. pilosicoli strain WesB were centrifuged at 1000 g for 
10 min at 4C, then the cells were resuspended in cold PBS (pH 7.2), and washed  
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three times. The cells were suspended at a concentration of 10
8 cell ml
-1 in PBS and 
subjected to four cycles of freeze-thawing followed by sonication on ice for four 
cycles of 30 s with a 2 min rest between each cycle. The sonicate was centrifuged at 
10,000 xg for 30 min and the supernatant was separated for blot assay (Hampson et 
al., 2000). The total protein concentration was quantified using the Biorad Protein 
Assay kit, according to the manufacturer‘s instructions.  
      Ten micrograms of cell protein was separated by 12.5% (w/v) denaturating SDS-
PAGE  in  a  Tris-glycine  buffer  system.  The  loaded  protein  was  then 
electrophoretically transferred to a 0.2 m nitrocellulose membrane. The membrane 
was blocked with TBS-T (Tris buffered saline supplemented with 0.05% v/v Tween 
20) containing 5% (w/v) skim milk powder for 1 h followed by three washings with 
TBS-T. The membrane was assembled into a multi-screen apparatus for multiple sera 
analysis. Mouse sera were diluted 50 fold in 100 l TBS-T, added to the membrane 
through  the  wells  of  the  multi-screen  probe  and  incubated  for  1  h  at  room 
temperature with gentle mixing. The membrane was reacted with a 1:5000 dilution of 
goat anti-mouse  IgG alkaline phosphatase conjugate for 1 h at room temperature 
followed by three washes with TBS. The membrane was developed with developing 
buffer  containing NBT  and BCIP.  For the Western blot using recombinant  His6-
protein, 10 g of the recombinant protein was used. All other procedures were the 
same as previously described. 
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2.7 EFFICACY ANALYSIS OF RECOMBINANT PROTEINS 
Four novel recombinant proteins with a high level of expression and purity (NAV-
P3, NAV-P13, NAV-P22, and NAV-P31), were selected to determine their efficacy 
as candidate vaccine antigens against IS in a mouse model. Two separate efficacy 
trials were applied to assess the efficacy of the selected four recombinant proteins, 
each consisting of four separate vaccine groups in addition to negative and infection 
control  groups.  In  each  efficacy  trial,  each  recombinant  protein  was  separately 
formulated as a mono component vaccine (monovalent vaccine) to vaccinate separate 
group of mice. 
 
2.7.1 Mice 
For each efficacy trial, in total 72 C3H/HeJ female mice at 5-weeks of age were 
obtained  from  the  Western  Australian  State  Animal  Resource  Centre  and  were 
housed in groups of 12 mice per cage in the Animal House at Murdoch University.  
 
2.7.2 Mouse diets 
The mice were fed on a commercial pelleted basal mouse diet (18.9% protein, 5.2 % 
fat,  crude  fibre;  digestible  energy  14.5  MJ  kg
-1)  from  their  arrival  until  10  days 
before  the  day  of  first  infection  with  B.  pilosicoli.  In  the  first  efficacy  trial,  the 
standard  diet  then  was  switched  to  an  experimental  diet,  which  was  a  blend  of 
standard balanced mouse diet supplemented with 50% (w/w) lactose and 50 p.p.m. 
zinc bacitracin (ZnB) (Jamshidian et al., 2004), while in the second efficacy trial it 
was  switched  to  a  similar  balanced  disaccharide-rich  diet  that  lacked  the  zinc 
bacitracin  (Nibbelink &  Wannemuehler, 1992;  Sacco et  al., 1997). The switched 
diets then were continued for the rest of the experiments.   
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2.7.3 Preparation of challenge inoculum 
To prepare active B. pilosicoli cells for challenge inoculums, B. pilosicoli human 
strain WesB was obtained from frozen stock held in the culture collection at the 
Reference Centre for Intestinal Spirochaetes, Murdoch University. The strain was 
originally isolated from an Aboriginal child with diarrhoea, and previously had been 
used for the experimental infection of pigs (Trott et al., 1996a), chickens (Trott et al., 
1995) and a human volunteer (Oxberry et al., 1998). The spirochaetal cells were 
propagated as previously described. At mid-exponential phase growth when the cells 
were actively motile, cell numbers were counted using a haemocytometer and at a 
density of approximately 10
8 cells ml
-1, the bacterial culture was use as an infectious 
inoculum.  
 
2.7.4 Preparation and formulation of recombinant His6-proteins for vaccination 
Four selected recombinant proteins for use in the vaccine trail were over-expressed 
as histidine tagged fusion proteins (His6- NAV-P3, His6- NAV-P13, His6- NAV-P22, 
and His6-NAV-P31) in E. coli Star
TM (DE3) pLys in 2x YT broth medium, and then 
purified under native and denature conditions using affinity chromatography. The 
purified proteins were dialysed against distilled water to remove excessive amount of 
salts, lyophilised to dryness and resuspended in PBS. The quality of the proteins was 
checked  by  SDS-PAGE,  and  their  concentrations  were  quantified  using  a 
densitometer,  as  previously  described.  To  formulate  four  separately  monovalent 
vaccines, 100 µg of each protein in 50µl PBS was emulsified in an equal volume of 
Freund‘s Incomplete Adjuvant in a total volume of 100 l. 
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2.7.5 Immunisation and experimental challenge 
The vaccination and challenge procedures were designed based on those  described 
by  Jamshidi  et  al  (2003),  with  modifications  (Table  2.9).  The  immunisation  and 
experimental  challenge  was  carried  out  in  two  separate  trials  at  different  times. 
NAV-P13 and NAV-P31 recombinant proteins were used in the first efficacy trial, 
and NAV-P3 and NAV-P22 recombinant proteins in the second trial.  
      In  each  trial,  for  each  recombinant  protein,  12  mice  were  used  as  a 
vaccinated/non  infected  group  and  12  mice  as  a  vaccinated/infected  group.  Each 
group of mice in the vaccination groups were injected subcutaneously twice at a 2 
week interval with 100 g of each monovalent His6-recombinant protein emulsified 
in Freund‘s Incomplete Adjuvant in a total volume of 100 l. In both efficacy trials 
two  control  groups  of  mice  including  12  mice  in  the  non-vaccinated/infected 
(infection control) and 12 mice in the non-vaccinated/non-infected (negative control) 
groups  also  were  assigned  and  left  non-vaccinated.  Two  weeks  after  the  second 
vaccination (boost), the 12 mice in the vaccinated/non infected group were killed to 
obtain blood and intestinal samples to analyse systemic and local antibody responses. 
The  12  mice  in  the  vaccinated/infected  group,  and  the  12  mice  in  the  infection 
control group were deprived of water for 1 h before infection, then all the mice were 
infected via gastric intubation with 500 l of fresh motile B. pilosicoli (human strain 
WesB) culture. The inoculation procedure was  repeated daily on the following 3 
days. The negative control group was not infected and the mice were killed to collect 
their  blood  and  intestine  samples,  as  for  the  pre-vaccinated  samples. 
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Table 2.9 Programme for efficacy trial of two experimental WesB recombinant subunit vaccines in groups of 12 five week-old C3H/HeJ mice. 
Programme  Day  Diet 
1
st Recombinant NAV-Pn 
Vaccinated Group 
2
nd Recombinant NAV-Pn 
Vaccinated Group 
Infection Control 
Group 
Negative Control 
Group 
vaccinated/infected 
group  
vaccinated/non 
infected group  
vaccinated/infected 
group  
vaccinated/non 
infected group  
Non-vaccinated/ 
Infected group 
Non-vaccinated/ 
Non-Infected 
group  
Immunisation 
Period 
Day 0 
1
st Vac.  Standard  100 µg protein 
in *FIA  (SC) 
100 µg protein 
in FIA  (SC) 
100 µg protein 
in  FIA   (SC) 
100 µg protein 
in   FIA  (SC) 
_  _ 
Day 14 
2
nd Vac.  Standard  100µg protein 
in  FIA   (SC) 
100µg protein 
in FIA  (SC) 
100µg protein 
in FIA  (SC) 
100µg protein 
in  FIA  (SC) 
_  _ 
Infection or 
Challenging 
Period 
Day 29 
1
st Inf. 
** S
+ or 
Teklad           ***+  _           ***+  _          ***+  _ 
Day 30 
2
nd Inf.  S
+ or Teklad  + 
_ 
+ 
_ 
+ 
_ 
Day 31 
3
rd Inf.  S
+ or Teklad  + 
_ 
+ 
_ 
+ 
_ 
Day 31 
4
th Inf.  S
+ or Teklad  + 
_ 
+ 
_ 
+ 
_ 
Post Infection 
Faecal 
Sampling 
Day 34  S
+ or Teklad  √  √  √  √  √  √ 
Every 3-4          
days  S
+ or Teklad  √  √  √  √  √  √ 
Post-mortem 
Sampling 
Day of 
highest 
bacterial 
shedding 
S
+ or Teklad 
(Blood, faecal and 
intestine tissue 
sampling) 
(Blood, faecal and 
intestine tissue 
sampling) 
(Blood, faecal and 
intestine tissue 
sampling) 
(Blood, faecal and 
intestine tissue 
sampling) 
(Blood, faecal and 
intestine tissue 
sampling) 
(Blood, faecal and 
intestine tissue 
sampling) 
 
*: FIA, Freund‘s Incomplete Adjuvant; * *: S
+ diet, Standard diet supplemented with 50 % (w/w) lactose and 50 p.p.m. ZnB; ***: (+), inoculation of 2 x 10
8 virulent cells 
in 500µl of bacterial culture medium administered orally; (−): No inoculation of the virulent bacterial cells; (√): Faecal sampling; The standard diet has been switched to 
Standard
+ diet or Teklad diet on day 19 of efficacy trial.   109 
2.7.5.1 Faecal sampling, culture and DNA detection 
Individual  faecal  samples  (3-4  pellets)  from  each  mouse  were  collected  before 
vaccination, before infection, and two times a week thereafter, starting 3 days after the 
last oral inoculation. Bacteriological swabs were inserted into the faeces and streaked 
onto selective Trypticase Soy agar (BBL) plates containing 5% (v/v) defibrinated ovine 
blood, 400 g spectinomycin ml
-1 and colistin and vancomycin each at 25 g ml
-1. The 
plates were incubated for 7–10 days at 37 ºC in an anaerobic environment (94% N2/6% 
CO2) generated using anaerobic Gaspak Plus sachets, before being examined.  
      The presence of spirochaetes was initially identified by the appearance of a zone of 
weak beta-haemolysis surrounding a low flat haze of bacterial growth. The suspected 
spirochaetal growth was examined by phase-contrast microscopy and then resuspended 
in 50 µl lysis buffer (TE, pH 8). The suspension was mixed by vortex and then heated in 
a boiling water bath for 5 min to lyse the cells and denature DNAses. The boiled cell 
extracts were then subjected to a PCR protocol which specifically amplifies an 823 bp 
segment of the 16S rRNA gene of B. pilosicoli using Acoli1 and Pilo-16-R primers (the 
primers sequences are presented in section 2.3.4.3). A 2.5 µl aliquot of the boiled cells 
was added to a 25 µl PCR reaction consisting of 1 x PCR buffer, 1.5 mM MgCl2, 0.6U 
of Taq DNA polymerase, 0.25 mM of each dNTP, and 12.5 pM of each primer. The 
PCR optimized cycling conditions are presented in Table 2.10, with modifications (La et 
al., 2003). The PCR products were subjected to electrophoresis in 1.2% agarose gel, 
stained by immersion for 30 min in ethidium bromide solution, and viewed over UV 
light. 
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Table 2.10 The optimized PCR cycling conditions for screening of B. pilosicoli DNA in 
mice faecal samples. 
First Denaturation 
Polymerization cycles 
Final 
Extension 
Number of 
Cycles 
Denaturation  Annealing  Extension 
95 C 
15 min. 
94 C 
30 Sec. 
52 C 
30 Sec. 
72 C 
30 Sec. 
72 C 
5 min  35 
 
 
 
2.7.5.2 Faecal samples, ELISA and mucosal IgG and IgA analysis 
In the efficacy trials for the NAV-P3, NAV-P13, NAV-P22 and NAV-P31 recombinant 
vaccines, faecal samples (3-4 fresh faecal pellets) from each mouse in the vaccinated 
(vaccinated/infected and vaccinated/non infected) groups, infection control group, and 
negative control group were collected in 1.5 ml microcentrifuge tubes before vaccination 
(pre-vaccination),  before  the  fist  day  of  challenge  (post-vaccination),  and  at  post-
mortem. Then based on the methods described by Haneberg et al. (1994) and Hochepied 
et al. (2002), 500 µl of cold PBS containing 5% skim milk and 0.5% proteinase inhibitor 
was added to each faecal sample and incubated at 4 C overnight until dissolved. Then 
after mixing by vortex the supernatant was collected by centrifugation at 16,000 xg for 
10 min and stored at -20°C until used.  
 
2.7.5.3 Blood samples 
For  each  recombinant  protein,  the  mice  in  the  vaccinated/non  infected  and  negative 
control groups were killed on day 28 of the efficacy trial while the vaccinated/infected 
group and infection control group were killed on the day of highest bacterial shedding. 
The  mice  were  euthanized  by  methoxyflurane  inhalation  followed  by  cervical   111 
dislocation and then their blood was collected by cardiac puncture in to 2 ml tubes. The 
blood samples were allowed to stand for 4 hour at room temperature and overnight at 4 
ºC until a clot formed. After removal of the clot, serum was centrifuged at 2000 xg for 
10 min at 4C to pellet the debris. The serum samples were removed and mixed with an 
equal volume of 100% glycerol, and stored at -20 C. The clear supernatants were used 
for ELISAs, as described later. 
 
2.7.5.4 Post-mortem samples 
For all mice that were killed, the luminal surface of the caecal and colonal walls were 
rubbed with sterile bacteriological swabs, which were cultured for B. pilosicoli in the 
same way as described for faecal swabs. Large intestinal contents equal to three to four 
faecal pellets also were collected from the caecums and colons in 500 µl of cold PBS 
containing 5% skim milk and 0.5% of proteinase inhibitor for antibody quantification. 
Sections of the caecal and colon walls were excised and rinsed in cold PBS to remove 
digesta and then were placed in 10% (v/v) buffered formalin for subsequent histological 
examination. The fixed tissue was processed through to paraffin blocks, cut at 4 µm and 
stained with haematoxylin and eosin. 
 
2.7.6 Assays for antibody responses 
After being optimized, Enzyme-linked immunoabsorbent assays (ELISA) and Western 
immunoblot  analysis  were  used  to  evaluate  the  systemic  and  mucosal  IgG  and  IgA 
responses against the histidine tagged recombinant proteins. 
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2.7.6.1 Optimizing of ELISA conditions to analyse antibody responses 
The four recombinant proteins (NAV-P3, NAV-P13, NAV-P22, and NAV-P31) and a 
whole  cell  B.  pilosicoli  protein  preparation  were  tested  using  the  same  range  of 
conditions  to  determine  the  optimal  conditions  for  detection  of  specific  antibodies. 
Throughout all steps of the ELISA 50µl volumes of reagents were used, except in the 
blocking step where 100 µl was used. The ELISA plates were NUNC maxisorb, and the 
standard blocking solution was 5% Diplomat skim milk in PBS/Tween (0.05%) [v/v]. 
Plates were coated with 25ng (2 rows), 50ng (2 rows), 100 ng (2 rows), and 200 ng (2 
rows) of each protein in a 0.1 M carbonate buffer pH 9.5 (160 ml of 0.2 M   Na2CO3, 
340 ml of 0.2 M NaHCO3), and were incubated overnight at 4°C. After incubation, the 
plates were washed three times with PBS-T and blocking solution was added for 60 min 
at  room  temperature  to  block  excess  binding  capacity.  The  blocking  solution  was 
removed and the plates rinsed three times with PBS-T. The negative and positive sera 
were diluted 1:50, 1:100, and 1:200 in TBS-T and added to the correct lanes on the 
ELISA plates. Each plate was incubated for 1 hour at 37°C then washed three times with 
PBS-T. A 1:2000 dilution of goat anti-mouse IgG HRP conjugated in TBS-T was added 
as a secondary antibody, and incubated for 1 hour at 37°C. The plates were washed three 
times with PBS (pH 7.4). The BIO-RAD colour substrate reagent (9 parts A, 1 part B) 
was added to the wells and the plates developed for 15 min. The reaction was stopped 
with 2 % [w/v] oxalic acid, and the absorbance read at OD405 nm. The optimum quantity 
of protein was assessed by a) the maximum absorbance value b) the difference between 
the positive absorbance and the negative absorbance. The same procedure was carried 
out to optimize the ELISA conditions for mucosal IgG and IgA analysis, except a 1:2   113 
dilution of negative and positive faecal extract was used as primary antibody, and goat 
anti-mouse IgG or IgA HRP conjugated was used as secondary antibody.  
 
2.7.6.2 Optimizing Western blot conditions to analyse antibody responses 
Different amounts of quantified recombinant or whole cell bacterial proteins (1000ng, 
2000ng, 3000ng, 4000ng and 5000ng) were loaded onto SDS PAGE gels, as previously 
described. These gels were electro-blotted onto nitrocellulose membranes overnight and 
each  blotted  membrane  was  tested  against  different  serum  dilutions  (1:25  and  1:50, 
1:100) of known negative and positive mouse sera raised against NAV-P3, NAV-P13, 
NAV-P22,  and  NAV-P31,  which  previously  had  been  confirmed  by  Western 
immunoblotting. 
 
2.7.6.3 ELISA for systemic and colonic IgG and IgA 
The ELISA method used the optimal quantity of either each recombinant protein or a 
whole  cell  protein  preparation  of  B.  pilosicoli  per  well  plus  the  optimum  blocking 
solution and diluent. The process was the same as in the optimization step (2.7.6.1) with 
optimize dilutions of mouse serum (1:200 for NAVP-3, 13, 22, and 31) or faecal extract 
samples (1:2) being added to wells in the ELISA plates.  
 
2.7.6.4 Western immunoblot analysis of systemic and colonic IgG and IgA 
Systemic and colonic antibodies were analysed by Western blot using either 3000 ng of 
recombinant protein or 5000 ng of whole cell B. pilosicoli protein preparation as antigen. 
The  procedure  was  the  same  as  that  described  previously  (2.4.4.3),  except  that    114 
secondary IgG and IgA antibodies (goat anti-mouse IgG-HRP or IgA-HRP conjugated; 
1:4000  dilution)  were  used  to  detect  mouse  primary  antibodies,  and  horseradish 
peroxidase substrate solution (HRP 10 mg, 16.6 ml PBS pH7.4, 3.325 ml methanol and 
10µL of hydrogen peroxide) was used to develop the colour.  
 
 
 
2.7.6.5 Data analysis and statistics 
Data were calculated for each group of 12 mice during the experimental vaccination and 
efficacy  trial.  Comparisons  were  made  between  the  four  groups  of  mice  for  each 
experimental vaccine. The ELISA values for group systemic and local IgG and IgA were 
calculated as means ± SD. The statistical differences of the ELISA titres between groups 
of mice in each experiment were analysed using one way analysis of variance (ANOVA) 
in Microsoft Office Excel. The faecal excretion of B. pilosicoli for each animal in each 
experimental group of infected mice was recorded as positive or negative to create a 
simple ratio of infected samples per total samples collected for each group. The day of 
highest shedding rates in the infection control group was used to calculate colonisation 
rates during each efficacy trials at the post infection period. The ratios for each group 
were compared using Chi-square analysis.  
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CHAPTER THREE 
 
 
RESULTS 
 
 
3.1 IN SILICO ANALYSIS OF PREDICTED ORFS 
3.1.1 BlastP functional prediction 
Twenty four ORFs from the partially completed B. pilosicoli genome sequence were 
subjected  to  functional  annotation  using  BlastP.  These  were  given  a  temporary 
nomenclature,  starting  with  NAV,  until  such  time  as  the  full  genome  sequence  is 
finished. Of these 24 ORFs, 9  including NAV-P3, 13, 20, 22, 24, 25, 27, 30 and 31 were 
predicted as encoding proteins involved in ABC-type oligopeptide transport systems, 2  
(NAV-P51 and 52) as  encoding putative glycosyltransferase proteins, 2 (NAV-P8 and 9) 
as encoding protein-export membrane proteins (secD),  9 (NAV-PX, NAV-P18, 19, 21, 
23, 29, 45, 50 and 53) as encoding proteins with enzyme activities, and finally 2 ORFs 
(NAV-P5 and 15) as encoding an outer membrane protein and a membrane associated 
lipoprotein respectively. The results of the functional homology search for all ORFs are 
summarized in Table 3.1. 
 
3.1.2 Protein domain prediction by Pfam analysis 
The 24 ORFs also were analysed by the Pfam algorithm to predict the structural and 
functional building blocks of the encoded proteins. Seven ORFs (NAV-P3, 20, 22, 24, 
27,  30 and 31) were predicted to  encode proteins  with  motifs suggesting they were 
extracellular solute-binding proteins, 3 ORFs (NAV-P8, 9, and 13) encoded proteins with 
functional domains suggesting  protein export membrane proteins, one ORF (NAV-P25)   116 
encoded  a binding-protein-dependent transport system inner membrane component, 2 
ORFs (NAV-P5, 29) encoded proteins with a LysM domain, 2 ORFs (NAV-P18, 45) 
encoded putative haemolysins, one ORF (NAV-P15) encoded a member of the ApbE 
family of lipoproteins, and the products of the remaining ORFs (NAV-P19, 21, 50, 51, 
52, and 53) had motifs consistent with enzymatic activities (Table 3.2.). 
 
3.1.3 Prediction of subcellular location  
3.1.3.1 Prediction of location by PSORTb analysis  
Using  the  PSORTb  tool,  six  ORFs  (NAV-PX,  NAV-P5,  21,  51,  52,  and  53)  were 
predicted to encode cytoplasmic proteins, 6 ORF products (NAV-P8, 9, 18, 23, 25 and 
45) were located in the cytoplasmic membrane, 9 ORF products (NAV-P3, 13, 20, 22, 
24, 27, 30, 31, and 50) were associated with   the periplasmic membrane, two ORF 
products (NAV-P15 and 29) were outer membrane proteins, and ORF product NAV-P19 
was predicted to be an extracellular protein (Table 3.3). 
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Table 3.1 Functional annotation of candidate genes (ORFs) by BlastP homology search. 
Gene ID 
BlastP homology analysis 
Possible identity, Accession No.  E-value  Possible protein 
subcellular location 
NAV-PX
  ATP-dependent Clp protease, ATPase subunit, 
CAI44263.1 
1e-72 
 
_ 
NAV-P3
  ABC-type oligopeptide transport, ZP_00312756.1  e-121  Periplasmic component 
NAV-P5  Outer membrane protein TmpB, B43592  1e-12  Outer membrane protein 
NAV-P8  Protein-export membrane protein (secD), 
AAC65398.1 
2e-82  Secretory protein 
NAV-P9  Protein-export membrane protein (SecD), 
CAG35535.1 
6e-40 
 
Secretory protein 
NAV-P13  ABC-type transport system, ZP_00099372.1|  9e-80 
 
Periplasmic component/ 
surface lipoprotein 
NAV-P15  Thiamine biosynthesis lipoprotein apbE precursor, 
NP_781676.1| 
4e-40  Membrane-associated 
lipoprotein 
NAV-P18
  Hemolysin-related protein, NP_228654.1|  2e-52  _ 
NAV-P19
  O-sialoglycoprotein endopeptidase, 
NP_973102.1| 
1e-80 
 
_ 
NAV-P20
  ABC-type oligopeptide transport system, 
ZP_00312756.1| 
e-116 
 
Periplasmic component 
NAV-P21
  Collagenase and related proteases, 
ZP_00313417.1| 
5e-88 
 
_ 
NAV-P22
  ABC-type oligopeptide transport system, 
ZP_00312756.1| 
1e-81 
 
Periplasmic component 
 
NAV-P23
  Hemolysins and related proteins containing CBS 
domains, ZP_00294963.1 
1e-67 
 
_ 
NAV-P24
  ABC-type oligopeptide transport system, 
ZP_00312756.1 
e-107 
 
Periplasmic component 
 
NAV-P25
  Oligopeptide/dipeptide ABC transporter, permease 
protein, NP_971681.1| 
e-107 
 
_ 
NAV-P27  ABC-type oligopeptide transport system, 
ZP_00312756.1| 
4e-67 
 
Periplasmic component 
 
NAV-P29  LysM domain/M23/M37 peptidase domain protein, 
NP_973351.1 
8e-46 
 
_ 
NAV-P30  ABC-type amino acid transport, ZP_00103739.2  2e-57  Periplasmic component 
NAV-P31  ABC-type amino acid transport, ZP_00103739.2  4e-57  Periplasmic component 
NAV-P45  Hemolysin III, AAU06976.1|  9e-46  _ 
NAV-P50  Galactose/glucose-binding protein, AAF97729.1|  4e-73  _ 
NAV-P51  Putative glycosyltransferase protein, CAH07263.1  1e-65  _ 
NAV-P52  Putative glycosyltransferase protein, CAH07263.1  2e-71  _ 
NAV-P53  Putative peptidase, YP_071235.1|  4e-37  _ 
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Table 3.2 Recognizing functional domains of candidate genes by sequence comparison 
using Pfam homology analysis. 
Gene ID 
Protein domain 
Seq.from  Seq. to  Length  Domain function 
NAV-PX
  272  470  199  ATPase family associated with various cellular activities 
(AAA) 
NAV-P3
  64  450  387  Bacterial extracellular solute-binding proteins, 
NAV-P5  128  181  54  PG_binding_2; LysM domain 
NAV-P8  61  92  32  SecD/SecF GG Motif; Protein export membrane protein 
NAV-P9  51  79  29  SecD/SecF GG Motif; Protein export membrane protein 
NAV-P13  6  341  336  Basic membrane protein; Protein export membrane 
protein 
NAV-P15  10  27  18  ApbE family of lipoproteins 
NAV-P18
  9  201  193  Domain of unknown function; transmembrane region 
annotated as hemolysins or  intracellular CBS domains 
NAV-P19
  23  306  284  Peptidase_M22; Glycoprotease family 
NAV-P20
  69  455  287  SBP_bac_5; Bacterial extracellular solute-binding 
proteins, family 5 Middle 
NAV-P21
  86  302  217  Peptidase_U32; MEROPS peptidase family U32 
NAV-P22
  66  348  283  SBP_bac_5; Bacterial extracellular solute-binding 
proteins, family 5 Middle 
NAV-P23
  1  195  195  DUF21; transmembrane region of unknown function 
NAV-P24
  70  83  14  SBP_bac_5; Bacterial extracellular solute-binding 
proteins, family 5 Middle 
NAV-P25
  119  342  223  BPD_transp_1; Binding-protein-dependent transport 
system inner membrane component 
NAV-P27  1  239  329  SBP_bac_5; Bacterial extracellular solute-binding 
proteins, family 5 Middle 
NAV-P29  150  193  44  LysM; LysM domain 
NAV-P30  43  265  223  SBP_bac_3; Bacterial extracellular solute-binding 
proteins, family 3 
NAV-P31  43  265  223  SBP_bac_3; Bacterial extracellular solute-binding 
proteins, family 3 
NAV-P45  12  212  201  HlyIII; Haemolysin-III related 
NAV-P50  2  233  222  Cellulase; Cellulose (glycosyl hydrolase family 5) 
NAV-P51  4  191  188  glycosyl_transf_2; Glycosyl transferase family 2 
NAV-P52  4  183  180  glycosyl_transf_2; Glycosyl transferase family 2 
NAV-P53  4  169  166  Creatinase/Prolidase N-terminal domain; Creatinase_N 
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Table 3.3 Prediction of subcellular localization of candidate gene products using the 
PSORTB v.2.0 analysis tool. 
Protein 
ID 
Subcellular 
location 
Localization 
Score  Motif  Signal 
peptide 
No. of 
Transmembrane 
helices 
NAV-PX
  Cytoplasmic  2.00  Unknown  No  No 
NAV-P3
  Periplasmic  9.44  Unknown  No  1 internal helix 
NAV-P5  Cytoplasmic  8.96  Unknown  No  No 
NAV-P8  Cytoplasmic Membrane  10.00  Unknown  No  6 internal helices 
NAV-P9  Cytoplasmic Membrane  10.00  Unknown  No  6 internal helices 
NAV-P13  Periplasmic  2.00  Unknown  No  1 internal helix 
NAV-P15  OuterMembrane  9.49  Unknown  No  1 internal helix 
NAV-P18
  Cytoplasmic Membrane  9.83  Unknown  Yes  4 internal helices 
NAV-P19
  Extracellular  9.71  Unknown  No  1 internal helix 
NAV-P20
  Periplasmic  9.44  Unknown  No  1 internal helix 
NAV-P21
  Cytoplasmic  8.96  Unknown  No  No 
NAV-P22
  Periplasmic  9.44  Unknown  No  No 
NAV-P23
  Cytoplasmic Membrane  9.46  Unknown  No  4 internal helices 
NAV-P24
  Periplasmic  9.44  Unknown  No  1 internal helix 
NAV-P25
  Cytoplasmic Membrane  10.00  Unknown  No  7 internal helices 
NAV-P27  Periplasmic  9.44  Unknown  No  No 
NAV-P29  Outer Membrane  8.97  Unknown  No  3 internal helices 
NAV-P30  Periplasmic  10.00  Unknown  No  No 
NAV-P31  Periplasmic  10.00  Unknown  No  No 
NAV-P45  Cytoplasmic Membrane  10.00  Unknown  No  7 internal helices 
NAV-P50  Periplasmic  5.77  Unknown  No  1 internal helix 
NAV-P51  Cytoplasmic  8.96  Unknown  No  No 
NAV-P52  Cytoplasmic  8.96  Unknown  No  No 
NAV-P53  Cytoplasmic  2.00  Unknown  No  No 
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3.1.3.2 Analysing by SignalP 
SignalP predicted that 14 ORF products including NAV-PX, NAV-P3, 5, 8, 9, 19, 23, 
27, 29, 45, 51, 52, and 53 were non-secretory proteins whereas NAV-P13, 15, 18, 20, 
22,  24,  25,  30,  31,  and  50  were  secretory  proteins.  The  results  of  signal  peptide 
prediction are presented in Table 3.4. 
 
 
3.1.3.3 Prediction of lipoprotein signal peptide (SpII) by LipoP 1.0 
 
LipoP 1.0 predicted that seven ORFs (NAV-P3, 13, 20, 22, 24, 30, and 31) encoded 
products with lipoprotein signal peptides (Table.3.5).    
 
3.1.3.4 TMpred 
Using  TMpred,  all  ORFs  except  NAV-P5  and  NAV-P53  were  predicted  to  contain 
between 1-7 transmembrane helices. For instance, in NAV-P3 there were two strong N-
terminal  transmembrane  helices  with  lengths  of  22  and  19  amino  acids  at  positions 
located from 4-25 and 270-288 respectively (Figure 3.1). NAV-P45, NAV-P9, NAV-P8, 
and NAV-P25 had 7, 6, and 5 had N-terminal transmembrane segments containing the 
highest numbers of helices respectively (Table 3.6). 
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Table 3.4 Prediction of signal peptide in ORFs products by SignalP 3.0 using neural 
networks  (NN)  and  hidden  Markov  model  (HMM)  prediction  for  Gram-negative 
bacteria. 
Protein 
ID 
SignalP-NN result  SignalP-HMM result 
Signal P  Position  Cleavage 
site  Signal P  Cleavage 
site  Prediction 
NAV-PX
  NO   –  –  No  –  Non-secretory protein 
NAV-P3
  Yes  1-18  18-19  No  –  Non-secretory protein 
NAV-P5  NO  –  –  No  –  Non-secretory protein 
NAV-P8  NO  –  –  No  –  Non-secretory protein 
NAV-P9  Yes  33  42-43  No  –  Non-secretory protein 
NAV-P13  Yes  10, 
1-21 
21-22  Yes  21-22  Secretory protein 
NAV-P15  Yes  14, 
1-19 
19-20  Yes  26-27  Secretory protein 
NAV-P18
  Yes  31, 
1-30 
30-31  Yes  30-31  Secretory protein 
NAV-P19
  No  –  –  No  –  Non-secretory protein 
NAV-P20
  No  –  –  No  –  Secretory protein 
NAV-P21
  No  –  –  No  –  Non-secretory protein 
NAV-P22
  Yes  7, 
1-22 
22-23  Yes  22-23  Secretory protein 
NAV-P23
  No  –  –  No  –  Non-secretory protein 
NAV-P24
  Yes  21  36-37  Yes  34-35  Secretory protein 
NAV-P25
  Yes  29  28-29  Yes  29-30  Secretory protein 
NAV-P27  No  –  –  No  –  Non-secretory protein 
NAV-P29  No  –  –  No  –  Non-secretory protein 
NAV-P30  Yes  1-20  20-21  Yes  22-23  Secretory protein 
NAV-P31  Yes  24, 
1-23 
23-24  Yes  22-23  Secretory protein 
NAV-P45  Yes  30  33-34  No  –  Non-secretory protein 
NAV-P50  Yes  9, 
1-21 
21-22  Yes  21-22  Secretory protein 
NAV-P51  No  –  –  No  –  Non-secretory protein 
NAV-P52  No  –  –  No  –  Non-secretory protein 
NAV-P53  No  –  –  No  –  Non-secretory protein 
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Table 3.5  Prediction of lipoprotein signal peptide (signal peptidase II) in candidate 
gene products using LipoP 1.0 
Protein ID  Lipoprotein signal peptide  Cleavage site  Score  Position + 2 
NAV-PX
  No  –  –  – 
NAV-P3
  Yes  14-16  6.57754  S 
NAV-P5  No  –  –  – 
NAV-P8  No  –  –  – 
NAV-P9  No  –  –  – 
NAV-P13  Yes  16-17  13.8613  G 
NAV-P15  No  –  –  – 
NAV-P18
  No  –  –  – 
NAV-P19
  No  –  –  – 
NAV-P20
  Yes  17-18  7.82273  S 
NAV-P21
  No  –  –  – 
NAV-P22
  Yes  15-16  9.57954  S 
NAV-P23
  No  –  –  – 
NAV-P24
  Yes  30-31  8.17654  G 
NAV-P25
  No  –  –  – 
NAV-P27  No  –  –  – 
NAV-P29  No  –  –  – 
NAV-P30  Yes  16-17  9.44179  S 
NAV-P31  Yes  16-17  11.0547  S 
NAV-P45  No  –  –  – 
NAV-P50  No  –  –  – 
NAV-P51  No  –  –  – 
NAV-P52  No  –  –  – 
NAV-P53  No  –  –  – 
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Table 3.6  Prediction of N-terminal transmembrane helices in candidate gene products 
using TMpred. 
Protein ID 
No of 
Helix 
Position of TM helix 
Length of 
TM 
helix 
Score of TM 
helix 
NAV-PX
  2  174-196, 396-419  23, 24  757, 787 
NAV-P3
  2  4-25, 270-288  22, 19  769, 686 
NAV-P5  No  –  –  – 
NAV-P8  5  7-25, 338-358,360-380, 385-
410, 462-482 
19,21,21, 26, 
21 
2718, 2614, 210, 
1657, 2286 
NAV-P9  6  29-49, 156-174, 180-203, 206-
229, 258-280, 290-309 
21, 19, 24, 24, 
23, 20 
2265,2855, 1761, 1366, 2421, 
2205 
NAV-P13  3  4-21, 153-172, 220-27  18, 20, 18  1848, 1124, 566 
NAV-P15  1  7-25  19  2769 
NAV-P18
  4  4-26, 66-86, 100-120, 135-153  23, 21, 21, 19  2264, 1109, 2076, 1209 
NAV-P19
  1  83-100  18  1183 
NAV-P20
  1  1-19  19  1677 
NAV-P21
  2  176-194, 619-638  19, 20  827,1007 
NAV-P22
  2  1-20, 162-183  20, 22  1254, 1087 
NAV-P23
  4  1-18, 55-75, 98-116, 145-164  18, 21, 19, 20  225, 1710, 1752, 1122 
NAV-P24
  1  14-33  20  2356 
NAV-P25
  5  13-31, 124-143, 161-183, 206-
228, 267-290, 314-336 
19, 20, 23, 23, 
24, 23 
2341, 2000, 2145, 1932, 
1894, 927 
NAV-P27  1  272-292  21  797 
NAV-P29  3  40-58, 307-323, 338-359  19, 17, 22  2762, 673, 1021 
NAV-P30  1  1-18  18  1514 
NAV-P31  1  1-18  18  1447 
NAV-P45  7  21-64, 46-64, 85-104, 107-
131, 135-152, 164-184, 198-
218 
20, 19, 20, 25, 
18, 21, 21 
1966, 1901, 1707, 2223, 
2082, 2281, 1574 
NAV-P50  1  5-21  17  1777 
NAV-P51  1  139-159  21  541 
NAV-P52  1  214-233  20  744 
NAV-P53  No  –  –  – 
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Figure 3.1 Hydrophobicity analysis of the N-terminal 527 amino acids of NAV-P3. The 
profile was determined using the TMpred transmembrane regions detection programme; 
hydrophobic residues have a positive score while hydrophilic residues have a negative 
score. 
 
 
3.1.4  Calculation  of  G+C  content  and  estimation  of  molecular  weight  of  ORF 
products 
The results of the G+C content of ORFs and theoretical molecular weight of the ORF 
products  as  estimated  using  the  BioEdit  Sequence  Alignment  Editor  (version  4.8.6 
Department of Microbiology North Carolina State University) are summarised in Table 
3.7. Nucleotide numbers varied from 2181 bp (NAV-P21) to 813 bp (NAV-P30), and 
GC% content varied form 33.94% (NAV-P5) to 26.10% (NAV-P52).  
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Table 3.7 The G+C content of ORFs and theoretical molecular weight of their products. 
Genes ID 
Nucleotide  Protein 
Size (bp)  G+C (%)  A+T (%)  No. of AA 
MW 
(Daltons) 
NAV-PX
  1782  28.06  71.94  594  67419.11 
NAV-P3
  1581  29.35  70.65  527  60352.01 
NAV-P5  654  33.94  66.06  218  24963.47 
NAV-P8  1509  33.33  66.67  503  55209.72 
NAV-P9  942  26.96  73.04  314  35232.54 
NAV-P13  1059  33.81  66.19  353  38013.16 
NAV-P15  1011  27.70  72.30  337  38348.27 
NAV-P18
  1380  28.12  71.88  460  52600.53 
NAV-P19
  1023  33.43  66.57  341  37357.58 
NAV-P20
  1593  30.07  69.93  531  61099.24 
NAV-P21
  2181  27.37  72.63  727  82169.05 
NAV-P22
  1050  30.67  69.33  350  39403.82 
NAV-P23
  1269  28.61  71.39  423  47377.47 
NAV-P24
  1641  31.39  68.31  547  62781.93 
NAV-P25
  1038  33.72  66.28  346  39077.37 
NAV-P27  948  32.59  67.41  316  36035.01 
NAV-P29  1176  28.74  71.26  392  44000.18 
NAV-P30  813  31.00  69.00  271  30516.98 
NAV-P31  813  31.98  68.02  271  30312.76 
NAV-P45  660  29.55  70.45  220  25169.89 
NAV-P50  1017  26.94  73.06  339  3863.10 
NAV-P51  1113  26.59  73.41  371  44437.66 
NAV-P52  996  26.10  73.90  332  39595.99 
NAV-P53  1188  30.30  69.70  396  44452.81   126 
3.2 DISTRIBUTION ANALYSIS OF THE CANDIDATE GENES AMONGST B. 
PILOSICOLI AND B. AALBORGI  STRAINS 
The distribution analyses of the selected genes by PCR showed that 20 of the 24 were 
highly conserved amongst different strain of B. pilosicoli from pigs and humans, and 
amongst  the  two  B.  aalborgi  strains  (Figure  3.2).  Four  genes  (NAV-P25,  NAV-P51, 
NAV-P52, and NAV-P53) demonstrated a low distribution (Figures 3.2 and 3.3), and 
therefore were discarded. The results of the distribution study by PCR are summarized 
in Tables 3.8 and 3.9.    127 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Gel electrophoresis of the various genes showing distribution analysis by 
PCR.  A)  NAV-PX,  B)  NAV-P15,  C)  NAV-P31.  P1-P23)  Amplified  DNA    from 
porcine strains of B. pilosicoli, B1-B5) Amplified DNA from human strains of B. 
pilosicoli,  A1-A2)  Amplified  DNA  from  B.  aalborgi,  C)  Positive  control,  N) 
Negative control and M) 1 kb standard DNA marker; The specification of the strains 
are listed in Table 2.1. 
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Figure 3.3 Gel electrophoresis of the various genes showing distribution analysis 
by PCR. A) NAV-P51, B) NAV-P15, C) NAV-P52. A) Gel electrophoresis of the 
NAV-P51 gene showing distribution analysis by PCR. B) Gel electrophoresis of the 
NAV-P52  gene  distribution  analysis  by  PCR.  P1-P23)  Amplified  DNA    from 
porcine strains of B. pilosicoli, B1-B5) Amplified DNA from human strains of B. 
pilosicoli,  A1-A2)  Amplified  DNA  from  B.  aalborgi,  C)  Positive  control,  N) 
Negative control  and M) 1 kb standard DNA marker;  The specification of the 
strains are listed in Table 2.1. 
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Table 3.8  PCR results of distribution analysis of the candidate genes amongst different strains of B. pilosicoli and B. aalborgi.  
 
Candidate 
genes 
Flanking 
Primers 
Porcine strains  Human strains 
P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14  P15  P16  P17  P18  P19  P20  P21  P23  B1  B2  B3  B4  B5  A1  A2 
NAV-PX  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  + 
NAV-P3  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  +  -  +  +  +  +  +  +  +  -  - 
NAV-P5  Half gene  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  -   +  +  +  +  +  +  +  +  +  -  - 
NAV-P8  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  -  - 
NAV-P9  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  - 
NAV-P13  Half gene  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  - 
NAV-P15  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  - 
NAV-P18
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  -  - 
NAV-P19
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  - 
NAV-P20
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  +  -  +  +  +  +  +  +  +  +  - 
NAV-P21
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  -  - 
NAV-P22
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P23
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  -  - 
NAV-P24
  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  +  - 
NAV-P25
  Half gene
  +  +  -  +  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  - 
NAV-P27  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  - 
NAV-P29  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P30  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  - 
NAV-P31  Half gene
  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P38  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  -  - 
NAV-P45  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  -  - 
NAV-P50  Half gene
  +  +  +  +  +  +  +  +  +  +  +  -  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  - 
NAV-P51  Half gene
  -  -  -  -  +  +  +  +  -  +  -  +  -  -  -  -  -  -   -  +  -  +  -  -  +  +  +  -  - 
NAV-P52  Half gene
  -  -  -  -  -  +  -  +  -  -  -  -  -  -  -  -  +  -  -  -  +  +  -  -  -  -  -  -  - 
NAV-P53  Half gene
  +  +  +  +  +  +  -  +  +  +  +  -  +  +  +  +  +  -  +  -  +  +  +  +  +  +  +  -  - 
 
  P1-P23, porcine strains of B. pilosicoli; B1-B5, human strains of B. pilosicoli; A1-A2, strains of B. aalborgi. (+) indicates that the gene was present. 
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Table 3.9 Summary of results of the gene distribution study by PCR amongst different 
strains of B. pilosicoli and B. aalborgi. 
 
 
NO.  Gene 
%  Distribution 
 in  
22 porcine strains 
of B. pilosicoli 
%  Distribution in  
5 human strains of  
B. pilosicoli 
%  Distribution in  
2 human strains  
of  B. aalborgi 
1  NAV-PX  100  100  50.0 
2  NAV-P3  91.0  100  50.0 
3  NAV-P5  100  100  0.0 
4  NAV-P8  100  100  0.0 
5  NAV-P9  100  100  0.0 
6  NAV-P13  95.5  100  50.0 
7  NAV-P15  100  100  0.0 
8  NAV-P18  91.0  100  0.0 
9  NAV-P19  100  100  0.0 
10  NAV-P20  91.0  100  50.0 
11  NAV-P21  91.0  100  0.0 
12  NAV-P22  100  100  100 
13  NAV-P23  95.5  100  0.0 
14  NAV-P24  91.0  100  50.0 
15  NAV-P25  86.4  100  50.0 
16  NAV-P27  100  100  50 
17  NAV-P29  100  100  100 
18  NAV-P30  100  100  50.0 
19  NAV-P31  100  100  100 
20  NAV-P45  91.0  100  0.0 
21  NAV-P50  95.5  100  50.0 
22  NAV-P51  59.0  60.0  0.0 
23  NAV-P52  22.7  20.0  0.0 
24  NAV-P53  86.4  100  0.0   131 
3.3 GENE CONSERVATION AMONGST B. PILOSICOLI STRAINS  
 
3.3.1 Comparative analysis of the NAV-PX, NAV-P3, NAV-P8 and NAV-P9 genes 
and their proteins 
The NAV-PX, NAV-P3, NAV-P8 and NAV-P9 genes in the six human and porcine strains 
of  B.  pilosicoli  in  which  they  were  sequenced    showed  98-100%  similarity  at  the 
nucleotide level and 99-100% similarity at the translated peptide level with those in the 
sequenced B. pilosicoli strain 95/1000 (Table 3.10). The peptide sequence for NAV-P8 in 
B. pilosicoli strain 95/1000 was identical with that of the type strain of B. pilosicoli 
strain P43/6/78
T. Also the peptide sequence of NAV-PX in B. pilosicoli strain 95/1000 
was  identical  with  that  in  B.  pilosicoli  WesB  and  ―S.  jonesii‖.  The  details  of  the 
sequence data are presented in appendix C1-4. 
 
Table 3.10 Peptide similarities between B. pilosicoli strain 95/1000 and candidate gene 
sequences obtained from six human and porcine strains of B. pilosicoli. 
ORFs 
Strains 
HRM2B  Margaret  “S. jonesii”  V1H91  WesB  P43/6/78
T 
NAV-PX  99.8%  99.8%  100%  99.8%  100%  NA 
NAV-P3  99.4%  99.4%  99.2%  99.6%  99.8%  99.8% 
NAV-P8  99.4%  99.8%  99.8%  99.8%  99.0%  100% 
NAV-P9  99.0%  99.0%  99.3%  99.0%  99.3%  99.6% 
 
 
3.3.2 Comparative analysis of the NAV-PX gene and NAV-PX protein.  
The NAV-PX  gene in  the 20  Brachyspira  species  strains  in  which it was  sequenced 
shared 99.3-99.7% similarity at the nucleotide level and 99.7-100% at the amino acid   132 
level. The nucleotide sequence for NAV-PX in B. pilosicoli strain 95/1000 was identical 
with those in B. intermedia strains OR2 and OF11, while predicted  peptide sequences of 
NAV-PX in nine strains including B. pilosicoli strains ―S. jonesii‖, WesB and Q98.0026, 
B. innocens strains B256, Q91-12233 and Q91-1530-1, B. intermedia strains OR2 and 
OF11, and B. hyodysenteriae strain 155.11 were identical to those in B. pilosicoli strain 
95/1000. The other strains had one or two amino acid differences (Table 3.11), and these 
occurred throughout the molecule. Five strains had a substitution of asparagine for serine 
at peptide position 154. 
 
Table 3.11 Amino acid substitutions in NAV-PX peptides of 8 strains of B. pilosicoli, 
and  of  B.  aalborgi  513
T  and  B.  hyodysenteriae  884  compared  to  the  B.  pilosicoli 
reference strain 95/1000 (accession no. AY466377). 
Number 
of strains 
Strain ID 
Position of different 
amino acid 
Amino acid in 
sequenced strain 
Amino acid in 
strain 95/1000 
2  HRM2B 
V1H91 
154  Asparagine(N)  Serine(S) 
3 
513
T 
M1 
P43/6/78
T 
225  Aspartic Acid(D)  Glutamic Acid(E) 
1  Margaret  483  Asparagine(N)  Aspartic Acid(D) 
1  884  569  Aspartic Acid(D)  Glutamic Acid(E) 
1  HRM7 
154, 
444 
Asparagine(N) 
Methionine(M) 
Serine(S) 
Isoleucine(I) 
2 
D17 
16242.94 
8, 
154 
Lysine(K) 
Asparagine(N) 
Glutamic Acid(E) 
Serine(S) 
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3.3.3 Phylogenetic analysis of Brachyspira spp. based on the NAV-PX sequences  
The  dendrogram  constructed  based  on  1785  bp  of  the  NAV-PX  sequences  from  20 
Brachyspira spp. strains is shown as Figure 3.4. The sequences start at the ATG start 
codon and end at the stop codon. Six of the 12 (50%) strains of B. pilosicoli were located 
in  cluster  IV,  whilst  others,  including  95/1000,  were  found  in  clusters  I,  II  and  III, 
together with those of the other Brachyspira species.  
 
 
 
 
 
 
 
                     
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Dendrogram constructed by the Neighbor-joining method from the MEGA 
3.0 software using the entire 1785 bp NAV-PX gene. This tree includes NAV-PX genes 
from 20 strains of intestinal spirochaetes. The number adjacent to the nodes shows the 
bootstrap percentage and the scale bar represents 0.0005 nucleotide substitutions per 
site. 
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3.4 GENERATION OF pTrcHis A RECOMBINANT PLASMID CONTAINING 
ORFs FOR E. coli EXPRESSION 
Twenty genes, including 12 whole genes after the start codon and 8 genes after the 
signal peptide or transmembrane cleavage sites (Table 3.12) were successfully cloned 
into the pTrcHis A expression vector. Between 8-12 E. coli colonies were screened by 
colony  PCR  using  forward  and  reverse  primers  specific  to  the  vector  sequence. 
Amplified products with the expected size specific for each recombinant construct were 
analysed  by  standard  agarose  gel  electrophoresis  (Figure  3.5).  All  the  recombinant 
plasmids that contained the correct sized inserts were purified and subjected to 5´ and 3´ 
sequencing,  as  described  in  section  2.5.1.9.  The  edited  and  translated  consensus 
sequences as amino acid sequences of all the inserted fragments were in the correct 
reading frame. Examples are shown in Figure 3.6.   
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Table 3.12 Summary information about the recombinant pTrcHis A vector constructs 
containing ORFs. 
Gene ID  Gene size 
(bp)  Vector  Cloning Host  Cloned position  Vector + insert 
size (bp) * 
NAV-PX
 
1782  pTrcHisA  JM109  4 -1785  1970 
NAV-P3
 
1581  pTrcHisA  JM109  43-1584  1770 
NAV-P5  654  pTrcHisA  BL21  4-654  840 
NAV-P8  1509  pTrcHisA  JM109  382-1509  1316 
NAV-P9  942  pTrcHisA  JM109  178-942  953 
NAV-P13  1059  pTrcHisA  JM109  67-1059  1245 
NAV-P15  1011  pTrcHisA  JM109  4-1010  1196 
NAV-P18
  1380  pTrcHisA  JM109  4-1380  1566 
NAV-P19
  1023  pTrcHisA  JM109  4-1023  1208 
NAV-P20
  1593  pTrcHisA  JM109  64-1593  1779 
NAV-P21N
  2181  pET  BL21  4-1200  1386 
NAV-P22
  1050  pTrcHisA  JM109  70-1050  1169 
NAV-P23
  1269  pTrcHisA  JM109  4-1269  1155 
NAV-P24
  1641  pTrcHisA  JM109  4-1641  1827 
NAV-P27  948  pTrcHisA  JM109  4-948  1134 
NAV-P29  1176  pTrcHisA  JM109  4-1176  1362 
NAV-P30  813  pTrcHisA  JM109  70-813  999 
NAV-P31  813  pTrcHisA  JM109  70-813  999 
NAV-P45  660  pTrcHisA  JM109  4-660  846 
NAV-P50  1017  pTrcHisA  JM109  4-1017  1203 
* The size of the PCR product after screening of recombinant vector construct (vector + 
insert) using pTrcHis A forward and reverse primers. 
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Figure  3.5  Agarose  gel  electrophoresis  from  PCR  screening  of  E.  coli  colonies 
harbouring the recombinant pTrcHis A vector containing NAV-P genes. A) Lanes 1-9 
and 12;  positive colonies containing pTrcHis A + NAV-P3 , lanes 10 and 11; negative 
colonies,  M  1  kbp  DNA  marker  B)  Lanes  1-2,  3-11;    positive  colonies  containing 
pTrcHis A + NAV-P25 , lanes 3 and 12; negative colonies, M 1 kbp DNA marker. 
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Figure 3.6 Chromatograms of constructed recombinant pTrcHis A containing NAV-P3 
(A) and NAV-PX (B) genes. Both chromatograms showed inserted fragments were in the 
correct reading frame of expression. 
 
 
     CGA     TGG       GGA       TCC      TGC    AGC       AAA  
    Arg    Trp     Gly       Ser     Cys   Ser       Lys 
         
pTrcHis A Upstream         Bam HI      NAV-P3 N-terminal Sequence 
    Sequence      Restriction Site      From amino acid No. 15 
         
     CGA     TGG       GGA       TCC      AGC    AAA       AAA  
    Arg    Trp     Gly       Ser     Ser   Lys       Lys 
         
pTrcHis A Upstream         Bam HI      Clpx N-terminal Sequence 
    Sequence       Restriction Site      From amino acid No. 2 
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3.5 RECOMBINANT PROTEIN EXPRESSION, PROTEIN SOLUBILITY, AND 
PROTEIN PURIFICATION 
Because of time limitations, only 12 of the 20 cloned genes (NAV-PX, NAV-P3, 8, 9, 13, 
20, 21N,  22, 27, 30, 31,  and  45) [Table 3.12] were selected for expression of their 
products  according  to  the  results  obtained  from  in  silico  analysis  and  distribution 
analysis. Of the 12, nine  (NAV-PX, NAV-P3, 13, 20, 21 N, 22, 27, 30, and 31) were 
successfully expressed in the E. coli expression system by screening 8-12 colonies of 
each  recombinant  construct  for  their  expression  using  a  Western  blot  assay.  Two 
examples of expression screening are presented in Figure 3.7. The expressed proteins 
were checked for their solubility as described in section 2.4.2.2. Six proteins (NAV-P3, 
20,  22,  27,  30,  and    31)  which  were  also  predicted  by  PSORTb  to  be  periplasmic 
molecules were expressed as soluble forms while three proteins (NAV-PX,  NAV-P13 
and NAV-P21 N)  with a cytoplasmic localization were expressed as insoluble forms. 
The  soluble  and  insoluble  expressed  proteins  then  were  purified  under  native  and 
denaturing  conditions  respectively,  as  described  in  section  2.5.3  (Figure  3.8).  All 
purified recombinant proteins were separated by SDS-PAGE and electro-transferred to a 
nitrocellulose membrane for Western blot analysis using anti-6x His antibody (Figure 
3.9). Finally the concentration of each recombinant protein was estimated by using SDS- 
PAGE  and  taking  a  densitometer  reading  by  loading  serial  dilutions  of  the  purified 
protein  in  comparison  with  protein  standards,  as  described  in  section  2.5.4.4.  Two 
examples of protein quantifications are illustrated in Figure 3.10. Information regarding 
protein expression and purification is summarised in Table 3.13. The actual molecular 
weights of the mature proteins were almost similar to the predicted size of the proteins.    139 
 
 
Table 3.13 Summary of recombinant protein expression and purification.  
 
Gene
  Host Cell
 
Induction Condition    Recombinant Protein
 
Cell Density at 
Induction 
 (OD 600) 
Induction 
Time (h) 
Final conc. Of 
IPTG 
Temperature 
(ºC) 
 
 
Mature 
Protein Size  
(kDa)  
Solubility  Purification Type 
Expression  
Level 
(%) 
NAV-PX  BL-21  1.0  12  0.5  37 °C    67.41  Insoluble  Denature  0.5 
NAV-P3  BL-21  1.0  12  0.5  37 °C    60.35  Soluble  Denature  5.0 
NAV-P13  BL-21  0.8  8  0.5  37 °C    38.01  Insoluble  Denature  7.5 
NAV-P20  BL-21  1.0  12  0.1  37 °C    61.10  Soluble  Native  3.0 
NAV-P21N  JM109  1.0  8  1  37 °C    43.90  Insoluble  Denature  1.5 
NAV-P22  BL-21  0.8  12  0.1  37 °C    39.40  Soluble  Native  5.3 
NAV-P27  BL-21  0.8  5  0.1  37 °C    36.04  Soluble  Native  3.0 
NAV-P30  BL-21  0.8  8  0.1  37 °C    30.52  Soluble  Native  4.5 
NAV-P31  BL-21  0.8  8  0.1  37 °C    30.31  Soluble  Native  8.0   140 
      Three genes (NAV-P8, NAV-P9, and NAV-P45) failed to express their proteins even 
after using different sets of cloning primers, using pTrcHis A or pET vectors under 
different  conditions  of  expression  (induction  time,  IPTG  concentration,  induction 
temperature) or by growing in  LB, 2x YT or Terrific Broth (Table 3.14). 
 
 
 
Table 3.14 Alternative conditions for expression of NAV-P8, NAV-P9, and NAV-P45 
gene products. 
Gene ID  Oligo Label 
Res. 
Site 
Oligo Sequence (5´→ 3´) 
Plasmid 
Vectors 
Host 
Cell 
NAV-P8 
NAV-P8-382.CF1 
NAV-P8-1509CR1 
BamH 1 
EcoR 1 
TTTGGATCCAGTGAGGTTGGTATAAGAAAG 
CTTGAATTCTTAAATAAAGAAGAAACCAGC 
pTrcHis A  BL21 
NAV-P8 
NAV-P-382.TCF2 
NAV-P8-1509TCR2 
Nde 1 
BamH 1 
ATACATATGAGTGAGGTTGGTATAAGAAAG 
ATAGGATCCTTAAATAAAGAAGAAACCAGCTTT 
pET  BL21 
NAV-P9 
NAV-P9-178.CF1 
NAV-P9-943.CR1 
BamH 1 
EcoR 1 
TTTGGATCCGGTATAGATTTTGCAGGCG 
TTCGAATTCTTATGCTTTTTTTCCTTTCATA 
pTrcHis A  BL21 
NAV-P9 
NAV-P9-178,TCF2 
NAV-P9-943.TCR2 
Nde 1 
BamH 1 
ATACATATGGGTATAGATTTTGCAGGC 
ATAGGATCCTGCTTTTTTTCCTTTCATAAATAA 
pET  BL21 
NAV-P45 
NAV-P45-4.TCF1 
NAV-P45-660.TCR1 
Nde 1 
BamH 1 
ATAGGATCCACCGCTAATTCAAAATGCATTA 
ATAGAATTCAGAAATCACATATTGGTATAAAAA 
pET  BL21 
NAV-P45 
NAV-P45-123.TCF2 
NAV-P45-660.TCR2 
Nde 1 
BamH 1 
ATACATATGGTAAATAAAAACTATGTGCTTCC 
ATAGAATTCAGAAATCACATATTGGTATAAAAAC 
pET  BL21 
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Figure 3.7 Western blot screening of expressed histidine-tagged recombinant proteins 
using mouse monoclonal anti-polyhistidine antibody. A) Results of the screening of 12 
E. coli colonies containing recombinant pTrcHis A+ NAV-P31, Lanes 1-12, positive 
expression  of  NAV-P31  recombinant  protein  in  2x  YT  medium,  Lane  13,  positive 
control.  B)  Results  of  the  screening  of  8  E.  coli  colonies  containing  recombinant 
pTrcHis  A+  NAV-P13,  Lanes  1-8,  positive  expression  of  NAV-P13  recombinant 
protein in 2x YT medium, Lane 9, positive control. M, protein mass marker.  
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Figure 3.8 SDS-PAGE analyses of recombinant proteins expressed in E. coli. A) Native 
purification  of  NAV-P31;  Lane  1,  clear  lysate,    Lanes  2-5,  washes  with  50  mM 
imidazole, Lanes 6-10, elutions with 250 mM immidazole. B) Native purification of 
NAV-P27; Lane 1, clear lysate,  Lanes 2-4, washes with 25 mM imidazole, Lanes 5-9, 
elutions with 250 mM immidazole M,  protein mass marker. The arrows indicate the 
position of the recombinant proteins. 
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Figure 3.9 A) Western blot detection of purified histidine-tagged recombinant proteins 
using mouse monoclonal anti-polyhistidine antibody. B) Coomassie-stained 12% SDS-
PAGE gel of  purified histidine-tagged recombinant proteins. M,  protein mass marker. 
Lane 1,  ClpX. Lane 2, NAV-P3. Lane 3, NAV-P13. Lane 4, NAV-P20. Lane 5, 
NAV-P21 N-terminal. Lane 6,  NAV-P22. Lane 7, NAV-P27. Lane 8,  NAV-P30. 
Lane 9,  NAV-P31. 
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Figure 3.10 Protein quantification by loading serial dilutions of recombinant protein 
samples in parallel with protein standards (BSA or mixture of BSA and lysosyme) on an 
SDS-PAGE gel and analysing the acquired destained gel image using a densitometer. A) 
Lane 1-5, serial dilutions of ClpX recombinant protein, Lanes 6-10, serial dilutions of 
NAV-P13  recombinant  protein,  Lanes  11-14,  protein  standard  BSA  (Bovine  Serum 
Albumin) from 100 ng to 1000 ng concentrations. B) Lane 1-3, serial dilutions of NAV-
P31 recombinant protein, Lanes 4-7, protein standard (mixed BSA and lysosyme) from 
100 ng to 1000 ng concentrations, M,  protein mass marker. 
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3.6 IN VITRO IMMUNOGENICITY ANALYSIS OF RECOMBINANT 
PROTEINS 
 
3.6.1 Immuno-blot reactivity of recombinant proteins with convalescent swine sera  
 
The nine purified histidine tagged recombinant proteins (NAV-PX, NAV-P3, NAV-P13, 
NAV-P20,  NAV-P21  N-terminal,  NAV-P22,  NAV-P27,  NAV-P30,  and  NAV-P31) 
were screened for their reactivity with a set of sera from healthy and convalescent pigs 
(section 2.6.1.1 Table 2.8) by Western blot assay. Eight proteins (NAV-PX, NAV-P3, 
NAV-P13,  NAV-P20,  NAV-P21  N-terminal,  NAV-P22,  NAV-P30,  and  NAV-P31) 
were shown to be strongly immunoreactive. Weak blot reactivities also were observed 
between negative control sera and NAV-P3, 13, 20, 21N, 22, 30, and 31 recombinant 
proteins. The results of immuno-blot reactions between recombinant proteins and pig 
sera are summarized in Table 3.15, and selected immuno-blot reactions are illustrated in 
Figures 3.11 and 3.12.  
 
 
 
3.6.2 Immuno-blot reactivity of recombinant proteins with murine hyperimmune 
sera raised against B. pilosicoli strain WesB  
 
Western blot analysis of the nine purified recombinant proteins (NAV-PX, NAV-P3, 
NAV-P13,  NAV-P20,  NAV-P21  N-terminal,  NAV-P22,  NAV-P27,  NAV-P30,  and 
NAV-P31) identified immuno-reactivity between those proteins and mouse polyclonal 
antibody raised against a bacterin preparation of B. pilosicoli strain WesB (Figure 3.13).  146 
 
 
 
Table 3.15 Results of immuno-blot reactions of purified recombinant proteins with a pool of pre-infected, and experimentally infected pig 
sera. 
 
Recombinant 
Protein 
Pig serum samples* 
N1  N2  N3  M1  M2  M3  P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13 
NAV-PX  –  –  –  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P3  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P13  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P20  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P21N  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P22  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P27  –  –  –  ±  ±  ±  +  ±  –  –  +  +  +  +  +  +  +  +  + 
NAV-P30  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
NAV-P31  ±  ±  ±  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  + 
  
*N1-N3: Sera from pre-infected pigs, M1-M3 hyperimmune sera from pig vaccinated with killed B. pilosicoli cells, P1-P6: Sera from pigs 
experimentally challenged with B. pilosicoli and showing seroconversion at PM, P7-P13: Sera from pigs experimentally challenged with 
B. pilosicoli and colonised at PM. (–): Indicates not reactive, (±): Indicates weakly reactive, (+): Indicates reactive with a specific band.  147 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Western immuno-blot reactivity of recombinant proteins with porcine 
convalescent sera.  A) NAV-PX protein, B) NAV-P13 protein, Lanes 1-3, uninfected 
pig  control  sera,  Lanes  4-12,  sera  from  pigs  experimentally  infected  with  B. 
pilosicoli and showing sero-conversion at post mortem, Lanes 13-19, sera from pigs 
experimentally infected with B. pilosicoli and  showing bacterial colonisation in the 
caecum,  M,    protein  mass  marker.  The  arrow  indicates  the  reaction  of  the 
recombinant protein. 
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Figure 3.12 Western immuno-blot reactivity of recombinant proteins with porcine 
convalescent  sera.    A)  NAV-P31  protein,  B)  NAV-P22  protein,  Lanes  1-3, 
uninfected pig control sera, Lanes 4-12, sera from pigs experimentally infected with 
B. pilosicoli and showing sero-conversion at post mortem, Lanes 13-19, sera from 
pigs experimentally infected with B. pilosicoli and  showing bacterial colonisation in 
their  caecum,  M,    protein  mass  marker.  The  arrow  indicates  the  reaction  of  the 
recombinant protein. 
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Figure 3.13 Immuno-blot reactivity of purified recombinant proteins with murine 
hyperimmune sera against B. pilosicoli strain Wes B. Lanes 1-9: Specific bands of 
recombinant  proteins  NAV-PX,  NAV-P3,  NAV-P13,  NAV-P20,  NAV-P21  N-
terminal,  NAV-P22,  NAV-P27,  NAV-P30,  and  NAV-P31  with  murine  sera.  M, 
protein mass marker. 
 
 
3.7 IN VIVO IMMUNOGENICITY ANALYSIS OF RECOMBINANT 
PROTEINS 
 
 
3.7.1 Immunising mice with recombinant proteins 
 
 
     The  nine  purified  histidine  tagged  recombinant  proteins  (NAV-PX,  NAV-P3, 
NAV-P13, NAV-P20, NAV-P21 N-terminal, NAV-P22, NAV-P27, NAV-P30, and 
NAV-P31) were analysed for their antigenicity by immunizing five C3H/HeJ mice 
with each protein. The hyperimmune sera obtained from all groups of immunized 
mice were found to be immunoreactive with their specific proteins in comparison 
with sera from the negative group using Western blot analysis. Selected Western 
immuno-blot  reactions  are  illustrated  in  Figures  3.14  and  3.15.  The  mouse 
hyperimmune sera raised against the nine recombinant proteins (NAV-PX, NAV-P3, 
NAV-P13, NAV-P20, NAV-P21 N-terminal, NAV-P22, NAV-P30, and NAV-P31) 
also showed immunoreactivity with their specific native proteins in the whole cell 
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preparation of B. pilosicoli strain WesB. Two selected Western blot are illustrated in 
Figures 3.16 and 3.17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 Western immuno-blot showing reactivity of recombinant proteins with 
their specific mice hyperimmune sera. A) NAV-P3 protein, B) NAV-P13 protein, 
Lanes  1-5,  negative  serum  samples  from  un-vaccinated  mice,  Lanes  6-10, 
hyperimmune serum samples from vaccinated mice. M, protein mass marker. The 
arrows indicate the position of each recombinant protein. 
 
 
 
75 
kDa      M         1        2       3       4        5       6        7       8        9       10 
50 
37 
25 
20 
A 
50 
37 
25 
20 
kDa 
75 
 M         1        2       3       4        5       6        7       8        9       10 
B   151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Western immuno-blot showing reactivity of recombinant proteins with 
their specific mice hyperimmune sera. A) NAV-P22 protein, B) NAV-P31 protein, 
Lanes  1-5,  negative  serum  samples  from  un-vaccinated  mice,  Lanes  6-10, 
hyperimmune serum samples from vaccinated mice. M, protein mass marker. The 
arrows indicate the position of each recombinant protein. 
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Figure 3.16 Western immuno-blot showing reactivity of mouse serum raised against 
recombinant proteins (A: NAV-P3 protein, B: NAV-P13 protein) with a whole cell 
preparation of B. pilosicoli strain WesB. Lanes 1-5, individual negative mouse sera 
from  un-vaccinated mice,  Lanes  6-10,  individual  hyperimmune mouse sera from 
vaccinated  mice  with  recombinant  protein.  M,  protein  mass  marker.  The  arrows 
indicate the position of each native protein. 
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Figure 3.17 Western immuno-blot showing reactivity of mouse serum raised against 
recombinant proteins (A: NAV-P22 protein, B: NAV-P31 protein) with a whole cell 
preparation of B. pilosicoli strain WesB. Lanes 1-5, individual negative mouse sera 
from  un-vaccinated mice,  Lanes  6-10,  individual  hyperimmune mouse sera from 
vaccinated  mice  with  recombinant  protein.  M,  protein  mass  marker.  The  arrows 
indicate the position of each native protein. 
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3.8 TRIAL OF VACCINE EFFICACY USING THE RECOMBINANT 
PROTEINS IN MICE  
 
 
3.8.1 Analysis of systemic antibody responses  
 
 
3.8.1.1 Analysis of systemic antibody responses by ELISA 
 
The  systemic  IgG  responses  of  the  mice  immunised  with  the  four  recombinant 
histidine  tagged  proteins  NAV-P3,  NAV-P13,  NAV-P22,  and  NAV-P31  are 
summarised in Table 3.16 and illustrated in Figures 3.18 and 3.19. Vaccination of 
non-infected mice with each recombinant protein resulted in significant increases of 
serum IgG against the corresponding proteins. A similar trend was seen with the 
infected groups of mice, where with all four antigen groups the vaccinated infected 
mice had significantly higher antibody levels then the non-vaccinated infected mice. 
The infection did not significantly increase levels in non-vaccinated mice. Neither 
vaccinated mice nor vaccinated/infected mice showed any significant systemic IgA 
levels in ELISA to either the recombinant proteins or to whole cell native proteins of 
B. pilosicoli strain WesB. 
 
 
3.8.1.2 Analysis of  systemic antibody responses by Western blot 
 
 
Western blot analysis of sera from the experimentally vaccinated mice confirmed 
that the systemic antibody responses induced by monovalent vaccination with the 
four recombinant proteins were directed against their specific vaccine antigens, and 
also directed to their native proteins in a whole cell preparation of B. pilosicoli WesB 
(Figures 3.20 and 3.21). In some serum samples the reactivity of the sera from non-
vaccinated/infected mice to the whole cell preparation as antigen contributed to the 
systemic responses to the bacterial native proteins after inoculation of a live bacterial   155 
suspension.  On  the  other  hand,  analysis  of  the  systemic  IgG  responses  in  sera 
obtained from the vaccinated mice showed strong reactivity to their native proteins in 
a whole cell preparation of B. pilosicoli before and after infection.  
 
 
Table 3.16 Means and standard deviations of group systemic IgG titres (OD values) 
in four groups of mice for each of four recombinant vaccines.  
Experimental 
recombinant  
vaccine 
Non-infected  Infected 
*P-value 
(ANOVA) 
Non-vaccinated 
group 
Vaccinated 
groups 
Non-vaccinated / 
Infected group 
Vaccinated / 
Infected groups 
NAV-P3  0.198 ± 0.039
a  2.935 ± 0.153
b  0.277± 0.114
a  3.211± 0.123
c  <0.001 
NAV-P13  0.179 ± 0.083
a  2.554 ± 0.490
b  0.295 ± 0.222
a  2.548 ± 0.455
b  <0.001 
NAV-P22  0.134 ± 0.059
a  2.195 ± 0.444
b  0.078 ± 0.012
a  2.608 ± 0.417
b  <0.001 
NAV-P31  0.149 ± 0.058
a  1.806 ± 0.706
b  0.219 ± 0.094
a  2.436 ± 0.499
b  <0.001 
 
* Within each row, values with a different superscript letter differ at the 5% level of 
significance. 
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Figure  3.18  ELISA  values  (systemic  IgG  responses)of  the  mice  vaccinated  with 
experimental  recombinant  vaccines;  A)  NAV-P3;  B)  NAV-P13;  1-12,  individual 
mouse antibody titres in vaccinated and non-vaccinated groups either infected or not 
infected. 
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Figure 3.19 ELISA values (systemic IgG responses) of the mice vaccinated with 
experimental recombinant vaccines; A) NAV-P22; B) NAV-P31; 1-12, individual 
mouse antibody titres in vaccinated and non-vaccinated groups either infected or not 
infected. 
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Figure  3.20  Western  blot  analysis  of  the  systemic  IgG  responses  of  the  mice 
experimentally vaccinated with recombinant protein.  A) Immunoblot reactivity of 
NAV-P3  vaccinated  sera  to  the  whole  cell  preparation  of  B.  pilosicoli.  B) 
Immunoblot reactivity of NAV-P13 vaccinated sera to the whole cell preparation of 
B.  pilosicoli.  Lanes  1-5,  individual  serum  samples  from  non-vaccinated/infected 
mice.  Lanes  6-17,  individual  serum  samples  from  vaccinated/infected  mice.  M, 
protein mass marker. The arrows indicate the position of the native proteins that 
reacted with their specific antibodies in mice sera. 
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Figure  3.21  Western  blot  analysis  of  the  systemic  IgG  responses  of  the  mice 
experimentally vaccinated with recombinant protein.  A) Immunoblot reactivity of 
NAV-P22  vaccinated  sera  to  the  whole  cell  preparation  of  B.  pilosicoli.  B) 
Immunoblot reactivity of NAV-P31 vaccinated sera to the whole cell preparation of 
B.  pilosicoli.  Lanes  1-5,  individual  serum  samples  from  non-vaccinated/infected 
mice.  Lanes  6-17,  individual  serum  samples  from  vaccinated/infected  mice.  M, 
protein mass marker. The arrows indicate the position of the native proteins that 
reacted with their specific antibodies in mice sera. 
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3.8.2 Analysis of local antibody responses  
 
 
3.8.2.1 Local IgG levels in samples obtained from the colon and caecum 
 
 
The local IgG levels in the mixed samples obtained from the caeca and colons of the 
NAV-P3, NAV-P13, NAV-P22, or NAV-P31 vaccinated groups showed significant 
elevations in comparison with the negative and infection control groups (Table 3.17).      
The local IgG levels showed significant increases in the NAV-P3, NAV-P13, and 
NAV-P22  vaccine  groups  in  comparison  with  the  non-vaccinated/non-infection 
control  (p<0.001)  and    the  non-vaccinated/infection  control  groups  (p<0.001) 
(Figures 3.22 and 3.23). In the NAV-P31 group, IgG levels of the vaccinated mice 
tended  to  show  a  slight  but  non-significant  increase  compared  with  the  non-
vaccinated group (p>0.05).  
 
Table 3.17 Means and standard deviations of group local IgG titres (OD values) in 
four groups of mice during the vaccination trials.  
Experimental 
Recombinant 
Vaccine 
Pre-infection  Post-infection 
*P-value 
(ANOVA) 
Non-vaccinated 
group 
Vaccinated 
groups 
Non-vaccinated 
/ Infected group 
Vaccinated / 
Infected groups 
NAV-P3  0.036±0.004
a  1.263 ± 0.47
c  0.101 ± 0.036
b  1.434 ± 0.581
c 
<0.001 
NAV-P13  0.0476 ± 0.008
a  0.139 ± 0.029
b  0.055 ± 0.009
a  0.306 ±0.088
c 
<0.001 
NAV-P22  0.040 ± 0.004
a  0.192 ± 0.089
b  0.058 ± 0.007
a  0.327 ± 0.117
c 
<0.001 
NAV-P31  0.037 ± 0.008
a  0.056 ± 0.0148
b  0.055 ±0.010
b  0.083 ± 0.0135
c 
<0.001 
 
*Within each row, values with a different superscript letter differ at the 5% level of 
significance. 
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Figure  3.22  Local  IgG  responses  measured  by  ELISA  in  mixed  faecal  samples 
obtained  at  post-mortem  from  colons  and  caeca  of  the  mice  vaccinated  with 
experimental recombinant vaccines; A) NAV-P3 vaccine; B) NAV-P13 vaccine; 1-
12, individual mouse local antibody titres in vaccinated and non-vaccinated groups 
either infected or not infected. 
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Figure  3.23  Local  IgG  responses  measured  by  ELISA  in  mixed  faecal  samples 
obtained  at  post-mortem  from  colons  and  caeca  of  the  mice  vaccinated  with 
experimental recombinant vaccines; A) NAV-P22 vaccine; B) NAV-P31 vaccine; 1-
12, individual mouse local antibody titres in vaccinated and non-vaccinated groups 
either infected or not infected. 
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3.8.2.2 Analysis of  local IgG responses by Western blot 
 
The  extracts  of  the  collected  mixed  samples  from  the  colons  and  caeca  of  the 
vaccinated mice that showed IgG responses to recombinant proteins in ELISA were 
analysed by Western blot to investigate their reactivity to a whole cell preparation of 
B. pilosicoli. The samples from the NAV-P31 group had weak local IgG reactivity, 
but the three other groups had a stronger local IgG response to the native proteins in 
the whole cell preparation of B. pilosicoli (Figure 3.24).  
 
 
 
3.8.2.3 Analysis of local IgA responses  
 
The extracts of collected mixed faecal samples from the colons and caeca of the four 
vaccinated groups were applied in ELISA and Western immunoblot to assay their 
reactivities to their specific recombinant proteins. Application of different conditions 
resulted in no detectable trace of local IgA responses to the recombinant proteins.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.24  Western  blot  analysis  of  the  local  IgG  responses  of  the  mice 
experimentally vaccinated with recombinant protein.  A) Immunoblot reactivity of 
NAV-P3 vaccinated faecal samples to the whole cell preparation of B. pilosicoli. B) 
Immunoblot  reactivity  of  NAV-P13  vaccinated  faecal  samples  to  the  whole  cell 
preparation  of  B.  pilosicoli.  Lanes  1-5,  individual  faecal  extracts  from  non-
vaccinated/infected  mice.  Lanes  6-17,  individual  faecal  extracts  from 
vaccinated/infected mice. M, protein mass marker. The arrows indicate the position 
of the native proteins that reacted with their specific antibodies in mice sera. 
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3.8.3 Faecal shedding of B. pilosicoli after infection  
 
The culture results for the mice in the two efficacy trials are summarized in Tables 
3.18 and 3.19 respectively. One day before the infection, faecal samples from all 
groups  of  mice  were  culture  negative  with  respect  to  B.  pilosicoli.  The  highest 
numbers of positive samples were recorded at 14 days post-infection in trial I and 16 
days post-infection in trial II.  
       
3.8.3.1 Efficacy trial I 
In trial I, three mice vaccinated with NAV-P13, five mice vaccinated with NAV-P31, 
and eight mice in the infection control group showed evidence of colonisation on day 
14 post-infection. These differences were significant (P<0.05) with respect to the 
number of colonised mice. The individual and group colonisation results and also the 
cumulative results of the group colonisation are presented in Tables 3.18 and 3.20. 
      Excretion of B. pilosicoli by the non-vaccinated infection control group was first 
detected in 3 mice 7 days after the last inoculation, and increased to 7 and 8 mice 11 
and 14 days after the last inoculation respectively. Keeping these mice more than 14 
days resulted in a reduction of  numbers of positive mice from 8 to 5 on day 18 and 
then to 2 mice on day 21 post-infection. In contrast, on day 7 post-infection one 
mouse in the NAV-P13 vaccinated group and 3 mice in the NAV-P31 vaccinated 
group showed bacterial shedding, and then on day 14 post-infection the number of 
positive mice increased to 3 and 5, respectively. The remaining mice in these two 
groups  remained  culture  negative  for  B.  pilosicoli  until  day  14  post-infection. 
Keeping the vaccinated mice for more than 14 days after challenge resulted in a 
reduction  of  the  numbers  of  colonised  mice  from  3  to  zero  for  the  NAV-P13 
vaccinated group, and from 5 to zero for the NAV-P31 vaccinated group on day 21   166 
post-infection. The number of infected mice in the infection control group decreased 
with time, and only two were still positive at post mortem culture.  
      In efficacy trial I on day 14 post-infection (the day of the highest colonisation 
rate for infection control group), the ratios of the  cumulative number of positive 
faecal samples to the total number of faecal samples for the three groups were 9/72, 
12/72,  and  25/72  for  NAV-P13,  NAV-P31,  and  the  infection  control  group 
respectively (Table 3.20). Comparing these ratios using Chi-square analysis revealed 
a  significant  difference  between  the  vaccinated  groups  and  the  non-vaccinated 
infection control group (P<0.05) with respect to the number of colonised mice.  
 
3.8.3.1 Efficacy trial II 
Overall two mice vaccinated with NAV-P3, four mice vaccinated with NAV-P22, 
and nine mice in the infection control group showed evidence of colonisation with B. 
pilosicoli. These differences were significant (P<0.05) with respect to the number of 
colonized  mice.  The  individual  and  group  colonisation  results  and  also  the 
cumulative  results  of the  group  colonisation for efficacy trial  II  are presented in 
Tables 3.19 and 3.20. 
      Four mice in the infection control group excreted B. pilosicoli in their faeces on 
day 6 post-infection, and then the numbers of infected mice increased to 7 and 9 on 
days  9  and  12  post-infection  respectively.  The  number  of  infected  mice  in  the 
infection  control  group  remained  constant  until  the  end  of  trial  (day  16  post-
infection),  based  on  the  results  obtained  from  post  mortem  culture.  For  the 
experimentally vaccinated mice, one mouse in the NAV-P3 group, and two mice in 
the NAV-P22 were positive for B. pilosicoli 6 days after experimental infection. The 
number of positive mice in these groups subsequently increased to 2 and 4 in each   167 
group 16 days after infection. The remaining mice were negative until the end of the 
experimental period.  
      On day 16 post-infection (the day of the highest colonisation rate for the infection 
control group), the ratios of the cumulative number of positive faecal samples to the 
total number of faecal samples for the three groups were 7/72, 12/72, and 29/72 for 
NAV-P3,  NAV-P22,  and  the  infection  control  group  respectively  (Table  3.20). 
Comparing these ratios using Chi-square analysis revealed a significant difference 
between the vaccinated groups and non-vaccinated infection control group (P<0.05) 
with respect to the number of colonised mice.  
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Table  3.18  Individual  colonisation  results  for  the  vaccinated  and  non-vaccinated 
mice  orally  challenged  with  B.  pilosicoli  in  efficacy  trial  I.  Colonisation  was 
determined by culture of faeces and PCR of the growth on the plates. 
 
Mice 
groups 
Mouse 
No. 
Days post-infection 
-1  4  7  11  *14  18  21 
NAV-P13 
vaccinated 
1  –  –  –  –  –  –  – 
2  –  –  –  –  –  –  – 
3  –  –  –  –  –  –  – 
4  –  –  –  –  –  –  – 
5  –  –  –  +  +  +  – 
6  –  –  –  –  –  –  – 
7  –  –  –  –  –  –  – 
8  –  –  +  +  +  +  – 
9  –  –  –  –  –  –  – 
10  –  –  –  –  –  –  – 
11  –  –  –  –  –  –  – 
12  –  –  –  –  +  +  – 
Total colonised mice  0/12  0/12  1/12  2/12  3/12  3/12  0/12 
NAV-P31 
vaccinated 
1  –  –  +  +  +  +  – 
2  –  –  –  –  –  –  – 
3  –  –  –  –  –  –  – 
4  –  –  –  –  –  –  – 
5  –  –  +      +  +  +  – 
6  –  –  –  –  –  –  – 
7  –  –  –  –  –  –  – 
8  –  –  +  –  +  –  – 
9  –  –  –  –  –  –  – 
10  –  –  –  –  –  –  – 
11  –  –  –  –  +  –  – 
12  –  –  –  –  +  –  – 
Total colonised mice  0/12  0/12  3/12  2/12  5/12  2/12  0/12 
Non-
vaccinated 
Infection 
control 
1  –  –  –  –  –  +  – 
2  –  –  –  +  +  –  – 
3  –  –  –  +  +  –  – 
4  –  –  –  –  –  +  + 
5  –  –  –  +  +  +  + 
6  –  –  +  +  +  –  – 
7  –  –  +  +  +  –  – 
8  –  –  –  +  +  +  – 
9  –  –  –  –  –  –  – 
10  –  –  +  +  +  –  – 
11  –  –  –  –  +  –  – 
12  –  –  –  –  –  +  – 
Total colonised mice  0/12  0/12  3/12  7/12  8/12  5/12  2/12 
 
The  culture  and  PCR  results  are  based  on  the  culture  of  mixed  faecal  samples 
obtained from caeca and colons of the mice at post mortem. (+) and (–) indicate 
culture positive and negative for B. pilosicoli confirmed by PCR. *The day of the 
highest colonisation rate for infection control group 
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Table  3.19  Individual  colonisation  results  for  the  vaccinated  and  non-vaccinated 
mice  orally  challenged  with  B.  pilosicoli  in  efficacy  trial  II.  Colonisation  was 
determined by culture of faeces and PCR of the growth on the plates. 
 
Mice 
groups 
Mouse 
No. 
Days post-infection 
-1  3  6  9  12  *16 
NAV-P3 
vaccinated 
1  –  –  –  –  –  – 
2  –  –  –  –  –  – 
3  –  –  –  –  –  – 
4  –  –  –  –  –  – 
5  –  –  +  +  +  + 
6  –  –  –  –  –  – 
7  –  –  –  –  –  – 
8  –  –  –  –  –  – 
9  –  –  –  +  +  + 
10  –  –  –  –  –  – 
11  –  –  –  –  –  – 
12  –  –  –  –  –  – 
Total colonised mice  0/12  0/12  1/12  2/12  2/12  2/12 
NAV-P22 
vaccinated 
1  –  –  –  +  –  + 
2  –  –  –  –  +  – 
3  –  –  –  –  –  – 
4  –  –  +  +  –  + 
5  –  –  –            +  + 
6  –  –  –  –  –  – 
7  –  –  –  –  –  – 
8  –  –  –  –  –  – 
9  –  –  –  –  –  – 
10  –  –  +  +  +  + 
11  –  –  –  –  –  – 
12  –  –  –  –  –  – 
Total colonised mice  0/12  0/12  2/12  3/12  3/12  4/12 
Non-
vaccinated 
Infection 
control 
1  –  –  –  –  –  – 
2  –  –  –  –  +  + 
3  –  –  +  +  +  + 
4  –  –  +  +  +  + 
5  –  –  –  +  +  + 
6  –  –  +  +  +  + 
7  –  –  –  +  +  + 
8  –  –  –  –  –  – 
9  –  –  –  +  +  + 
10  –  –  +  +  +  + 
11  –  –  –  –  –  – 
12  –  –  –  –  +  + 
Total colonised mice  0/12  0/12  4/12  7/12  9/12  9/12 
 
The  culture  and  PCR  results  are  based  on  the  culture  of  mixed  faecal  samp les 
obtained from caeca and colons of the mice at post mortem.  (+) and (–) indicate 
culture positive and negative for B. pilosicoli confirmed by PCR. *The day of the 
highest colonisation rate for infection control group   170 
Table  3.20  Cumulative  group  colonisation  results  for  the  vaccinated  and  non-
vaccinated mice orally challenged with B. pilosicoli in efficacy trials I and II.  
 
Efficacy trial  Mouse group  Number of positive 
samples  P-value 
Trial I 
NAV-P13  9/72 
<0.05  NAV-P31  12/72 
Control  25/72 
Trial II 
NAV-P3  7/72 
<0.001  NAV-P22  12/72 
Control  29/72 
 
 
 
 
3.8.4 Clinical signs and pathological changes 
  
      The caecae and colons of the colonised mice did not show obvious gross changes 
compared to those of the mice that were not colonised. Histological examination 
revealed some mild abnormalities such as an increase in the numbers of goblet cells 
and focal disruption of the epithelium in both caecal and colonic samples. Except for 
those  mild  reactions  to  infection,  no  severe  pathological  changes  or  any  end  on 
attachment of spirochaetes to the luminal epithelium were observed in the stained 
section from animals that were culture positive (Figure 3.25). 
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Figure 3.25 Haematoxylin and eosin stained sections of caecal tissue from C3H/HeJ 
mice infected with B. pilosicoli strain WesB. The epithelium shows focal disruptions 
(A), and an increase in goblet cells numbers (arrows), and numerous spirochaete-like 
forms in the lumen of the caecum (B). (Magnification x 400). 
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CHAPTER FOUR 
DISCUSSION 
 
4.1 INTRODUCTION 
Over the past decade, vaccine development has experienced revolutionary changes 
through the availability of new knowledge and methodology in molecular biology 
and  biotechnology.  Several  sophisticated  technologies  associated  with  genome 
mining and functional genomics have enabled scientists to uncover the molecular 
bases of interactions between pathogenic microorganisms and host cells. Different 
strategies including genomics, transcriptomics, proteomics, and metabolomics, alone 
or in combinations have played key roles in deciphering genetic codes from DNA to 
RNA, proteins, and finally metabolites, and in defining the relationships between 
genotype and phenotype of a particular micro-organism in different environments. In 
this  dynamic  link  between  genotype  and  phenotype,  gene  expression  and  its 
regulation  enable  micro-organisms  to  adapt  to  stresses  caused  by  environmental 
changes  or host immune responses during infections. The application of ―omics‖ 
technologies along with the completing and refining of bioinformatics algorithms 
allows the identification of potential protective components of bacterial pathogens 
that can be used for future vaccine development. The genomic approach to vaccine 
development has been called ―reverse vaccinology‖ (Mora et al., 2003). This new 
approach  in  vaccine  development  has  the  potential  to  identify  new  bacterial 
molecules for use in recombinant vaccines for human and animal pathogens.  
      The aim of this study was to apply ―reverse vaccinology‖ in the identification of 
components  for  use  as  subunits  in  vaccines  for  protection  against  B.  pilosicoli 
infection.  This  is  the  first  application  of  the  reverse  vaccinology  approach  to  B.   173 
pilosicoli.  It  is  recognised  that  there  are  other  approaches  that  can  be  used 
independently  or  together  with  reverse  vaccinology  to  identify  potential  vaccine 
candidates. These have been described in chapter one, and will not be described 
further in relation to the work that was conducted in this PhD programme. 
      The investigation undertaken in this thesis used a small subset of B. pilosicoli 
genes and  put them through a screening flow involving a bioinformatics analysis, a 
distribution study, expression of the gene products, and finally immunogenicity and 
efficacy  trials  of  the  appropriate  gene  products  in  order  to  recognize  potentially 
useful vaccine antigens. These components of the investigation will be discussed 
sequentially.   
 
4.2 BIOINFORMATICS ANALYSIS 
Access to an incomplete genome sequence of B. pilosicoli within our group provided 
the opportunity for the first time to retrieve and select some important ORFs from the 
bacterial genome using different bioinformatics tools in a process called in silico 
analysis. This approach resulted in functional annotation of several hundred ORFs 
which  were  classified  as  cytoplasmic,  cytoplasmic  membrane,  periplasmic,  outer 
membrane,  and  extracellular  proteins  based  on  their  localization  prediction. 
Considering the short timeframe for this PhD study, a subset of 24 putative genes 
was selected to be analysed using reverse vaccinology. The final selection of these 
genes was not under the direct control of the author, but was dictated by commercial 
considerations of the industry partner that was funding the study.       
       Generally,  surface  exposed  or  secreted  proteins  are  the  most  promising 
immunogenic  candidates  for  vaccine  development  against  bacterial  infections 
(Zagursky & Russell, 2001; Adu-Bobie et al., 2003; Grandi, 2003). In this study   174 
BlastP functional prediction and Pfam domain prediction were used to functionally 
annotate 24 ORFs and predict their possible subcellular localization based on their 
similarity with known proteins in other bacteria (Table 3.1 and 3.2). Since 30%-50% 
of predicted ORFs in bacterial genomes are genes with no associated function, other 
bioinformatics tools rather than the standard search algorithms like BlastP functional 
prediction  and  Pfam  domain  prediction  were  needed  to  assign  subcellular 
localization of the gene product (Zagursky & Russell, 2001). Therefore in this study 
PSORTB  v.2.0  (http://www.psort.org/psortb/),  SignalP  3.0 
(http://www.cbs.dtu.dk/services/SignalP/),  LipoP  1.0 
(http://www.ch.embnet.org/software/TMPRED_form.html),  and  TMpred 
(http://www.ch.embnet.org/software/TMPRED_form.html) were selected for use in 
identifying  predicted  secreted  or  surface  associated  proteins  based  on  special 
structures and signatures like secretory leader sequences or transmembrane helices. 
      Three  important  and  useful  signatures  for  detecting  membrane  associated  or 
secretory  proteins  are  signal  peptidase  I  and  II  cleavage  sites  and  N-terminal 
transmembrane helices in the N-terminal of secreted proteins (Grandi, 2001; Setubal 
et al., 2006). These can be identified using the SignalP, SpLip (Setubal et al., 2006), 
LipoP, TMpred, and PSORTb  programs. The application of these four programs on 
all the predicted ORFs of B. pilosicoli resulted in identification of several signal 
peptides  and  transmembrane  helices  in  their  predicted  products  which  helped  to 
predict  their  cellular  localizations  and  assign  them  as  membrane  associated  or 
secretory proteins, and furthermore they detected region that encoded the possible 
mature proteins. 
      The  application  of  the  PSORTb  analysis  tool  on  the  24  ORFs  assigned  their 
products as cytoplasmic proteins (NAV-PX, AV-P5, 21, 51, and 52), cytoplasmic   175 
membrane proteins (NAV-P8, 9, 18, 23, 25, and 45), periplasmic membrane proteins  
(NAV-P3, 13, 20, 22, 24, 27, 30, 31, and 50), outer membrane proteins (NAV-P15, 
29), and an  extracellular protein (NAV-P19). SignalP analysis of the ORFs detected 
the presence of signal peptidase I cleavage sites in the products of the 14 ORFs NAV-
PX, NAV-P3, 5, 8, 9, 19, 23, 27, 29, 45, 51, 52, and 53, allocating their products as 
non-secretory  proteins,  while  NAV-P13,  15,  18,  20,  22,  24,  25,  30,  31,  and  50 
products were assigned as secretory proteins. Analysis of the ORFs with the TMpred 
prediction tool resulted in detection of 1-7 transmembrane helices in the products of 
all ORFs, except for NAV-P5 and NAV-P53.  
      The overall results obtained from PSORTb analysis to localize ORFs products 
were  almost  in  accordance  with  the  results  obtained  from  SignalP  analysis.  For 
instance NAV-PX, NAV-P5, 8, 9, 23, 45, 51, and 52 were predicted as cytoplasmic 
and cytoplasmic membrane proteins by PSORTb, and were assigned as non-secretory 
proteins by SignalP; and NAV-P3, 15, 20, 22, 24, 30, 31, and 50  were predicted as 
periplasmic or outer membrane proteins by PSORTb and were identified as secretory 
proteins by SignalP.   
      Since lipoproteins anchor the inner face of the Gram-negative outer membrane to 
the  peptidoglycan  cell  wall  and  have  functions  such  as  adhesions,  enzymes, 
transporters,  binding  proteins,  toxins  and  a  variety  of  other  capacities  that  are 
essential for virulence (Madan Babu & Sankaran, 2002),  they are of great interest in 
understanding the molecular pathogenesis of spirochaete infections and immunity 
(Setubal et al., 2006). Therefore, it was a priority to include lipoprotein molecules as 
potential valuable immunogenic components for further evaluation. In this respect, 
including genes encoding lipoprotein molecules amongst the 24 selected ORFs was 
an appropriate strategy to take.   176 
      Unfortunately, the available computational  tools  for detecting signal  peptides, 
and their abilities to detect signal peptide cleavage sites vary significantly, and are 
often  less  than  satisfactory  (Zhang  &  Henzel,  2004).  Furthermore,  spirochaete 
lipobox sequences exhibit more plasticity than those of other bacteria, which makes 
the  application  of  normal  prediction  algorithms  to  emerging  sequence  data 
problematic  (Setubal  et  al.,  2006).  For  instance,  Psort  sensitivity  (13–35%)  was 
considerably less than that of SpLip (93–100%), due in part to the requirement of 
Psort  for  Ala  or  Gly  at  the  ‖1  position,  a  rule  based  on  E.  coli  lipoproteins; 
furthermore,  the  percentage  of  false-positive  lipoprotein  predictions  by  Psort  (4–
27%) is greater than that of SpLip (0–1%) due in part to the lack of rules in LipoP 
excluding unprecedented amino acids such as Lys and Arg in the ‖1 position (Setubal 
et al., 2006). Therefore in this study to overcome the weak accuracy of prediction of 
lipoprotein signal peptides within the encoded products of B. pilosicoli ORFs, the 
LipoP program was used in addition to the more routine algorithms SignalP and 
PSORTb.  
      The predicted results obtained from LipoP  analysis showed that the predicted 
products from seven of the 24 ORFs, NAV-P3, 13, 20, 22, 24, 30, and 31, contained a 
lipoprotein  signal  peptide  (signal  peptidase  II)  in  the  N-terminal  regions  of  their 
products. Comparing the results obtained from LipoP analysis with those obtained 
from PSORTb and SignalP analyses revealed that five ORF products, NAV-P3, 20, 
22, 30, and 31, that were predicted to be periplasmic or outermembrane component 
by  PSORTb  or  as  secretory  proteins  by  SignalP,  were  also  predicted  to  have 
lipoprotein signal peptides in their N-terminal sequences.         177 
     The  overall  results  obtained  from  in  silico  analysis  showed  that  five  ORF 
products, NAV-P3, 20, 22, 30, and 31 were potentially important, and they were 
selected with the others for the next step of the reverse vaccinology approach.  
 
4.3 DISTRIBUTION ANALYSIS OF PUTATIVE ORFS 
When developing recombinant vaccines it is important that the subunit protein is 
found in all or nearly all strains of the species against which protection is sought. 
Therefore the next step of this study concentrated on examining the distribution of 
the selected   ORFs amongst different strains of B. pilosicoli.  
      One or two sets of primers were designed for each of 24 ORF and used in PCRs 
applied to a large set of 25 B. pilosicoli strains representing the potential range of 
genetic variability of different human and animal strains from different countries. 
The primers were designed to amplify all or almost 50% of each ORFs sequence in 
the mid portion. A conservative selection criterion was used (i.e. the gene was to be 
found in at least 23 of these strains), representing a 90% distribution in the 25 strains. 
For ORFs with less than 90% distribution other set of primers were designed to be 
complementary with different positions of the ORF sequences, to cover the potential 
heterogenicity of the primer sites. At this stage 20 ORFs (83%) were found to be 
conserved, suggesting that their products might be useful for further examination.  
      The  genomic  DNA  of  B.  aalborgi  strains  A1  and  A2  were  used  as  negative 
controls in the distribution study, and nine of the tested ORFs were shown to be 
amplified  in  one  or  both  strains.  This  was  not  a  particular  problem  for  vaccine 
development, as a recombinant vaccine for B. pilosicoli in humans based on shared 
proteins might also be expected to confer some protection against B. aalborgi.    178 
      The distribution of the gene NAV-PX was tested in a wider variety of Brachyspira 
species  strains  than  were  the  other  genes  because  this  gene  had  previously  been 
described in B. pilosicoli (Trott et al., 2003). An 878 bp portion of the gene was 
amplified from most strains of B. pilosicoli and B. intermedia tested, and from strains 
of  the  other  Brachyspira  species.  It  was  clear  that  the  gene  was  widespread  in 
different species of the genus, particularly in B. pilosicoli and B. intermedia.  
      In total, 20 out of 24 ORFs fulfilled the defined criterion for distribution, and 
were selected for the next step of reverse vaccinology. All had been predicted by in 
silico  analysis  to  encode  protein  export  membrane  proteins,  outer  membrane 
proteins, chaperons, or proteins with enzyme activity. 
 
 
4.4 GENE HOMOLOGY AND PHYLOGENETIC ANALYSIS 
 
To  investigate  potential  sequence  variability,  the  whole  coding  regions  of  ORFs 
NAV-P3, NAV-P8, and NAV-P9 from five B. pilosicoli strains were sequenced and 
compared, as was the ORF for NAV-PX over 20 strains of different Brachyspirae 
species. There was insufficient time and resources to conduct this analysis for all the 
genes encoding potential vaccine candidates.  
      The NAV-P3, NAV-P8, and NAV-P9 genes encoded proteins with predicted sizes 
of 60.35, 55.21, and 35.23 kDa respectively. NAV-P3 is a member of ABC-type 
oligopeptide transport that is predicted to be localized in the periplasmic space of B. 
pilosicoli, while NAV-P8 and NAV-P9 are members of a group of protein-export 
membrane  proteins  which  are  predicted  to  be  secretory  proteins.  Only  relatively 
minor differences were found in the NAV-P3, NAV-P8, and NAV-P9 gene sequences 
amongst the five B. pilosicoli, strains and this produced additional confidence that 
the gene products would be conserved across all strains.    179 
      The  1785  bp  NAV-PX  gene  that  was  first  described  by  Trott  and  colleagues 
(2003) and named clpX encodes a protein with a predicted size of 67.42 kDa without 
a signal peptide and trans-membrane domain. It is assumed to be an inner membrane 
protein of B. pilosicoli with low density localization in the outer membrane. NAV-
PX or clpX is a member of a family of molecular chaperones and proteases which are 
responsible  for  degradation  and  elimination  of  abnormal  proteins  and  unstable 
proteins in both prokaryotes and eukaryotes (Gottesman et al., 1993). Only relatively 
minor differences were found in the NAV-PX gene sequences of the Brachyspira 
species strains from which it was sequenced (99.3-99.7% similarity to clpX in B. 
pilosicoli 95/1000). The dendrogram constructed from the similarity matrix of the 
sequenced  NAV-PX  gene  in  these  20  Brachyspira  strains  showed  that  whilst  the 
genes from half of the B. pilosicoli strains clustered in group 4, those of the other 
strains  were  located  elsewhere  (Figure  3.4).  The  general  imperfect  match  of  the 
dendrogram with the accepted phylogeny of the Brachyspira species may have been 
associated with recent mutational changes or horizontal gene transfer and genetic 
recombination  between  the  species.  There  was  no  strong  clustering  of  the  B. 
pilosicoli strains according to host species of origin, and this is consistent with such 
strains crossing species boundaries and being potentially zoonotic (Hampson et al., 
2006b). 
 
 
4.5 GENE CLONING AND PROTEIN EXPRESSION 
 
In this study a prokaryotic E. coli system was used for expression of recombinant 
proteins  because  of  the  bacterium‘s  high  transformation  efficiency,  simplicity  of 
cultivation, speed, and low cost. The process of expression of the B. pilosicoli ORFs 
in a heterologous host cell was a complex multi-step cellular process, and was often   180 
problematic. For some ORFs like NAV-PX and NAV-P21N, expression levels of the 
proteins were too low, or the proteins were insoluble or unstable. In order to improve 
production  of  the  recombinant  proteins  a  number  of  conditions,  including  the 
plasmid vector, fusion partner, induction conditions, solubility, transformation host 
and expression host were evaluated and optimized. 
      Nine of 12 selected ORFs that had been cloned in two different vectors (pTrcHis 
A and pET 19b) were over-expressed. The products of the other three (NAV-P8, 
NAV-P9,  and  NAV-P45)  were  functionally  annotated  as  secretory  D  factors  and 
haemolysin  III, and these products appeared to be toxic for the host cells during 
expression,  even  using  pET  19b  vectors  in  combination  with  different  host  cells 
cultured in different media.  
      The  pTrcHis  A  vector  that  was  applied  to  over-express  the  other  nine 
recombinant proteins is an N-terminal polyhistidine (6xHis) tagged member of the 
pTrcHis A, B, and C vectors which are derived from pSE420, and all use the trc 
promoter  for  high-level  regulated  expression  of  recombinant  proteins  in  E.  coli 
(Egon, 1983; Brosius et al., 1985; Brosius, 1992). The 6xHis affinity tag is poorly 
immunogenic, and at pH 8.0 the tag is small and uncharged, and therefore does not 
generally  affect  secretion,  compartmentalization,  or  folding  of  the  fusion  protein 
within the cell. In most cases, the 6xHis tag also does not interfere with the structure 
or function of the purified protein. The 6xHis affinity tag facilitates binding to Ni-
NTA  Agarose,  and  allows  the  immobilization  of  the  protein  on  metal-chelating 
substances that can be detected by Anti-His antibodies (Hochuli et al., 1987; Schmitt 
&  Stunnenberg,  1993).  Nitrilotriacetic  acid  (NTA)  is  a  tetra-dentate  chelating 
adsorbent that occupies four of the six ligand binding sites in the coordination sphere 
of the nickel ion, leaving two sites free to interact with the 6xHis tag. NTA binds   181 
metal ions far more stable than other available chelating resins, and retains the ions 
under  a  wide  variety  of  conditions,  especially  under  stringent  wash  condition 
(Hochuli, 1989). The NTA matrices can therefore bind 6xHis-tagged proteins more 
tightly  than  matrices  of  iminodiacetic  acid  (IDA)  (Porath  et  al.,  1975),  hence 
allowing  the  purification  of  proteins  from  less  than  1%  of  the  total  protein 
preparation to  more than 95% homogeneity in  one step  (Janknecht et al., 1991). 
Since the interaction between Ni-NTA and the 6xHis tag of the recombinant protein 
does not depend on tertiary structure, the protein can be purified either under native 
or denaturing conditions. The decision whether to purify 6xHis-tagged proteins under 
native  or  denaturing  conditions  depends  on  protein  subcellular  location  and 
solubility, the accessibility of the 6xHis tag, the availability of renaturing procedures, 
the downstream application, and whether biological activity must be retained. 
      In purification under native condition the 6xHis-taged protein must be soluble. 
Although most proteins tend to be produced in the form of inclusion bodies, there is 
generally some soluble form of the target protein that can be purified in its native 
form.  In  this  study,  five  proteins  (NAV-P20,  22,  27,  30,  31)  with  periplasmic 
subcellular localizations were expressed in soluble forms in E. coli cells. Thus these 
proteins  were  purified  under  native  condition  using  Ni-NTA  column 
chromatography.  In  some  cases  the  6xHis-taged  protein  is  hidden  by  tertiary 
structure of the native protein, so that soluble proteins require denaturation before 
they can be purified on Ni-NTA. NAV-PX and NAV-P21N that were assumed to be 
cytoplasmic  components,  and  NAV-P3  and  NAV-P13  with  predicted  periplasmic 
localization were mostly expressed in the form of inclusion bodies; therefore they 
required  solubilisation  to  expose  their  6xHis  tags  before  purification  by  affinity 
chromatography.    182 
      In order to produce biologically useful recombinant proteins, it is necessary to 
convert improperly folded inclusion body proteins into their native conformations in 
which they are soluble. Protein insolubility may be caused by a variety of factors 
including the need for general molecular chaperones, cofactors, or protein partners 
for proper folding (Luo & Hua, 1998; Sun et al., 2005). The properties of proteins, 
such  as  hydrophobic  and  hydrophilic  regions  of  the  amino  acids  in  the  protein 
sequences govern the protein structure and folding. As can be seen from Figure 3.1, 
the  distribution  pattern  along  the  amino  acid  sequences  of  full  length  NAV-P13 
showed three hydrophobic regions in its N-terminal. These hydrophobic N-terminal 
domains may be the crucial factors that contribute to the formation of full length 
NAV-P13 inclusion bodies. The proteins are more predisposed to aggregation due to 
increased intermolecular interactions of regions of the folding polypeptide chain. In 
the present work, intact NAV-PX, NAV-P20, NAV-P21N, and NAV-P27 proteins 
and  truncated  NAV-P3,  NAV-P13,  NAV-P22,  NAV-P30,  and  NAV-P31  proteins 
were over-expressed in E. coli. The N-terminal deletions in truncated proteins were 
specifically designed to eliminate the N-terminal signal peptides and transmembrane 
domains of the full-length proteins. Five proteins (NAV-P20, 22, 27, 30, and 31) 
were expressed as soluble forms whilst four (NAV-PX, NAV-P3, 13, and 21N) were 
expressed as insoluble forms. Of the truncated proteins, NAV-P22, 30, and 31 were 
mostly expressed in their native forms, whilst most of the truncated NAV-P3 and 
NAV-P13 proteins still existed in an insoluble form. A procedure then was carried 
out to improve the protein solubility by lysis of the bacterial pellet in Tris buffer 
containing  high  concentration  of  chaotropic  agents  (8M  urea)  under  alkaline 
conditions (pH 8). The results suggested that charge distribution provided by the high 
alkaline pH along the protein chain was responsible for solubilisation of histidine   183 
tagged recombinant proteins from inclusion bodies. Thus, the pH has an essential 
role in destabilizing the inclusion body aggregation. In addition, the presence of a 
thiol containing reducing agent, in this case 20 mM DDT, allowed reduction of inter-
chain disulfide bonds by thiol-sulfide exchange, and increased the solubilisation of 
the aggregated protein. The use of DTT has the advantage that it does not have to be 
removed prior to initiation of the refolding by dialysis. 
 
4.6 IN VITRO AND IN VIVO IMMUNOGENICITY TRIALS  
An efficient vaccine against a pathogen has to generate protective immune responses 
in a large portion of individuals, against all strains of the pathogen. The next step in 
the  screening  of  the  candidate  recombinant  proteins  that  were  produced  was  to 
examine their in vitro and in vivo immunogenicity. The immunogenicity or potential 
ability  of  an  antigen  to  induce  an  immune  response  depends  on  its  nature, 
configuration, accessibility to the immune system, and its association with bacterial 
virulence or invasive mechanisms.  
      A  serum  library  was  assembled  to  assess  immunological  reactivity.  This 
consisted  of  convalescent  sera  from  individual  hosts  naturally  or  experimentally 
infected with different strains of the target pathogen, therefore containing a range of 
polyclonal antibodies directed against surface antigens, virulence factors and other 
antigens of the pathogen. Subsequently this serum library was applied for in vitro 
immunogenicity screening of the recombinant proteins, testing their reactivities using 
Western  immunoblot.  The  serum  was  derived  from  individual  pigs  naturally  or 
experimentally infected with B. pilosicoli strains and was applied to nine purified 
recombinant  proteins  (NAV-PX,  NAV-P3,  13,  20,  21N,  22,  27,  30,  and  31), 
confirming their immunoreactivites with almost all the serum samples. The weak   184 
reactivities between negative control pig sera and NAV-P3, 13, 20, 21N, 22, 30, and 
31 suggest that these animals had prior exposure to B. pilosicoli or other related 
spirochaetes before bleeding.  Furthermore hyperimmune sera from mice that had 
been immunised with a bacterin vaccine prepared from B. pilosicoli strain WesB 
showed  strong  reactivities  with  the  recombinant  proteins  in  Western  blot,  and 
reconfirmed the results obtained from the pig serum reactivities. The specificity of 
this  reactivity  was  further  verified  by  blocking  of  the  serum  with  its  specific 
recombinant protein prior to blot reactions with WesB whole cell protein. 
      The overall results obtained from the in vitro and in vivo immunogenicity assays 
confirmed that the nine investigated recombinant proteins were immunogenic and 
appropriate for selection as potential vaccine candidates in subsequent efficacy trials. 
Owing to time constraints, only four of the recombinant fusion proteins were selected 
for the efficacy trial in mice, whilst the remaining five proteins are still available as 
potential vaccine candidates for use in future studies. 
 
4.7 EFFICACY TRIALS IN A MOUSE MODEL 
As this study was focused on development of a vaccine for humans, and because a 
mouse model of B. pilosicoli has previously been described (Jamshidian et al., 2004), 
this method was used in the current study. Clearly, it would also be possible to use 
these vaccine candidates to protect other species, such as chickens and pigs, but this 
was outside the limited timeframe and scope of the work described in the thesis. 
      In the efficacy trial, comparison of the mean systemic IgG levels before and after 
challenging  with  live  bacteria  demonstrated  that  vaccination  of  mice  with  two 
subcutaneous  injections  of  the  four  candidate  proteins  resulted  in  significant 
differences (P-value< 0.001) between the vaccinated groups and the non-vaccinated   185 
control  groups.  Testing  the  antisera  to  native  bacterial  proteins  using  Western 
immunoblot before and after bacterial inoculation confirmed that the recombinant 
proteins derived from B. pilosicoli strain WesB induced substantial systemic IgG 
responses  in  the  mice.  This  helped  confirm  the  validity  of  the  conditions  of 
experimental vaccine preparation in Freund‘s incomplete adjuvant (FIA), and gave 
confidence to further investigations aiming to induce systemic responses against B. 
pilosicoli proteins in mice. On the other hand, the weak local IgG responses in the 
colons  and  caecae  of  the  mice  indicated  that  the  subcutaneous  route  of  vaccine 
administration was not effective at inducing a strong mucosal IgG antibody response 
in the mouse gut.  
       In  general  most  subunit  antigens  whether  or  not  they  are  natural  products, 
recombinant products, or synthetic peptides usually are poor antigens and fail to be 
highly immunogenic. This may be because of a variety of different reasons such as 
incorrect  processing  by  the  immune  system,  rapid  clearance,  stimulation  of  an 
inappropriate immune response, and / or lack of critical B-cell or T-cell epitopes. 
Potentially, some of these failures  can be overcome by administrating of subunit 
antigens with proper adjuvants or immunopotentiators (Edelman, 2000). Therefore it 
is critical to select a good adjuvant to enhance the immunogenicity of a recombinant 
protein  and  stimulate  a  strong  humoral  response.  FCA  or  FIA    have  been  used 
extensively in many experimental immunology studies in animal models owing to 
their  high  efficacy  (Lindblad,  2000).  In  most  cases,  Freund‘s  adjuvants  quickly 
induce high titres of high-affinity antibodies (Johnston et al., 1991; Deeb et al., 1992; 
Gamberini  et  al.,  2005).  FCA  activates  T  cell  populations,  providing  necessary 
lymphokines for B cell stimulation and maturation, but its use has been limited due 
to production of granuloma and subsequent abscesses in animals. To reduce animal   186 
discomfort, it is recommended to substitute FIA as an alternative for FCA, as in most 
cases FIA also can induce acceptable humoral responses (Stewart-Tull, 1996).  
      In the current study ELISA tests on some samples, including colonic and caecal 
contents  and  tissue  extracts,  failed  to  identify  local  IgA  responses  in  the  four 
vaccinated groups of mice before and after infection. Local IgA is believed to be 
important in protecting mucosa surfaces, so in future studies mucosal immunisation 
would be an attractive alternative to parenteral vaccination because it can produce 
both systemic and mucosal immunity (Ruiz-Buttons et al., 2000; Jaganathan & Vyas, 
2006).  From  a  theoretical  standpoint,  the  possibility  to  manipulate  the  mucosal 
immune system towards immunity without tolerance is the best way to protect the 
host from colonisation or invasion by mucosal pathogens (Czerkinsky & Holmgren, 
1994). Therefore, to develop a more efficient vaccine for B. pilosicoli, it would be 
useful  to  examine  different  delivery  routes  and  alternative 
adjuvants/immunomodulators.  The  completely  non-toxic,  recombinantly  produced 
cholera  toxin  B-subunit  (CTB)  and  E.  coli  heat-labile  enterotoxin  (LTB)  with 
retained adjuvant activity have proven to be very useful tools to generate increased 
mucosal immune responses induced by oral, nasal, vaginal, or rectal administration 
(Pizza et al., 2001). CTB or LTB can also serve as efficient mucosal carriers for 
inducing  mucosal  immune  responses  to  various  antigens  or  peptides  chemically 
linked  to  or  genetically  fused  to  CTB/LTB  (Lebens  et  al.,  2002).  It  seems  that 
mucosal vaccines against various microbial pathogens may be developed based on 
CTB or LTB, or analogous substances as vectors (Holmgren et al., 1993).  
      Toll-like  receptor  ligands  like  CpG  oligonucleotides  [(unmethylated  cytidine-
phosphate-guannosine (GpG) with appropriate flanking regions (CpG motifs)] are 
responsible for stimulatory effects of bacterial DNA on vertebrate immune systems,   187 
and  can strongly stimulate innate and adaptive immunity in mucosal tissues when 
administered at mucosal surfaces (Krieg & Davis, 2002). CpG motifs in bacterial 
DNA or synthetic oligodeoxynucleotides stimulate dendritic cells and macrophages 
through the Toll/IL-1-receptor signalling pathway to produce Th1 cytokines such as 
IFN-γ,  IL-1β,  and  IL-12.  Further,  such  interactions  upregulate  co-stimulatory 
molecules on APCs, and promote B cell proliferation and differentiation in antibody-
forming  cells  (Wagner,  2002).  Oral  administration  of  CpG  DNA  without  any 
bacterial antigen co-delivery has been shown to induce innate immune responses 
which  are  associated  with  partial  protection  against  challenge  with  Listeria 
monocytogenes  and  Francisella  tularensis  in  the  murine  gastrointestinal  tract 
mucosa,  and  the  protection  could  be  maintained  indefinitely  by  repeatedly 
administering CpG DNA two to four times per month. Thus, repeated administration 
of CpG ODN may provide a safe means of conferring long-term protection against 
infectious pathogens (Klinman et al., 1999).  
      Based  on  unpublished  results  obtained  in  our  group  from  experimental 
vaccination  of  C3H/Hej  mice  with  recombinant  His6-BmpB  protein,  100  µg  was 
established to be the optimum level of protein to use (Report on project ―Vaccines 
for  swine  dysentery  and  intestinal  spirchaetosis‖,  April  2004,  Division  of  Health 
Sciences, Murdoch University). Therefore in this study 100 µg of each protein was 
used in in-vivo immunogenicity and efficacy trials to induce antibody responses in 
mice. Generally, the suggested optimal amount of recombinant protein as a dosage 
that  can  be  administered  in  mice  is  between  15-60  µg  based  on  mono  or 
multicomponent vaccine formulations (Gamberini et al., 2005; Giuliani et al., 2006). 
The optimal amount must be in a range that can induce strong humoral responses 
without suppression or toleration of the immune system. For instance, although the   188 
100  µg  protein  in  the  vaccines  used  in  this  study  induced  sufficient  immune 
responses in the vaccinated mice, it is likely that the protein content in each dose of 
vaccine could be reduced by further optimizations trials in mice. Again, this was 
beyond the scope of the current PhD programme.  
       In  general,  the  immunological  characterization  of  an  experimental vaccine  is 
interpreted  as  the  ability  of  the  preparation  to  invoke  an  appropriate  immune 
response to its major constituent antigens. The immune response may be in the form 
of serum antibodies, secretory antibodies, cell-mediated immunity, or a combination 
of  these.  The  best  approach  to  characterization  of  the  immune  response  may  be 
qualitative,  such  as  immunoblotting  to  check  for  the  presence  of  antibodies  to 
specific antigens (Burnette, 1981), quantitative, such as immunosorbent assays to 
measure the level of antibody response to a particular antigen (Melville-Smith et al., 
1983), or functional, such as toxin neutralization (Gillenius et al., 1985), to assess the 
magnitude of the functional activity of the response. In this study, Western blot and 
ELISA  were  used  to  evaluate  systemic  and  local  antibody  responses  to  the 
experimental  vaccines.  In  particular  it  was  thought  that  local  colonic  antibody 
responses would be important in limiting colonisation by the spirochaetes. In both 
assays recombinant protein and whole cell preparation of B. pilosicoli were applied 
as antigen to identify antibody responses in the mice. The results obtained from the 
vaccinated groups were interpreted in comparison to those in two control groups of 
mice; one as a negative control without vaccine administration or bacterial infection 
to  help  evaluate  the  systemic  and  local  antibody  responses,  and  the  other  as  an 
infection  control  group  without  vaccination,  but  inoculation  with  B.  pilosicoli  to 
allow a comparison with the extent of infection in the vaccinated mice.    189 
      Following  challenge,  some  of  the  inoculated  mice  started  to  show  bacterial 
shedding in their faeces. This demonstrated that the mouse model of B. pilosicoli was 
working, and hence could be useful for assessing vaccine efficacy. The onset and 
duration of bacterial shedding was different between the four vaccinated groups and 
the two infection control groups. In efficacy trial I, on day 14 post-infection 8 out of 
12 (66.7 %) mice in the infection control group showed faecal shedding while in the 
NAV-P13 and NAV-P31 vaccinated groups three  (25 %) and five (41.7 %) mice 
demonstrated bacterial shedding in their faeces respectively. In efficacy trial II on 
day 16 post-infection 75 % of the mice in the infection control group were showing 
bacterial shedding while in the NAV-P3 and NAV-P22 vaccinated groups only 16.7 
% and 33.4% of the mice were shedding bacteria respectively. The onset of bacterial 
shedding in the faeces began on days 6 or 7 post-infection in both efficacy trials, and 
then increased to the highest number on days 14 and 16 post-infection. Overall, in 
both efficacy trials there were significant differences (P<0.05) between the number 
of the colonised mice in the infection control groups compared with those in the 
vaccinated groups. Hence this provided evidence that the vaccines were having some 
effects on reducing colonisation. In efficacy trail I, keeping the infected mice more 
than 14 days  resulted in a reduction in  the number of positive mice in both  the 
vaccinated and infection control groups. Therefore, in respect to bacterial shedding, 
the results obtained in the mouse model under the conditions used are most reliable 
between 14 -16 days post-infection. 
      The NAV-P3 vaccinated group with the highest level of systemic IgG (mean: 
1.434 OD value) showed the lowest number of the colonised mice (16.7 %). On the 
other hand, mice vaccinated with NAV-P31 with the lowest levels of systemic IgG 
(mean: 0.083 OD value) had the greatest number of colonised mice (41.7 %). This   190 
suggests  that  high  levels  of  circulating  IgG  to  the  recombinant  proteins  were 
associated with protection in the colon. 
     At post-mortem, the caecal size and contents varied between mice, with some 
caeca being small and empty, and others being large and full of contents of varying 
consistency. There were no consistent group effects. The examined mucosal surface 
of all the caeca from the colonised mice in both vaccinated and control groups were 
grossly normal, and histological examination revealed only some mild abnormalities. 
No end-on attachment of spirochaetes to the luminal surface of the caecal or colonic 
enterocytes was observed in any of the mice. Hence looking for differences in the 
colonic  mucosa  in  mice  was  not  useful  as  an  indicator  of  potential  vaccine 
protection. Likewise the mice did not show any clinical signs that would be useful in 
evaluating vaccine-induced protection. 
      In  work by others,  experimental  infection of C3H/HeJ and C3H/HeOuJ mice 
with avian (isolate 42167), porcine (P43/6/78), or human (S. jonesii) isolates of B. 
pilosicoli via gastric intubation also resulted in colonisation with the spirochaetes. 
End-on attachment to the apical surface of enterocytes was seen for the avian and 
porcine isolates but not for the human isolate (Sacco et al., 1997). It is not clear 
whether  or  not  it  is  coincidental  that  in  that  study  and  the  current  work  end-on 
attachment  did  not  occur  with  a  human  strain  of  B.  pilosicoli.  It  is  possible  for 
example  that  mice  lack  receptors  on  their  enterocytes  for  human  strains  of  B. 
pilosicoli.  Clearly  to  investigate  such  possibilities,  further  experimental  infection 
studies  are  required  using  different  animal  species  (eg  other  strains  of  mice, 
chickens, and pigs) in different combinations with B. pilosicoli strains isolated from 
humans and other animal species.  
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4.8 SUMMARY AND FURTHER WORK 
The  research  undertaken  and  presented  in  this  thesis  has  greatly  improved 
understanding of a genome based approach to evaluate and detect potential vaccine 
candidates against intestinal spirochaetosis caused by B. pilosicoli. This was the first 
application  of  the  ―reverse  vaccinology‖  approach  to  possible  development  of  a 
subunit vaccine against B. pilosicoli. The approach allowed several gene products as 
recombinant proteins to be evaluated for their immunogenicity and potential efficacy 
in a mouse model of experimental infection. This research demonstrated for the first 
time that B. pilosicoli gene products overexpressed in E. coli are capable of inducing 
systemic and mucosal immune responses in mice. Furthermore, the protective effects 
of NAV-P3, 13, 22, and 31 recombinant proteins suggest a possible functional role of 
these proteins in B. pilosicoli colonisation and pathogenicity. This work has opened 
the route for further vaccine studies for B. pilosicoli.  
      Given that vaccines containing several antigens have been shown to confer better 
protection than those containing only one or two antigens (Olin et al., 1997), further 
efficacy  trials  using  combinations  of  the  four  antigens  in  one  multicomponent 
vaccine might increase the breadth of the vaccine coverage and potency.  
      Immune  responses  within  ―mucosa-associated  lymphoid  tissue‖  (MALT)  may 
occur independently of systemic immunity, with distinctive regulatory mechanisms 
and  the  induction  of  dimeric  secretory  IgA  (SIgA)  at  the  mucosal  surface 
(Czerkinsky & Holmgren, 1994). In addition, the trafficking of primed B and T cells 
between  mucosal  sites,  regulated  by  specific  adhesion  molecules,  such  as  α4β7 
integrin  on  lymphocytes  and  MAdCAM-1  on  mucosal  blood  vessels,  leads  to 
dissemination of the mucosal immune response (Quiding et al., 1995). Thus using 
techniques to deliver antigen directly to the mucosal surface of the gut in such a way   192 
as to induce immunity rather than immunological tolerance may provide even better 
protection  than  that  observed  here.  The  co-administration  of  the  antigens  with 
cholera  toxin  or  related  toxins  as  adjuvant  (Holmgren  et  al.,  1993), 
microencapsulation  of  antigen  in  biodegradable  matrices  such  as  homo-  or  co-
polymers of glycolidic and lactic acids (Cohen et al., 1991; Eldridge et al., 1991), or 
using  live  attenuated  pathogens  such  as  Salmonella  Typhimurium  to  express  the 
heterologous  target  antigen  (Ascon  et  al.,  1998)  are  all  possible  approaches  that 
could  be  used  in  the  future  to  help  optimize  the  efficacy  of  vaccines  against  B. 
pilosicoli.  
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APPENDICES 
 
Appendix A. Equipments, chemicals, kits and software suppliers  
 
A.1 Suppliers of laboratory instruments 
 
Equipment 
 
ABI 373A DNA sequencer 
 
Supplier 
 
PE Applied Biosystems, USA 
Biological Safety Cabinet  Gelman Sciences, Australia 
Bunsen burner    Analite, Australia 
Centrifuge; Avanti(tm) J-25 I    Beckman, USA 
Centrifuge; BHG Hermle Z 231 M    John Morris Scientific, Australia   
Electronic balance  Denver Instrument Company, USA 
ELISA reader    EFLAP, Finland 
ELISA plates, maxisorb  NUNC 
Gel-Doc 1000   Bio-Rad Laboratories, USA 
GS Gene Linker UV Chamber  Bio-Rad Laboratories, USA 
Haemocytometer  Weber, UK 
Laminar flow cabinet    Gelman Clemco, Australia 
Microcentrifuge tubes;0.5 ml   
Microcentrifuge tubes;1.5 ml  Sarstedt, Germany 
Microcentrifuge tubes;2 ml       Quality Scientific Products, USA 
Microplate reader, model 3550-UV  Bio-Rad Laboratories, USA 
Milli-Q ultrapure water system  Millipore, Australia 
Mini-Protein dual slab cell      Bio-Rad Laboratories, USA 
Mini protean II transfer tank  Bio-Rad Laboratories, USA 
Mini Sub™ DNA cell apparatus   Bio-Rad Laboratories, USA 
Multi-screen apparatus   Bio-Rad Laboratories, USA 
PCR tubes 200L  Quality Scientific Products, USA 
Phase contrast microscope  Olympus, Japan 
Polaroid 545i Camera    Polaroid Corporation, USA 
Power supply (power pack 300)  Bio-Rad Laboratories, USA 
proxPRESS Proteomic Imaging System  PerkinElmer Life Science, USA 
Reciprocol shaker  Brooke, Crompton, and Parkinson, 
Rotary mixer  Ratek Instruments Pty Ltd, Australia 
Speed Vac Savent Concentrator  Savent, Lorton, VA, USA 
Spectrophotometer, UV/ Vis -100-02  Shimadzu Corporation, Japan 
Spectrophotometer, Lambda 25 UV   PerkinElmer Life Science, USA 
Sonicator  Het system, New York, USA 
Thermocycler; system 2400 and 9600  Applied Biosystems, USA 
Thermocycling tubes 0.2 ml   Multiply-Pro 
Timer  Crown Scientific, UK 
UVP transilluminator Model GPS 5000  Histon, Cambridge, England 
Vortex    Lab line instruments, USA 
Water bath;  Grant Instruments, UK 
Wide Mini Sub™ DNA cell apparatus  Bio-Rad Laboratories, USA 
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A.2 Resources of chemicals, raw materials, and animals 
 
Chemicals  Manufacturers 
 
Agar   
 
Becton Dickinson, USA 
ABI PRISM
TM Dye Terminator  PE Applied Biosystems 
Agarose  Bio-Rad Laboratory, USA  
Agarose LE Analytical Grade   Promega, Madison, WI, USA 
Ammonium persulfate      Bio-Rad Laboratory, USA 
Anti-human IgG-AP conjugate  Sigma, St Louis, Missouri, USA 
Anti-Pig IgG-AP conjugate  Sigma, St Louis, Missouri, USA 
Bacto-Tryptone  Becton Dickinson, USA 
Bacto-yeast Extract           Becton Dickinson, USA 
Beta-mercaptoethanol   Bio-Rad Laboratory, USA 
Biorad Protein Assay kit   Bio-Rad Laboratory, USA 
Bromophenol blue  Bio-Rad Laboratory, USA 
BCIP:  5-bromo-4 chloro-3-indolyl phosphate   Sigma Chemical Co., USA  
C3H/HeJ mice   Western Australian State Animal Resource Centre 
Calcium Chloride  Chem-Supply, Australia 
Chloroform  BDH Chemical, Australia 
Colistin  Sigma Chemical Co., USA 
Coomassie brilliant blue- 250   Bio-Rad Laboratory, USA 
Commercial Dye-binding assay kit  Bio-Rad Laboratory, USA 
Commercial pelleted basal mouse diet  Glen Forrest Stockfeeders, Australia 
D-Glucose   BDH Chemical, Australia   
Dimethylformamide  Sigma Chemical Co., USA 
Di-Potassium hydrogen orthophosphate  K2 
HPO4) 
 
Ajax Chemical, Australia 
DNA extraction kits;    
- QIAmp DNA stool mini kit  QIAGEN GmbH, Germany 
- QIAmp DNA tissue mini kit  QIAGEN GmbH, Germany 
- UltraClean
TM PCR Clean-up
TM Kit   MoBio Laboratories. USA 
- QIAprep Spin Miniprep Kit  QIAGEN GmbH, Germany 
- QIAquick spin PCR purification kit   QIAGEN GmbH, Germany 
- QIAquick Gel Extraction Kit   QIAGEN GmbH, Germany 
DNA ladder 100, 1000 bp  Promega, USA 
DNA sequencing kit   Applied BioSystems, USA 
dNTP  Fisher Biotech Int., Perth, WA, Australia 
Di-Potassium hydrogen orthophosphate  K2 
HPO4) 
Ajax Chemical, Australia 
E. coli JM109 competent cells   Promega, USA 
E. coli  BL21 Star 
TM (DE3) pLys  Invitrogen, USA 
Ethanol  BDH Chemical, Australia   
Ethylenediaminotetre-acetic acid  Ajax Chemical, Australia 
EDTA: Tetra-sodium salt   Ajax Chemical, Australia 
Gaspak Plus sachets (BBL)  Becton Dickinson, USA 
Foetal Calf Serum (FCS)   
Freund‘s Incomplete Adjuvant   Sigma Chemical Co., USA 
Gel Drying Kit  Promega, USA 
Glacial acetic Acid   Ajax Chemical, Australia 
Glutamine  ICN Biomedicals, USA  
Glyceral  BDH Chemical, Australia 
Goat anti-mouse IgG-AP conjugate  Sigma, St Louis, Missouri, USA 
Goat anti-mouse IgG HRP conjugated  Sigma, St Louis, Missouri, USA 
Goat anti-mouse IgA HRP conjugated  Sigma, St Louis, Missouri, USA 
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A.2 Resources of chemicals, raw materials, and animals (continued) 
 
Chemicals  Manufacturers 
 
Hydrochloric acid (HCl) 
 
BDH Chemical Australia 
IPTG(isopropyl-B-D-thiogalactopyranoside)  Progen Industries LTD, Australia  
Imidazole  Sigma Chemical Co., USA 
Isoamyl-alcohol  Ajax Chemical, Australia 
Isopropanol (propan-2-ol)  Fisons Pty Ltd, Australia 
Lactose  Sigma Chemical Co., USA 
Lysozyme  Boehringer Mannheim, West Germany 
Magnesium chloride  BDH Chemical, Australia 
Magnesium Sulfate  Chem-Supply, Australia 
Methanol  BDH Chemical, Australia 
Mouse ant-His IgG  Sigma, St Louis, Missouri, USA 
Newborn Calf Serum (NBCS)   
Nickel-nitrilotriacetic acid (Ni-NTA)   QIAGEN, Australia 
Nitro blue tetrazolium chloride (NBT)  Sigma Chemical Company, USA 
Nitrocellulose membrane, 0.45 m   Amersham 
Potassium Acetate  Ajax Chemical, Australia 
Potassium dihydrogen orthophosphate (KH2PO4)  Ajax Chemical, Australia 
Pre-stained protein marker,100 kDa  Bio-Rad, USA 
Primers  Geneworks, Adelaide, Australia 
Proteinase inhibitor cocktail   Sigma Chemical Company, USA 
Proteinase K  Boehringer Mannheim, West Germany 
QIAprep Spin Miniprep Kit  QIAGEN GmbH, Germany 
QIAquick spin PCR purification kit (50)  QIAGEN GmbH, Germany 
Restriction enzymes  Promega, USA 
RNAse  Boehringer Mannheim, West Germany 
SDS  Bio-Rad Laboratories, USA 
Sodium actetate (CH3COONa)  BDH Chemical Company  
Sodium Hydroxide (NaOH)  BDH Chemical Company 
Sodium Carbonate (NaHCO3)  Chem-Supply, Australia 
Sodium Chloride   Ajax Chemical, Australia 
Sodium dihydrogen orthophosphate (NaH2Po4)  Chem-Supply, Australia 
di-Sodium hydrogen orthophosphate (NaHPO4)  Chem-Supply, Australia 
Streptomycin  Sigma Chemical Co., USA 
Sulphuric acid  Ajax Chemical, Australia 
Temed  ICN Biomedicals, USA 
T4 DNA ligase   Promega, USA 
TRIS  Bio-Rad Laboratories, USA 
Trypticase soy agar (BBL)  Becton Dickinson, USA 
Trypticase soy Broth (BBL)  Becton Dickinson, USA 
Tween-20  Bio-Rad Laboratories, USA 
Ultrapure water   Fisher Biotech Int., Perth, WA, Australia 
Urea  Ajax Finechem, Australia 
Vancomycin  Sigma Chemical Co., USA 
Whatman no.3 filter paper  Whatman International Ltd, UK 
Zinc bacitracin (ZnB)  Jurox 
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A.3 Computer software suppliers     
 
Computer software  supplier 
 
Amplify program version 1.2 
 
By Bill Engels (University of Wisconsin) 
BioEdit Sequence Alignment Editor (version 
4.8.6) 
Department of Microbiology North Carolina State 
University 
Excel 2007  Microsoft, USA 
Molecular Analyst Software version 1.4   Bio-Rad Laboratories, USA 
Proteome 1D Analyser version V 1.10   PerkinElmer Life Science, USA 
SeqEd Version 1.0.3  ABI Applied Biosystems, USA 
SPSS 15.0 for Windows   SPSS Inc., USA 
UV WINLAB software   PerkinElmer Life Science, USA 
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Appendix B. Formulation of buffers, solutions and culture media 
  
  
B.1 Bacterial culture media  
 
Trypticase Soy Agar plates (TCA-CVS) (400 ml): 
Trypticase Soy Agar  16 g 
Distilled water  380 ml 
Autoclave  121°C / 20 min. 
Spectinomycin  400 g ml
-1 
Colistin methanesulfonate (Sodium salt)  25 g ml
-1 
Vancomycin hydrochloride  25 g ml
-1 
Defibrinated ovine blood    5% (v/v)  
 
Modified Kunkle’s Broth (1 litre) 
Trypticase Soy Broth (TSB)  32 g 
Yeast extract  12 g 
Glucose  7.0 g 
NaHCO3  3.0 g 
Distilled water  960 ml 
pH adjustment with HCl 50% at  7.4 
Foetal Calf Serum (FCS)  35 ml 
Newborn Calf Serum (NBCS)  5.0 ml 
Ethanolic cholesterol   0.02 g 
L-cysteine hydrochloride  1.5 g 
Resazurin (anaerobiosis indicator)  1 ml 
 
LB (Luria-Bertani) liquid medium (1 liter): 
Bacto tryptone  10 g 
Bacto yeast extract  5 g 
NaCl  10 g 
Distilled water up to  1000 ml 
pH adjustment with NaOH 10 M at  7.2 
 
LB Agar medium (1 liter): 
Bacto tryptone  10 g 
Bacto yeast extract  5 g 
NaCl  10 g 
Bacto-agar  15 g 
Distilled water up to  1000 ml 
pH adjustment with NaOH 10 M at  7.2 
 
2 x YT liquid medium (1 liter): 
Bacto tryptone  16 g 
Bacto yeast extract  10 g 
NaCl  5 g 
Distilled water up to  1000 ml 
pH adjustment with NaOH 10 M at  7.2 
 
2 x YT Agar medium (1 litre): 
Bacto tryptone  16 g 
Bacto yeast extract  10 g 
NaCl  5 g 
Bacto-agar  15 g 
Distilled water up to  1000 ml 
pH adjustment with NaOH 10 M at  7.2 
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B. Formulation of buffers, solutions and culture media (continued) 
 
Terrific Broth medium (1 litre): 
Bacto tryptone  12 g 
Bacto yeast extract  24 g 
glycerol  4 ml 
Distilled water up to  900 ml 
Autoclave 121°C at 15lb/sq.  20 min 
Sterile solution (0.17 M KH2PO4 & 0.72 M  K2HPO4)  100 ml 
 
 
B.2 Buffers and solutions for SDS PAGE and Western blot  
 
Alkaline phosphatise (AP) staining solutions: 
Development Buffer:
   
100 mM Tris.Cl, pH 9.5; 100 mM NaCl; 5 mM MgCl2 
NBT stock solution:  5% NBT in 70% dimethylformamide (store in aliquots at -20 °C) 
BCIP:  5% BCIP in 100% dimethylformamide (store in aliquots at -20 °C) 
Staining solution:  66 µl NBT and 33 µl BCIP stock solutions in 10 ml development buffer 
   
Horseradish peroxidise staining solution: 
HRP  10 mg 
PBS pH 7.4  16.6 ml 
Methanol  3.325 ml 
Hydrogen peroxide   10 µl 
 
4 X Running Gel Buffer (1.5 M Tris-Cl, pH 8.8): 
Tris (FW 121.1)  36.3 g 
ddH2O  150 ml 
pH adjustment with HCl at  8.8 
ddH2O up to  200 ml 
Store at 4°C in the dark  Up to 3 months 
 
4 X Stacking Gel Buffer (0.5 M Tris-Cl, pH 6.8): 
Tris (FW 121.1)  3.0 g 
ddH2O  40 ml 
pH adjustment with HCl at  6.8 
ddH2O up to  50 ml 
Store at 4°C in the dark  Up to 3 months 
 
2X SDS loading Buffer: 
4 X Stacking Gel Buffer pH 6.8  2.5 ml 
10% SDS  4.0 ml 
Glycerol  2.0 ml 
Bromophenol blue  2.0 mg 
Dithiotheritol (DDT; FW 154.2)  0.31 g 
ddH2O to  100 ml 
 
SDS Tank Buffer: 
Tris (FW 121.1)  30.28 g 
Glycine  144.13 g 
SDS  10 g 
ddH2O to  10 L 
 
SDS-PAGE Overlay Buffer:  
n-Butanol  95 % (v/v)  
Distilled water  5 % (v/v)  
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B. Formulation of buffers, solutions and culture media (continued) 
 
B.2 Buffers and solutions for SDS PAGE and Western blot (continued) 
 
Coomassie stain solution: 
Coomassie Brilliant blue R 250  0.025 %, 
Methanol  40 %, 
Acetic acid  7 % 
 
De-staining solution I: 
Methanol  400 ml 
Acetic acid  70 ml 
ddH2O  530 ml 
 
De-staining solution II: 
Acetic acid  70 ml 
Methanol  50 ml 
ddH2O  880 ml 
 
Transfer buffer (1 litre): 
Tris-Cl  3.03 g 
Glycine  14.41 g 
Methanol  200 ml 
SDS  1.0 g 
ddH2O  800 ml 
 
Tris-buffered Saline (TBS): 
Tris-Cl  12.11 g 
ddH2O  800 ml 
pH adjustment with conc. HCl  7.5  
NaCl  9.0 g 
ddH2O upto  1000 ml 
 
Tris-buffered Saline plus Tween(TBST): 
Tris-Cl  12.11 g 
ddH2O  800 ml 
pH adjustment with conc. HCl  7.5  
NaCl  9.0 g 
Tween-20  1 ml 
ddH2O upto  1000 ml 
 
 
B.3 Buffers and solutions for genomic DNA preparation and gel electrophoresis  
 
TAE Buffer 50 X:  
Tris base  242 g 
Glacial acetic acid  57.1 ml 
EDTA 0.5 M, pH 8.0  100 ml 
 
Ethidium Bromide (5 µg / µl): 
Ethidium Bromide  500 mg 
Distilled water  100 ml 
Use 1 µl / 10 ml gel 
 
Agarose 1.2%: 
Agarose  1.2 g 
TAE Buffer 1 X  100 ml 
Dissolve in microwave   
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B. Formulation of buffers, solutions and culture media (continued) 
   
 
TE buffer for CTAB DNA extraction: 
Tris-Cl, pH 8.0  10 mM 
EDTA, pH 8.0  1 mM 
 
CTAB/NaCl solution: 
CTAB  10 % (w/v) 
NaCl  0.7 M 
 
Chloroform/isoamyl alcohole solution : 
Chloroform  24 ml 
Isoamyl alcohole  1 ml 
 
 
 
 
 
B.4 Buffers and solutions for ELISA  
 
PBS (10 X): 
NaCl  80 g 
KCl  2 g 
Na2HPO4   14.4 g 
KH2PO4  2.4 g 
ddH2O up to  1 L 
Autoclave 121°C at 15lb/sq.  20 min 
 
Carbonate Buffer (100 mM): 
Na2CO3 (0.2M)  160 ml 
NaHCO3 (0.2M)  340 ml 
pH  9.6 
Autoclave 121°C at 15lb/sq.  20 min 
 
Oxaic acid solution 2%: 
Oxalic acid dihydrate  10 g 
ddH2O up to  500 ml 
 
   
B.5 Buffers and solutions for protein purification 
 
Protein Purification under Denaturing Conditions; Buffer B: 
NaH2Po4 . H2O  13.8 g 
Tris base   1.2 g  
Urea  480.5 g 
pH adjustment using NaOH  8.0 
ddH2O up to  1000 ml 
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B. Formulation of buffers, solutions and culture media (continued) 
 
 
Protein Purification under Denaturing Conditions; Buffer C: 
NaH2Po4 . H2O  13.8 g 
Tris base   1.2 g  
Urea  480.5 g 
pH adjustment using HCl  6.3 
ddH2O up to  1000 ml 
 
Protein Purification under Denaturing Conditions; Buffer D: 
NaH2Po4 . H2O  13.8 g 
Tris base   1.2 g  
Urea  480.5 g 
pH adjustment using HCl  5.9 
ddH2O up to  1000 ml 
 
Protein Purification under Denaturing Conditions; Buffer E: 
NaH2Po4 . H2O  13.8 g 
Tris base   1.2 g  
Urea  480.5 g 
pH adjustment using HCl  4.5 
ddH2O up to  1000 ml 
 
Protein purification buffers under native conditions; Lysis Buffer: 
NaH2Po4 . H2O  6.90 g  
NaCl  17.54 g  
Imidazole  0.68 g  
pH adjustment using NaOH  8.0 
ddH2O up to  1000 ml 
 
Protein purification buffers under native conditions; Wash Buffer: 
NaH2Po4 . H2O  6.90 g  
NaCl  17.54 g  
Imidazole  1.36g  
pH adjustment using NaOH  8.0 
ddH2O up to  1000 ml 
 
Protein purification buffers under native conditions; Elution Buffer: 
NaH2Po4 . H2O  6.90 g  
NaCl  17.54 g  
Imidazole  17.00 g  
pH adjustment using NaOH  8.0 
ddH2O up to  1000 ml 
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Appendix C. Sequence alignments  
 
C.1 Multiple sequence alignment of NAV-PX gene in Brachyspira strains 
 
                            10        20        30        40        50        60        70        80                
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ATGAGCAAAAAAAATAATAAGGAATATAAAAATAGAGAAGAGGCTTTTAGAGATTATTTTGAAAGCGTAAGTAAAATTGT  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          .....................A..........................................................  
pilo. 16242.94     .....................A..........................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                            90       100       110       120       130       140       150       160         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ATATACATTAAACTTAATATCTGATAGAAATGATATGACAAGAAGACTTTCTAATAATATCAATAGAGTATTAGGTTATG  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           170       180       190       200       210       220       230       240        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ATGATGAAACAATTATTAATGATGAAAAAACTGTAAATAACAATAATGATGAGATAGCTATATTAATAGATTCTATAAAA  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           250       260       270       280       290       300       310       320        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         AAAGATTTAAAAAAGATACATACATTTAAACAATATAATTTTAATATAGAAAGATTTATAAATGAGTTTGAATTAAATGA  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................    238 
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           330       340       350       360       370       380       390       400        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TGATGAAAGATTTATTTTATATTGTTTAATTACTTATACGATTTATGGGGATTCTATGTCTGCCATATCTGTAAGAAGAA  
pilo. Margaret     .......................................A........................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ........................................................................T.......  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   .......................................A........................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           .......................................A........................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           410       420       430       440       450       460       470       480        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TATTAGAACTCATCACAATGGATGCAGATATTTATATTAACAAGTATCATTATTTCGATAATAAAAGCAGATTAATGTCA  
pilo. Margaret     ............................................................G...................  
pilo. "S.jonesii"  ............................................................G...................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ............................................................G...................  
pilo. P43/6/78T    ............................................................G...................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ........................................T.....C.............G...................  
pilo. WesB         ............................................................G...................  
aalborgi. 513      ............................................................G...................  
inno. B265         ............................................................G...................  
inno. Q91-12233    ............................................................G...................  
inno. Q91-1530-1   ............................................................G...................  
inter. OR2         ..............................................C.............G...................  
inter. OF11        ..............................................C.............G...................  
hyo. 884           ..............................................C.............G...................  
hyo. 155.11        ............................................................G...................  
pilo. 95/1000      ..............................................C.............G...................  
 
                           490       500       510       520       530       540       550       560        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         AGCGGCATACTTGTTTTATCTCATGAGCCTTATTCAAGTATTGGTCTTTTAGAGGTATCTAATACTTTAATTACATTTGT  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           570       580       590       600       610       620       630       640        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TAATTCAAAGATAGTTTTTGCTTTTTTAGAAAAAGAAAGCTACGATTTAATATTAGATATTACAAACAAAGAAAATTATA  
pilo. Margaret     ..........................................T.....................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ..........................................T.....................................  
pilo. M1           ..........................................T.....................................    239 
pilo. P43/6/78T    ..........................................T.....................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ..........................................T.....................................  
pilo. WesB         ..........................................T.....................................  
aalborgi. 513      ..........................................T.....................................  
inno. B265         ................................................................................  
inno. Q91-12233    ..........................................T.....................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ..........................................T.....................................  
inter. OF11        ..........................................T.....................................  
hyo. 884           ................................................................................  
hyo. 155.11        ..........................................T.....................................  
pilo. 95/1000      ..........................................T.....................................  
 
                           650       660       670       680       690       700       710       720        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TAGATACAAAATCTAAAAAGAAGATTATAAAAGAGCCAAGAATATTAACACCAAAAGAGATAGTTTCCGAGCTTAACAAA  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ..................................T.............................................  
pilo. P43/6/78T    ..................................T.............................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ..................................T.............................................  
inno. B265         ................................................................................  
inno. Q91-12233    ......................A.........................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ......................A.........................................................  
inter. OF11        ......................A.........................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ......................A.........................................................  
 
                           730       740       750       760       770       780       790       800        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ACAGTAATAGGTCAAGATGATGCTAAAAAGGCATTATCAGTACATGCTTATTTACATTGTTTAAGAATAAATGGAAATAA  
pilo. Margaret     .........................................T......................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         .........................................T......................................  
pilo. M1           .........................................T......................................  
pilo. P43/6/78T    .........................................T......................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  .........................................T......................................  
pilo. WesB         .........................................T......................................  
aalborgi. 513      .........................................T......................................  
inno. B265         ................................................................................  
inno. Q91-12233    .........................................T......................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         .........................................T......................................  
inter. OF11        .........................................T......................................  
hyo. 884           .........................................T......................................  
hyo. 155.11        .........................................T......................................  
pilo. 95/1000      .........................................T......................................  
 
                           810       820       830       840       850       860       870       880        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         AGATATACCATTTAGGTCAAATATTCTTATGATAGGACCTACTGGTGTTGGTAAAACATATTTAGTAAAAACATTAGCAG  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           890       900       910       920       930       940       950       960        
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ATATTTTAGGTCTTCCATTTGCACGTGCAGATGTTACTACGCTTACTGAAACTGGTTATGTTGGAGATGATGTTGAGGTT  
pilo. Margaret     ................................................................................    240 
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ........................................A.......................................  
pilo. 16242.94     ........................................A.......................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           970       980       990       1000      1010      1020      1030      1040       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         GTTTTGTATAATCTTTATAAGAAGGCTAATGGCGATTTAGATAAAGCTCAGCATGGTATAGTATTTTTAGATGAGGTAGA  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ..A..........................................................................G..  
pilo. V1H91        .............................................................................G..  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ..A..........................................................................G..  
pilo. WesB         .............................................................................G..  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    .............................................................................G..  
inno. Q91-1530-1   ..A..........................................................................G..  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           1050      1060      1070      1080      1090      1100      1110      1120       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TAAGATAGCAAAAGCTGATGCACATCAATCTACCACAGGCAACCCTTCGGACAAGGCTGTTCAAGAGGCTTTGCTTTCTA  
pilo. Margaret     ...............................................................G................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ...............................................................G................  
pilo. P43/6/78T    ...............................................................G................  
pilo. D17          .................................T..G...........................................  
pilo. 16242.94     .................................T..G...........................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ...............................................................G................  
inno. B265         ...............................................................G................  
inno. Q91-12233    ...............................................................G................  
inno. Q91-1530-1   ...............................................................G................  
inter. OR2         .................................A..............................................  
inter. OF11        .................................A..............................................  
hyo. 884           ..........................................T....................G................  
hyo. 155.11        ...............................................................G................  
pilo. 95/1000      .................................A..............................................  
 
                           1130      1140      1150      1160      1170      1180      1190      1200       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TGATGAATGGAGAGGATATTAGAGTTCCTGAATTTGGCGACAGAAGAATGATGCATTCTAGTGACGGCATTGTTATGAAC  
pilo. Margaret     .........................G.....G................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           .........................G.....G................................................  
pilo. P43/6/78T    .........................G.....G................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  .........................G.....G........T.......................................  
pilo. WesB         ...............................G................................................  
aalborgi. 513      .........................G.....G................................................  
inno. B265         .........................G.....G................................................  
inno. Q91-12233    .........................G.....G................................................  
inno. Q91-1530-1   .........................G.....G................................T...............  
inter. OR2         .........................G.....G................................................  
inter. OF11        .........................G.....G................................................  
hyo. 884           .........................G.....G................................................  
hyo. 155.11        .........................G.....G................................................  
pilo. 95/1000      .........................G.....G................................................  
   241 
                           1210      1220      1230      1240      1250      1260      1270      1280       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ACTAAGAATATTTTATTTATTTTCGGCGGTGCTTTTGTGGGGCTTGAAGATATTATAAAGATGCGTCTTAAAGGTGAGAG  
pilo. Margaret     .....A..........................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        .....A..........................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ......................................T.........................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         .....A..........................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           .....A..........................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           1290      1300      1310      1320      1330      1340      1350      1360       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         CAGTTTGGGTTTTGGTTCTAATGCGGTTTTAAATAAACTTCAAAAGAATAAAATACTTAGTCAGGTTGATGTGAAAGATG  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ......................................................G.........................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ........................................................................A.......  
inter. OF11        ........................................................................A.......  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ........................................................................A.......  
 
                           1370      1380      1390      1400      1410      1420      1430      1440       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TAGAGAAATATGGTATGATACCAGAGTTTATAGGAAGAATACCAATAATTGTTACTCTAAATGAGCTTACTAAAGATAAT  
pilo. Margaret     ................................................................A...............  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           1450      1460      1470      1480      1490      1500      1510      1520       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         CTTAAAGATATATTGCTAAAAACTAAAGAATCACCTATAATAAAATATGTAGATTTCTTTAAAAGCATAGGAAAGAAGCT  
pilo. Margaret     ......A.........................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ............................................G...................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................    242 
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           1530      1540      1550      1560      1570      1580      1590      1600       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         AATATTAACAGATGATGCTATAAATTATATAGTGGATAAAGCTTCTACTATGAATATGGGAGCAAGGTCATTAAAAAGTA  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           1610      1620      1630      1640      1650      1660      1670      1680       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         TAGTTGAAACTGCTATGGTTAATATACTTTTTAATTTAGATGGTATAAAGGGTAATGCTTTAACTCTAACTAAAAAAGAT  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          ................................................................................  
pilo. 16242.94     ................................................................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ................................................................................  
hyo. 155.11        ...........................................A....................................  
pilo. 95/1000      ................................................................................  
 
                           1690      1700      1710      1720      1730      1740      1750      1760       
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
pilo.HRM2B         ATAGAGAAAGCATTTGAAGAGAGGGAGGTAGTAATTTCAAGCGATAAAGATTTTGTTAAAAAAACTAATATTGGTTTAAA  
pilo. Margaret     ................................................................................  
pilo. "S.jonesii"  ................................................................................  
pilo. V1H91        ................................................................................  
pilo. HRM7         ................................................................................  
pilo. M1           ................................................................................  
pilo. P43/6/78T    ................................................................................  
pilo. D17          .........................................T......................................  
pilo. 16242.94     .........................................T......................................  
pilo. Q98.0026.11  ................................................................................  
pilo. WesB         ................................................................................  
aalborgi. 513      ................................................................................  
inno. B265         ................................................................................  
inno. Q91-12233    ................................................................................  
inno. Q91-1530-1   ................................................................................  
inter. OR2         ................................................................................  
inter. OF11        ................................................................................  
hyo. 884           ..........................T.....................................................  
hyo. 155.11        ................................................................................  
pilo. 95/1000      ................................................................................  
 
                           1770      1780       
                   ....|....|....|....|....| 
pilo.HRM2B         AGAAGATAAAACTTATATGGCTTGA  
pilo. Margaret     .........................  
pilo. "S.jonesii"  .........................  
pilo. V1H91        .........................  
pilo. HRM7         .........................  
pilo. M1           .........................  
pilo. P43/6/78T    .........................  
pilo. D17          .........................  
pilo. 16242.94     .........................  
pilo. Q98.0026.11  .........................  
pilo. WesB         .........................  
aalborgi. 513      .........................  
inno. B265         .........................    243 
inno. Q91-12233    .........................  
inno. Q91-1530-1   .........................  
inter. OR2         .........................  
inter. OF11        .........................  
hyo. 884           .........................  
hyo. 155.11        .........................  
pilo. 95/1000      .........................  
 
 
 
C.2 Multiple sequence alignment of NAV-P3 gene in B. pilosicoli strains 
 
                      10        20        30        40        50        60        70        80        90       100                   
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATGAAAAAATATATTTTAATATTATTTTTTATAATAATATCTTGCAGCAAAAATAATACAAATAATTCTCTAATAGTAAATATAGGTCCAGAACCAAAAA  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ............................................................G.......................................  
95/1000      ....................................................................................................  
 
                     110       120       130       140       150       160       170       180       190       200          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        CTCTAGACCCAACATATACAGAAACCTATGACGGTTCAGCATATATAGCACATACATTTGAAGGATTAACTTCAAGAGATAAAGATGATAAATTAATACC  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     210       220       230       240       250       260       270       280       290       300          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        GGCAGTTGCTGAAAGTTGGGATATTAGCGAAGACTATTTAACATATACATTCTATTTAAGAACAAATGCTAAATGGTCTGACGGTAAAACAGTTACAGCT  
Margaret     A...................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         A..........................T.....................................................T..................  
P43/6/78T    ....................................................................................................  
95/1000      ...........................T........................................................................  
 
                     310       320       330       340       350       360       370       380       390       400          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AATGATTTTGTATATGCATGGCAAAGAGCAGTTGATCCAAAAGTAGCAAGCTCTGTAAGCTATCAATTAAACCCAATAAAAAATGCATCAAAAATCATAA  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     410       420       430       440       450       460       470       480       490       500          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AAGGAGAATTGCCACTAACAGAACTTGGAGTAAAAGCTATTGATGACTATACATTAGAAGTAAACTTAGAAAGCCCTACAGCATATTTCTTGGATTTACT  
Margaret     ........................................................................................T..A........  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ..........................................G.............................................T...........  
P43/6/78T    ....................................................................................................  
95/1000      ........................................................................................T..A........  
 
                     510       520       530       540       550       560       570       580       590       600          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TTCTATTACAATATATAGCCCGCTTAGAAAAGATATAATAGAGAAATACGGCGATGCTTGGACTCAAGAAGAATATATAGGAAATGGACCTTTTTTTCTT  
Margaret     .................................................................................................G..  
S."jonesii"  ....................................................................................................  
V1H91        ...C.............................................................................................G..  
WesB         .................................................................................................G..  
P43/6/78T    .................................................................................................G..  
95/1000      .................................................................................................G..  
 
                     610       620       630       640       650       660       670       680       690       700          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AAAGAACATATAAACAATGATAAAATAGTAATGGAAAAAAATACTAATTATTGGAACAAAGAAACAATAATACCTCAAACAATAACATTTTCATTATTAG  
Margaret     .................C..................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ...........................A........................................................................  
P43/6/78T    ...........................A........................................................................  
95/1000      ...........................A........................................................................  
 
                     710       720       730       740       750       760       770       780       790       800          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATAATCCAAATACAATAGTTGCATCTATACAAGACGGAACATTATTATTTGGAAGCAATCCTCCATTACAAGACATACCAAAATTAACAGAAGAAGGCTA  
Margaret     ...................A...................G..................C.........................................  
S."jonesii"  ...................A................................................................................  
V1H91        ...................A......................................C.........................................  
WesB         ...................A................................................................................  
P43/6/78T    ...................A..............T.................................................................  
95/1000      .........................................................................T..........................  
 
                     810       820       830       840       850       860       870       880       890       900          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TATTGATTATGTACCTTTGCTTGGAATATATTTTCTCTCTATAAACACAACAAATGAAGTGTTAAAAAACAAGAATGTAAGAAAAGCTCTTTCTTTAGCA  
Margaret     .............................................................G......................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................    244 
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     910       920       930       940       950       960       970       980       990       1000         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATAGACAGAAATTATATAGTAGAAAAAGTTACAAAAGGAAATGAAATACCAGCTGCTGCATTAGTACCATATTCTGTATTTGATATAGATGGTTCTTTCA  
Margaret     ....................................................................................................  
S."jonesii"  T.................................................C.................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        GAGAAAAAGGCAGAAATTATTTTAGTGTAAATGAAAATGATTATCAAAAAAACATAGAAGAAGCTAGAAGACTATTAGCAGAAGCAGGTTATAGTAATGG  
Margaret     ...........G.............C..................................................G.......................  
S."jonesii"  ...........G.............C..................................................G.......................  
V1H91        ...........G.............C..................................................G.......................  
WesB         ...........G.............C..................................................G.......................  
P43/6/78T    ...........G........................................................................................  
95/1000      ...........G........................................................................................  
 
                     1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        CAGCAACTTCCCTGTGTTGGAATATAGCGTAGAATCTCAAAGTTCATTAAATATATTTGAAGCTATTCAGCAGATGTGGAAAGAAAATCTTAATATAGAT  
Margaret     ......T.............................................................................................  
S."jonesii"  ......T.............................................................................................  
V1H91        ......T.............................................................................................  
WesB         ......T.............................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ACTAGAGTTAATCAGCTTGAATGGGGGGTTTTTATGCAAACAACTAGAGGAGATAAAAATTTTGAAATAGCACGCTCTGGTTGGATGGGTGATTATAATG  
Margaret     ..........................A.........................................................................  
S."jonesii"  ..........................A.........................................................................  
V1H91        ..........................A.........................................................................  
WesB         ..........................A.........................................................................  
P43/6/78T    ..........................A.........................................................................  
95/1000      ..........................A.........................................................................  
 
                     1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ACCCTATGACATTTTTAGATACATTTTTAAGCTATAGCCCTCAAAACACTGGAAGCTATTATAATAAAGAATATGAACAATTAATTCAATCAGCACTTAC  
Margaret     .............................................................C..C................................C..  
S."jonesii"  .............................................................C..C................................C..  
V1H91        ..............................................T..............C..C................................C..  
WesB         ..............................................T..............C..C................................C..  
P43/6/78T    .............................................................C..C...................................  
95/1000      .............................................................C..C................................C..  
 
                     1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TAATGGTGATAAAATATCTAGAATGCAAACATTACATAAAGCGGAAGATGTACTAATGGAAGATATGCCTTTTATTCCTTTATATTTTTATAATAGGGTA  
Margaret     ...................................................CT...........................................A...  
S."jonesii"  .................A........................A.........T...............................................  
V1H91        .................A........................A.........................................................  
WesB         ....................................................T.......G.......................................  
P43/6/78T    ..........................................A.........T...........................................A...  
95/1000      ....................................................T...........................................A...  
 
                     1510      1520      1530      1540      1550      1560      1570      1580       
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|. 
HRM2B        ATACTTGTTAGACCAGAATTAAAAGATGTTATGATAAGCAATGTAATACCTCCAAGATTTTTCTATGCTTATGTAGAGAAG  
Margaret     .................................................................................  
S."jonesii"  .................................................................................  
V1H91        .................................................................................  
WesB         .................................................................................  
P43/6/78T    .....................................................C...........................  
95/1000      .................................................................................  
 
 
 
C.3 Multiple sequence alignment of NAV-P8 gene in B. pilosicoli strains 
 
                      10        20        30        40        50        60        70        80        90       100                   
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATGAGTCATAATTTAAGGCTAGCATTCATAATTATAGGTCTTGCTATAATGGGTTGGTTTATCACTCCTACAGTAAGATGGTATTTTTTCACACCAGAAG  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ................................C........................................................T...T.C..T.  
P43/6/78T    ....................................................................................................  
95/1000      .................................................................................................... 
  
 
                     110       120       130       140       150       160       170       180       190       200          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATAAAAAAGAAGAAAGTAATATGTCATTAGATGAGATGATATCTAATGGATATACAAAAGAACAAATTGATGAGATTCAAAAGCTTAAACGTTTAAGGAG  
Margaret     ...............................................................................GTCT........CC.T..A..  
S."jonesii"  ...............................................................................GTCT........CC.T..A..  
V1H91        ..................................A.............................................TCT........CC.T..A..  
WesB         ..............................................G..............G.................GTC..........C.T..A..  
P43/6/78T    ...............................................................................GTCT.........C.T..A..  
95/1000      ...............................................................................GTCT........CC.T..A..  
   245 
                     210       220       230       240       250       260       270       280       290       300          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TGAGTCTGTAAATTTAGGATTAGACTTACAGGGCGGTATAAGAATAGTACTTCAGGCAGATTTTGAAGATTATGCCAACAAATTAGACAGAACAGCATTA  
Margaret     C..A................................................................................................  
S."jonesii"  C..A................................................................................................  
V1H91        C..A................................................................................................  
WesB         C..A.....G...........G..T.....A.....................................................................  
P43/6/78T    C..A................................................................................................  
95/1000      C..A.............................T................................G.................................  
 
                     310       320       330       340       350       360       370       380       390       400          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TCTCTTACTGCTGAAGAGAAAAATGATGCTATGGAAAGACTTATATCTAGATTAAGAGGAAGAATTGACCAATTTGGAGTTAGTGAGGTTGGTATAAGAA  
Margaret     ......................................................................................A.............  
S."jonesii"  ....................................................................................................  
V1H91        ......................................................................................A.............  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     410       420       430       440       450       460       470       480       490       500          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AGCAAGGCGATGACAGAGTGGTTGTTGAACTTCCTGGTGCTAGAGACCCTGATAGAATTAAAAGTGTTGTACTTAGCCAAGGTGCTCTCACTTTCAATTT  
Margaret     .A..................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        .A..................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ........................................................................................T...........  
 
                     510       520       530       540       550       560       570       580       590       600          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        GGTAGACCAAGAGGCTTCTGCTACAATTACTAGCAATGACTTACTTCTTGGAGTTTTCACTAATACTGCTAAAGTACCAGAAAACGACAAGCAAGTTTAT  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ...............................................................C....................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     610       620       630       640       650       660       670       680       690       700          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TTTTATAGCGAAAAAGATGACTTTGGAAGAAGAGTTAGAGGAGCTCCTGTATTTATAGAAAAAGAGGCTTCTTTAGATGGTTCTGCTTTAATTAATGCTA  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     710       720       730       740       750       760       770       780       790       800          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATGTAGGCGGCGGACAATTTGGAGAGGTTACTGTTGAGTTTGAACTTAATAATGAAGGAGCTGAACAGTTTGCATTAGTAACTGCTGCTAATGTTAATAG  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ..........T..C......................................................................................  
 
                     810       820       830       840       850       860       870       880       890       900          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AATGCTTGCTATTGTATTAGACGATAAAGTAATAAGTGCTCCTAATATCAATCAAGAGATTAGAGGCGGAAGAGGAGTTATTTCTGGAAGCTTTACTTTG  
Margaret     ....................................................................................................  
S."jonesii"  ......................................................G..A..........................................  
V1H91        ......................................................G..A..........................................  
WesB         ....................................................................................................  
P43/6/78T    ......................................................G..A........T.................................  
95/1000      ......................................................G..A..........................................  
 
                     910       920       930       940       950       960       970       980       990       1000         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        GAAGAAGCTCAAGATTTAGCTAGAATACTTAAAGAAGGTGCTTTGCCTTTAAAAGTAAGTGTTATAGAGGAAGAAGTTGTAGGTCAATCTATAGGTGCTG  
Margaret     ............................................A..................G....................................  
S."jonesii"  ............................................A..................G....................................  
V1H91        ............................................A..................G....................................  
WesB         ...............................................................G....................................  
P43/6/78T    ............................................A..................G....................................  
95/1000      ............................................A..................G....................................  
 
                     1010      1020      1030      1040      1050      1060      1070      1080      1090      1100         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ACTCTGTTAAGGCTGGTACTACTGCTTTATTTATGGCTGCAATATTAGTTGCTGTATTTATGATTGCTCTATATAGAGTATCTGGAGTTTTATCTACAAT  
Margaret     ....................................................................................................  
S."jonesii"  .T..................................................................................................  
V1H91        ....................................................................................................  
WesB         ..........................C.........................................................................  
P43/6/78T    ....................................................................G...............................  
95/1000      ....................................................................G...............................  
 
                     1110      1120      1130      1140      1150      1160      1170      1180      1190      1200         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AGCTATGCTTATAAACGTTATACTTATTATAGCTATACTTTCTCCTTTAAGATTTACTCTTACTTTGCCTGGTATAGCTGGTCTTATACTTACTATAGGT  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ...A................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     1210      1220      1230      1240      1250      1260      1270      1280      1290      1300         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATGGCAGTTGATGCTAACGTTATTATTTTTGAACGTATAAAAGATGAATTAAAAATAAAATCTAATATTTCTGATGCTATTATATCTGGTTATGACAGAG    246 
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ..................................................................G......................A..........  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     1310      1320      1330      1340      1350      1360      1370      1380      1390      1400         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        CTTTTGCTACAATATTTGACTCTAACATTACAACAATAATAGTAGCTTTAATACTATGGATATTTGGAAGCGGTCCTGTACAAGGTTTTGCTGTTACATT  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    .........................................................................C..........................  
95/1000      ...............................G....................................................................  
 
                     1410      1420      1430      1440      1450      1460      1470      1480      1490      1500         
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        GTTCTTTGGTATTTTAATAAACCTATTTACTGCTGTATTTATTACTAGATATATATATGAAGAAATTATTCGTACAAAACTTGTGAAGAAAGCTGGTTTC  
Margaret     ....................................................................................................  
S."jonesii"  ....................................................................................................  
V1H91        ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ............................................................G.......................................  
95/1000      A...................................................................................................  
 
                    
             ....|.... 
HRM2B        TTCTTTATT  
Margaret     .........  
S."jonesii"  .........  
V1H91        .........  
WesB         .........  
P43/6/78T    .........  
95/1000      .........  
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                      10        20        30        40        50        60        70        80        90       100                   
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        ATGAGCGAAAATATTAAAAAAAATAATGATGTTAAAAAAACTGAATATAATGATGTAACAAAAAATAAAATTCCTTTTGTTAAATTTATGCCTGTTGCGG  
Margaret     .............................................A......................................................  
V1H91        .............................................A......................................................  
S."jonesii"  .............................................A......................................................  
WesB         .............................................A......................................................  
P43/6/78T    .............................................A......................................................  
95/1000      .............................................A......................................................  
 
                     110       120       130       140       150       160       170       180       190       200          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        CTGTTATATCTAGTATATTATTTATAGCTTCTATTGGGCTTTTTATTAATAAATTGACTACTAATAGCTTTAATATGGGTATAGATTTTGCAGGCGGTGT  
Margaret     ....................................................................................................  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     210       220       230       240       250       260       270       280       290       300          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TGAATTACAAGTGAAAATTGATAATCCAGAAGTAATAAATATCGCTGAAATAAGAAATTTATACAGAAACTTTGGTACAGAAACTGTTAATATACAAGAG  
Margaret     ............A......T...................................................................C...........A  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ...................................................................................................A  
95/1000      ..........................T........................................................................A  
 
                     310       320       330       340       350       360       370       380       390       400          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        CTTGAAGGAGAAGATAATATCAATGCTTTTCTTTTAAGATTTAGAGGCTCTAATGAAGAATCTGATAGAGCTATGCAAGTGCTTTATGATAAATATACAA  
Margaret     .................................................................C.............................C....  
V1H91        ...............................................................................................N....  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     410       420       430       440       450       460       470       480       490       500          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AAGAAAAAGTAACTCTTATAGGAAGTAATATTATAAGCGGTGTTGTATCTTCTGATAATTTAAAACTAGCTTTCATACTTGTAATAGTGTCTTGGATTAT  
Margaret     ....................................................................................................  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    .........................................................................T..........................  
95/1000      .........................................................................T..........................  
 
                     510       520       530       540       550       560       570       580       590       600          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        CATTATGATATACATTACTATAAGATTTAATTATAGATATGCTTTCCCTGCTATTATTACTCTTATACATAATGTTGTTATAGTATTTGGTATACTTCTA  
Margaret     ....................................................................................................  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................    247 
 
                     610       620       630       640       650       660       670       680       690       700          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TTTTTGAATAAAGAGTTTTCTGTATTAGTTCTCTCTTCAATGCTTACTTTAATAGGTTATACAATCAACGACATAATAGTTGTATTTGATAGAATCAGAG  
Margaret     ....................................................................................................  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    .......................................................................T............................  
95/1000      ....................................................................................................  
 
                     710       720       730       740       750       760       770       780       790       800          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        AAAATGCTGATGTTAAAAGACCATTTAAAGAAATTGTTAATATAAGTCTTAATAATGTTGTAGGTAGAACTGTAATTACTGGTGTTTCTACATTGCTTGC  
Margaret     ....................................................................................................  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ................................................................................A...................  
95/1000      ................................................................C...............A...................  
 
                     810       820       830       840       850       860       870       880       890       900          
             ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
HRM2B        TGCTCTTGCTATAATGATATGGGGCGGATTTATACTTTATGATTTTGCTTTTACATTCTTTTGCGGTGTAGTGATAGGTACTTATGCTAGTAACTTTATT  
Margaret     ....................................................................................................  
V1H91        ....................................................................................................  
S."jonesii"  ....................................................................................................  
WesB         ....................................................................................................  
P43/6/78T    ....................................................................................................  
95/1000      ....................................................................................................  
 
                     910       920       930       940    
             ....|....|....|....|....|....|....|....|.. 
HRM2B        GCAAGCGGCCTTTTAATATTATTTATGAAAGGAAAAAAAGCA  
Margaret     ..........................................  
V1H91        ..........................................  
S."jonesii"  ..........................................  
WesB         ..........................................  
P43/6/78T    ..........................................  
95/1000      ..........................................  
 
 
 
 